

CITATION REPORT

List of articles citing

Inflammation and Alzheimerts disease

DOI: 10.1016/s0197-4580(00)00124-x
Neurobiology of Aging, 2000, 21, 383-421.

Source: <https://exaly.com/paper-pdf/32039530/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2257	Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. 2000 , 176, 85-9		24
2256	Ibuprofen, inflammation and Alzheimer disease. 2000 , 6, 973-4		44
2255	Combinations for cancer prevention. 2000 , 6, 974-5		42
2254	Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies. 2000 , 35, 1353-61		54
2253	Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. 2000 , 402, 77-85		40
2252	Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. 2000 , 157, 2003-10		100
2251	Inflammation in Alzheimer's disease: a view from the periphery. <i>Neurobiology of Aging</i> , 2000 , 21, 437-40; discussion 451-3	5.6	18
2250	Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?. <i>Neurobiology of Aging</i> , 2000 , 21, 441-5; discussion 451-3	5.6	95
2249	Cellular and molecular mechanisms of Alzheimer's disease inflammation. 2001 , 3-49		
2248	Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. 2001 , 166, 7527-33		459
2247	T-helper-1 and T-helper-2 responses in psychiatric disorders. 2001 , 15, 340-70		188
2246	Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. 2001 , 73, 887-96		488
2245	Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. 2001 , 171, 29-45		308
2244	Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. 2001 , 8, 1094-101		77
2243	Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. 2001 , 159, 439-47		240
2242	Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. 2001 , 39, 333-40		194
2241	Two-dimensional gel analysis of secreted proteins induced by interleukin-1 beta in rat astrocytes. 2001 , 39, 349-59		10

2240	Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. 2001 , 39, 361-70		25
2239	Immunological aspects of microglia: relevance to Alzheimer's disease. 2001 , 39, 381-91		168
2238	Functional role of TGF beta in Alzheimer's disease microvascular injury: lessons from transgenic mice. 2001 , 39, 393-400		25
2237	Estrogen (E2) and glucocorticoid (Gc) effects on microglia and A beta clearance in vitro and in vivo. 2001 , 39, 435-48		42
2236	Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. 2001 , 39, 449-57		85
2235	Ligand modulation of glial activation: cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin 1 beta and nitric oxide synthase II. 2001 , 39, 459-68		32
2234	3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. <i>Neurobiology of Aging</i> , 2001 , 22, 427-34	5.6	103
2233	Mechanism of glial activation by S100B: involvement of the transcription factor NFkappaB. <i>Neurobiology of Aging</i> , 2001 , 22, 765-72	5.6	93
2232	Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001 , 22, 837-42	5.6	244
2231	Inflammation, autotoxicity and Alzheimer disease. <i>Neurobiology of Aging</i> , 2001 , 22, 799-809	5.6	413
2230	Chemokines and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001 , 22, 909-13	5.6	84
2229	The role of TNF and its receptors in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001 , 22, 873-83	5.6	212
2228	Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. <i>Neurobiology of Aging</i> , 2001 , 22, 1007-12	5.6	193
2227	Similar activation of glial cultures from different rat brain regions by neuroinflammatory stimuli and downregulation of the activation by a new class of small molecule ligands. <i>Neurobiology of Aging</i> , 2001 , 22, 975-81	5.6	16
2226	Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001 , 22, 937-44	5.6	154
2225	Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. <i>Neurobiology of Aging</i> , 2001 , 22, 811-7	5.6	80
2224	Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. <i>Neurobiology of Aging</i> , 2001 , 22, 983-91	5.6	212
2223	Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. <i>Neurobiology of Aging</i> , 2001 , 22, 993-1005	5.6	441

2222	Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. <i>Neurobiology of Aging</i> , 2001 , 22, 849-61	5.6	77
2221	Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. <i>Neurobiology of Aging</i> , 2001 , 22, 819-22	5.6	27
2220	Key signaling pathways regulate the biological activities and accumulation of amyloid-beta. <i>Neurobiology of Aging</i> , 2001 , 22, 967-73	5.6	14
2219	Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. <i>Neurobiology of Aging</i> , 2001 , 22, 957-66	5.6	127
2218	Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. <i>Neurobiology of Aging</i> , 2001 , 22, 885-93	5.6	192
2217	Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. <i>Neurobiology of Aging</i> , 2001 , 22, 945-56	5.6	130
2216	Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. 2001 , 56, 581-8		146
2215	Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. 2001 , 301, 54-8		38
2214	Complement activation by neurofibrillary tangles in Alzheimer's disease. 2001 , 305, 165-8		125
2213	Inflammatory cytokine levels are influenced by interactions between THP-1 monocytic, U-373 MG astrocytic, and SH-SY5Y neuronal cell lines of human origin. 2001 , 313, 41-4		18
2212	Complement and apoptosis. 2001 , 38, 207-19		163
2211	Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction. 2001 , 24, S21-31		111
2210	Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction. 2001 , 24, 21-31		85
2209	Pleiotropic roles of formyl peptide receptors. 2001 , 12, 91-105		162
2208	The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. 2001 , 70, 603-14		252
2207	New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. 2001 , 17, 393-410		17
2206	Gene identification in Alzheimer's disease. 2001 , 2, 239-49		21
2205	Immunological aspects of alzheimer's disease: therapeutic implications. 2001 , 15, 325-37		14

2204	Neuroinflammation and the genetics of Alzheimer's disease: the search for a pro-inflammatory phenotype. 2001 , 13, 163-70	28
2203	beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. 2001 , 21, 1179-88	564
2202	Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. 2001 , 21, RC123	202
2201	Molecular and cellular mediators of Alzheimer's disease inflammation. 2001 , 3, 131-157	42
2200	Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. 2001 , 21, 1444-51	119
2199	Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity. 2001 , 12, 2199-202	81
2198	Enhanced expression of I-kappaB with neurofibrillary pathology in Alzheimer's disease. 2001 , 12, 2641-5	15
2197	From farm to table to brain: foodborne pathogen infection and the potential role of the neuro-immune-endocrine system in neurotoxic sequelae. 2001 , 4, 333-74	3
2196	Cognitive and neuropsychiatric side effects of mefloquine. 2001 , 13, 302	12
2195	Correlation of the expression level of C1q mRNA and the number of C1q-positive plaques in the Alzheimer Disease temporal cortex. analysis of C1q mrna and its protein using adjacent or nearby sections. 2001 , 12, 237-42	16
2194	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. 2001 , 341-361	8
2193	Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. 2001 , 21, 5703-14	174
2192	Protein expression in Down syndrome brain. 2001 , 21, 331-61	69
2191	High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta). 2001 , 108, 171-9	41
2190	Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. 2001 , 14, 1961-7	79
2189	Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. 2001 , 66, 972-80	76
2188	Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. 2001 , 54, 59-70	58
2187	Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. 2001 , 35, 72-9	315

2186	Immune function of microglia. 2001 , 36, 165-79	1005
2185	Immune function of astrocytes. 2001 , 36, 180-90	1020
2184	Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. 2001 , 105, 332-42	67
2183	Chemokines and their receptors in the central nervous system. 2001 , 22, 147-84	294
2182	Biological markers and the treatment of Alzheimer's disease. 2001 , 17, 119-25	14
2181	Therapeutic opportunities in polyglutamine disease. 2001 , 7, 419-23	65
2180	TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. 2001 , 7, 612-8	507
2179	Characterization of ionotropic glutamate receptors in human lymphocytes. 2001 , 133, 936-44	92
2178	A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. 2001 , 414, 212-6	1228
2177	Gridlock signalling pathway fashions the first embryonic artery. 2001 , 414, 216-20	448
2176	Inflammatory markers in Alzheimer's disease and multi-infarct dementia. 2001 , 122, 1985-95	61
2175	Induction of complement C9 messenger RNAs in human neuronal cells by inflammatory stimuli: relevance to neurodegenerative disorders. 2001 , 36, 1179-88	12
2174	An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. 2001 , 20, 705-32	1010
2173	Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease. 2001 , 6, 1207-1219	25
2172	Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. 2001 , 166, 7496-503	83
2171	Polymorphisms in inflammatory genes and the risk of Alzheimer disease. 2001 , 58, 1790-2	168
2170	Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. 2001 , 60, 906-16	118
2169	Regulation of microglia - potential new drug targets in the CNS. 2001 , 5, 655-668	18

2168	Helper-dependent adenoviral vector-mediated gene transfer in aged rat brain. 2001 , 12, 181-91	34
2167	Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. 2001 , 98, 7605-10	178
2166	Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. 2001 , 15, 2454-62	122
2165	Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. 2001 , 98, 10273-8	151
2164	Ozone-induced mucous cell metaplasia. 2001 , 60, 193	4
2163	New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. 2001 , 276, 32293-9	211
2162	Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response. 2001 , 276, 30142-9	53
2161	New concepts in the drug therapy of Alzheimer's disease. 2001 , 2, 1975-83	4
2160	Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. 2001 , 20, 731-6	83
2159	Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. 2002 , 277, 35282-8	92
2158	The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. 2002 , 99, 11830-5	356
2157	Inflammation, apoptosis, and Alzheimer's disease. 2002 , 8, 276-83	50
2156	Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. 2002 , 99, 10837-42	352
2155	Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. 2002 , 277, 49782-90	47
2154	Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. 2002 , 25, 537-62	268
2153	Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. 2002 , 96, 892-9	64
2152	Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. 2002 , 99, 1610-5	145
2151	Gene expression profile of the aging brain. 2002 , 59, 1712-4	28

2150	Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. 2002 , 58, 1418-22	53
2149	Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?. 2002 , 13, 95-165	37
2148	Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients. 2002 , 39, 400-2	64
2147	Additive effects of amyloid β fragment and interleukin-1 β on interleukin-6 secretion in rat primary glial cultures. 2002 , 10, 245	
2146	Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. 2002 , 7, 199-206	147
2145	Chemokine receptors in the brain: their role in HIV infection and pathogenesis. 2002 , 16, 1709-30	40
2144	Diet and risk of dementia: Does fat matter?: The Rotterdam Study. 2002 , 59, 1915-21	239
2143	Immunological and immunogenetic markers of successful and unsuccessful ageing. 2002 , 29-45	11
2142	Inflammation and Parkinson's disease. 2002 , 1, 221-42	34
2141	Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. 2002 , 24, 248-68	46
2140	Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. 2002 , 16, 601-3	261
2139	DNA microarray analysis of the aging brain. 2002 , 27, 299-306	91
2138	Randomized pilot study of nimesulide treatment in Alzheimer's disease. 2002 , 58, 1050-4	159
2137	Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. 2002 , 59, 880-6	275
2136	A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. 2002 , 277, 47373-9	270
2135	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). 2002 , 8, 295-8	49
2134	Air pollution and brain damage. 2002 , 30, 373-89	327
2133	Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF. 2002 , 58, 1415-8	14

2132	Atypical inflammation in the central nervous system in prion disease. 2002 , 15, 349-54	134
2131	Barriers to drug discovery and development for Alzheimer disease. 2002 , 16 Suppl 1, S1-8	19
2130	Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation.. 2002 , 116, 902-911	36
2129	Effects of caloric restriction on gene expression. 2002 , 6, 17-28; discussion 28-32	6
2128	Antioxidants as treatment for neurodegenerative disorders. 2002 , 11, 1407-35	169
2127	APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. 2002 , 41, 922-8	137
2126	A role for local inflammation in the formation of drusen in the aging eye. 2002 , 134, 411-31	872
2125	Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. 2002 , 160, 1583-7	120
2124	CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions. 2002 , 160, 841-8	45
2123	Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. 2002 , 173, 183-95	189
2122	Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. 2002 , 176, 336-41	112
2121	Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. 2002 , 21, 15-28	85
2120	Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha. 2002 , 10, 366-77	52
2119	Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. 2002 , 10, 187-200	6
2118	MAP kinase signaling cascade dysfunction specific to Alzheimer's disease in fibroblasts. 2002 , 11, 166-83	55
2117	Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. 2002 , 11, 257-74	189
2116	Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. 2002 , 11, 308-14	52
2115	Pharmacogenomics for the treatment of dementia. 2002 , 34, 357-79	39

2114	Is pharmacological prevention of Alzheimer's a realistic goal?. 2002 , 3, 365-80		13
2113	Beta-amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice. 2002 , 329, 111-5		20
2112	Inflammation in neurodegenerative disease--a double-edged sword. 2002 , 35, 419-32		927
2111	Formyl-peptide receptors revisited. 2002 , 23, 541-8		504
2110	The possible role of complement activation in Alzheimer disease. 2002 , 8, 519-23		64
2109	Receptors for chemotactic formyl peptides as pharmacological targets. 2002 , 2, 1-13		79
2108	Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. 2002 , 23, 1343-50		117
2107	Noradrenergic regulation of inflammatory gene expression in brain. 2002 , 41, 357-65		168
2106	Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. <i>Neurobiology of Aging</i> , 2002 , 23, 31-9	5.6	95
2105	Dietary melatonin selectively reverses age-related changes in cortical cytokine mRNA levels, and their responses to an inflammatory stimulus. <i>Neurobiology of Aging</i> , 2002 , 23, 633-8	5.6	41
2104	Proinflammatory effects of M-CSF and A beta in hippocampal organotypic cultures. <i>Neurobiology of Aging</i> , 2002 , 23, 349-62	5.6	30
2103	The glucocorticoid paradox of caloric restriction in slowing brain aging. <i>Neurobiology of Aging</i> , 2002 , 23, 707-17	5.6	97
2102	Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. <i>Neurobiology of Aging</i> , 2002 , 23, 787-94	5.6	86
2101	Concern over the amyloid vaccine: amyloid heterogeneity and Fc receptor signaling. <i>Neurobiology of Aging</i> , 2002 , 23, 667-70; discussion 683-4	5.6	1
2100	The role of microglia in Alzheimer's disease: friend or foe?. <i>Neurobiology of Aging</i> , 2002 , 23, 677-9; discussion 683-4	5.6	27
2099	Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. 2002 , 112, 827-40		93
2098	Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. 2002 , 23, 324-30		59
2097	Cytokines and the ageing brain. 2002 , 25, 546-7		10

2096	Beta-amyloid deposition in the brains of rats chronically infused with thiorphan or lipopolysaccharide: the role of ascorbic acid in the vehicle. 2002 , 322, 75-8	35
2095	No synergistic effect between -850 tumor necrosis factor-alpha promoter polymorphism and apolipoprotein E epsilon 4 allele in Alzheimer's disease. 2002 , 328, 71-3	20
2094	Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery. 2002 , 37, 31-40	1
2093	Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. 2002 , 22, 2434-42	211
2092	Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. 2002 , 54, 469-525	354
2091	. 2002 ,	
2090	Neuroinflammation in Neurodegeneration: Lessons from Alzheimer's Disease. 283-294	
2089	Pharmacogenomics in Alzheimer's disease. 2002 , 2, 59-84	28
2088	Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. 2002 , 22, 3376-85	243
2087	The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury. 2002 , 22, 6071-82	140
2086	Lack of association between plasma homocysteine and inflammation in psychogeriatric patients. 2002 , 14, 151-5	6
2085	Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease. 2002 , 74, 265-84	19
2084	T cells and aging, January 2002 update. 2002 , 7, d1056-183	304
2083	Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. 2002 , 22, 2246-54	327
2082	Protective Effects of Estrogen on Aging and Damaged Neural Systems. 2002 , 821-837	7
2081	Anti-inflammatory effects of cerebrocrast in a model of rat paw edema and on mononuclear THP-1 cells. 2002 , 441, 203-8	19
2080	A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. 2002 , 453, 319-24	24
2079	Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system. 2002 , 123, 91-101	26

2078	Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. 2002 , 124, 83-92	293
2077	Peripheral LPS administrations up-regulate Fas and FasL on brain microglial cells: a brain protective or pathogenic event?. 2002 , 124, 45-53	26
2076	Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. 2002 , 127, 160-8	109
2075	Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. 2002 , 131, 135-46	75
2074	Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. 2002 , 133, 160-74	19
2073	Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer's disease. 2002 , 36, 269-80	46
2072	Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. 2002 , 54, 1627-56	108
2071	Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. 2002 , 926, 69-79	39
2070	The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. 2002 , 951, 218-26	92
2069	The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. 2002 , 1, 279-84	163
2068	Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. 2002 , 37, 813-21	49
2067	The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. 2002 , 32, 1264-75	223
2066	Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. 2002 , 33, 1693-702	290
2065	Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. 2002 , 114, 574-7	58
2064	Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. 2002 , 70, 599-610	50
2063	Neuroplasticity in Alzheimer's disease. 2002 , 70, 402-37	87
2062	Inflammatory processes in amyotrophic lateral sclerosis. 2002 , 26, 459-70	411
2061	Exploring the formation of Alzheimer's disease senile plaques in silico. 2002 , 216, 301-26	46

2060	Neuroinflammation in Alzheimer's disease and prion disease. 2002 , 40, 232-9	366
2059	Role of p38 and p44/42 mitogen-activated protein kinases in microglia. 2002 , 40, 175-83	245
2058	Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. 2002 , 40, 260-9	311
2057	Microglia as neuroprotective, immunocompetent cells of the CNS. 2002 , 40, 133-9	751
2056	Microglia as a source and target of cytokines. 2002 , 40, 140-55	1250
2055	Immunization for Alzheimer's disease. 2002 , 56, 135-142	8
2054	Targeting APP metabolism for the treatment of Alzheimer's disease. 2002 , 56, 211-227	13
2053	Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease. 2002 , 56, 415-420	2
2052	Development of antiinflammatory therapy for Alzheimer's disease. 2002 , 56, 421-427	4
2051	Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses. 2002 , 19, 89-93	8
2050	Natural product extracts that reduce accumulation of the Alzheimer's amyloid beta peptide: selective reduction in A beta42. 2002 , 19, 129-33	14
2049	Statin therapy for Alzheimer's disease: will it work?. 2002 , 19, 155-61	140
2048	Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. 2002 , 54, 82-6	169
2047	CSF markers related to pathogenetic mechanisms in Alzheimer's disease. 2002 , 109, 1491-8	26
2046	Gene dose-dependent association of interleukin-1A [-889] allele 2 polymorphism with Alzheimer's disease. 2002 , 249, 1242-5	36
2045	Brain cytokines and disease. 2002 , 14, 262-78	11
2044	Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures. 2002 , 82, 1388-97	25
2043	Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. 2002 , 82, 1311-29	228

2042	Selective inhibition of Abeta42 production by NSAID R-enantiomers. 2002 , 83, 1009-12	137
2041	Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. 2002 , 83, 973-83	266
2040	Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. 2002 , 50, 2041-56	481
2039	Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. 2002 , 32, 360-71	199
2038	Inflammation and therapeutic vaccination in CNS diseases. 2002 , 420, 879-84	218
2037	Inflammation takes on Alzheimer disease. 2002 , 8, 936-8	39
2036	Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. 2002 , 962, 360-71	90
2035	Psychoneuroimmunology: new avenues of research for the twenty-first century. 2002 , 966, 400-8	25
2034	Possible involvement of ER chaperone Grp78 on reduced formation of amyloid-beta deposits. 2002 , 977, 327-32	17
2033	Possible protective mechanisms of heme oxygenase-1 in the brain. 2002 , 977, 501-6	12
2032	Local neuroinflammation and the progression of Alzheimer's disease. 2002 , 8, 529-38	204
2031	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. 2002 , 1, 1-31	147
2030	Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. 2003 , 20, 395-406	40
2029	Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression. 2003 , 20, 411-23	7
2028	Mechanisms of Abeta clearance and catabolism. 2003 , 4, 147-60	26
2027	Fas ligand-mediated apoptosis in degenerative disorders of the brain. 2003 , 23, 363-70	17
2026	Content of autoantibodies to bradykinin and beta-amyloid(1-42) as a criterion for biochemical differences between Alzheimer's dementias. 2003 , 136, 49-52	9
2025	Fas ligand-mediated apoptosis in degenerative disorders of the brain. 2003 , 23, 439-46	38

2024	A role for NOX NADPH oxidases in Alzheimer's disease and other types of dementia?. 2003 , 55, 307-13	91
2023	Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. 2003 , 25, 611-6	94
2022	Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. 2003 , 5, 385-98	33
2021	The vitamin-E analog trolox and the NMDA antagonist MK-801 protect pyramidal neurons in hippocampal slice cultures from IL-1beta-induced neurodegeneration. 2003 , 5, 433-42	19
2020	Protein misfolding and disease: the case of prion disorders. 2003 , 60, 133-43	48
2019	Induction of MC-1 immunoreactivity in axons after injection of the Fc fragment of human immunoglobulins in macaque monkeys. 2003 , 105, 58-64	8
2018	Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. 2003 , 105, 135-44	103
2017	Cytokine immunoreactivity in cortical and subcortical neurons in periventricular leukomalacia: are cytokines implicated in neuronal dysfunction in cerebral palsy?. 2003 , 105, 209-16	85
2016	Treatment of Alzheimer's disease: current status and new perspectives. 2003 , 2, 539-47	590
2015	Caloric restriction: life span extension and retardation of brain aging. 2003 , 2, 279-284	17
2014	Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. 2003 , 65, 1027-34	34
2013	Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice. 2003 , 977, 16-22	64
2012	Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. 2003 , 97, 35-53	51
2011	Activation of microglia: a neuroinflammatory role for CAP37. 2003 , 41, 64-72	29
2010	Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors. 2003 , 41, 191-8	59
2009	Astrocytic ceruloplasmin expression, which is induced by IL-1beta and by traumatic brain injury, increases in the absence of the IL-1 type 1 receptor. 2003 , 44, 76-84	37
2008	Effects of tumor necrosis factor-alpha central administration on hippocampal damage in rat induced by amyloid beta-peptide (25-35). 2003 , 71, 110-20	41
2007	Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. 2003 , 18, 1385-6	34

2006	Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. 2003 , 23, 48-88	71
2005	Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. 2003 , 54, 599-604	345
2004	Alzheimer vaccine: amyloid-beta on trial. 2003 , 25, 283-8	22
2003	Treatment of mild cognitive impairment: rationale, present and future strategies. 2003 , 179, 83-93	14
2002	New developments in dementia. 2003 , 107, 237-8	1
2001	Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. 2003 , 35, 80-4	96
2000	Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. 2003 , 85, 387-98	117
1999	Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. 2003 , 86, 907-16	43
1998	Tumour necrosis factor-alpha- vs. growth factor deprivation-promoted cell death: different receptor requirements for mediating nerve growth factor-promoted rescue. 2003 , 2, 83-92	10
1997	Tumour necrosis factor-alpha- vs. growth factor deprivation-promoted cell death: distinct converging pathways. 2003 , 2, 245-56	21
1996	Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure. 2003 , 51, 572-3	2
1995	Decrease of functional or cognitive capacity explains the lack of eye examination in visually impaired older persons. 2003 , 51, 573-4	2
1994	What is a geriatric syndrome anyway?. 2003 , 51, 574-6	88
1993	Dance/Movement Therapeutic methods in management of dementia. 2003 , 51, 576-7	21
1992	Possible model for successful care: burden of caregivers of centenarians. 2003 , 51, 577-8	6
1991	Interleukin-6-174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. 2003 , 51, 578-9	50
1990	Deep vein thrombosis in older patients. 2003 , 51, 579	1
1989	Lyme neuroborreliosis revealed as a normal pressure hydrocephalus: a cause of reversible dementia. 2003 , 51, 579-80	9

1988	The relationship between health and type of fracture in persons aged 65 and older. 2003 , 51, 580-2	0
1987	Satisfaction with primary care providers of older adults living in senior housing. 2003 , 51, 582-3	
1986	Cross-linked fibrin degradation products (D-dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. 2003 , 51, 1374-81	43
1985	Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies. 2003 , 23, 9-15	49
1984	Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. 2004 , 88, 337-48	76
1983	Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. 2003 , 139, 775-86	178
1982	Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. 2003 , 4, 234-8	111
1981	The impact of systemic infection on the progression of neurodegenerative disease. 2003 , 4, 103-12	341
1980	Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. 2003 , 992, 56-71	193
1979	Clinically tested drugs for Alzheimer's disease. 2003 , 12, 1143-51	20
1978	Degradation of beta-amyloid by proteolytic antibody light chains. 2003 , 42, 14328-34	59
1977	Humoral immune response to fibrillar beta-amyloid peptide. 2003 , 42, 11682-92	30
1976	Elevated levels of tumor necrosis factor alpha and mortality in centenarians. 2003 , 115, 278-83	230
1975	Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. 2003 , 278, 31831-7	226
1974	NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. 2003 , 112, 440-9	382
1973	Necrosis: a specific form of programmed cell death?. 2003 , 283, 1-16	517
1972	Inflammatory processes in Alzheimer's disease. 2003 , 27, 741-9	372
1971	No association between Glu298Asp endothelial nitric oxide synthase polymorphism and Italian sporadic Alzheimer's disease. 2003 , 341, 229-32	25

1970	Tumor necrosis factor alpha polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population. 2003 , 344, 135-7		22
1969	Heat shock protein-90-induced microglial clearance of exogenous amyloid-beta1-42 in rat hippocampus in vivo. 2003 , 344, 87-90		35
1968	Telomere shortening in T cells correlates with Alzheimer's disease status. <i>Neurobiology of Aging</i> , 2003 , 24, 77-84	5.6	332
1967	Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. <i>Neurobiology of Aging</i> , 2003 , 24, 553-61	5.6	78
1966	Is there a future for vaccination as a treatment for Alzheimer's disease?. <i>Neurobiology of Aging</i> , 2003 , 24, 391-5	5.6	34
1965	Differential effects of estrogen in the injured forebrain of young adult and reproductive senescent animals. <i>Neurobiology of Aging</i> , 2003 , 24, 733-43	5.6	73
1964	Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003 , 24, 521-36	5.6	208
1963	Peripheral cytokine release in Alzheimer patients: correlation with disease severity. <i>Neurobiology of Aging</i> , 2003 , 24, 909-14	5.6	61
1962	Dose-dependent effect of MK-801 on the levels of neuropeptides processing enzymes in rat brain regions. 2003 , 47, 177-89		15
1961	Hypothermia suppresses inducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells. 2003 , 110, 63-75		41
1960	The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. 2003 , 117, 909-19		69
1959	Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. 2003 , 119, 1185-97		32
1958	The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. 2003 , 121, 719-29		48
1957	Aluminum disrupts the pro-inflammatory cytokine/neurotrophin balance in primary brain rotation-mediated aggregate cultures: possible role in neurodegeneration. 2003 , 24, 261-8		52
1956	Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. 2003 , 43, 1-16		233
1955	Cerebrovascular requirement for sealant, anti-coagulant and remodeling molecules that allow for the maintenance of vascular integrity and blood supply. 2003 , 43, 164-78		38
1954	Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. 2003 , 5, 67-73		91
1953	Astrocytes: a cellular player in Abeta clearance and degradation. 2003 , 9, 279-80		50

1952	Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies. 2003 , 12, 121-32	63
1951	Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. 2003 , 14, 52-62	99
1950	Age-related inflammatory cytokines and disease. 2003 , 23, 15-39	419
1949	Immunologic and inflammatory mediators and cognitive decline in Alzheimer's disease. 2003 , 23, 103-15	8
1948	The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. 2003 , 17, 27-45	295
1947	Developments in Tryptophan and Serotonin Metabolism. 2003 ,	5
1946	Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. 2003 , 20, 399-418	26
1945	Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. 2003 , 112, 415-422	221
1944	Allele frequencies of +874T --> A single nucleotide polymorphism at the first intron of IFN-gamma gene in Alzheimer's disease patients. 2003 , 15, 292-5	11
1943	Highly Cited Papers in the Journals. 2003 , 58, M1098-M1102	
1942	Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. 2003 , 63, 690-8	31
1941	Intrathecal inflammation precedes development of Alzheimer's disease. 2003 , 74, 1200-5	295
1940	Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. 2003 , 73, 369-78	32
1939	Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. 2003 , 170, 5281-94	102
1938	Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. 2003 , 278, 18664-70	155
1937	Immunotherapeutic approaches to Alzheimer's disease. 2003 , 302, 834-8	253
1936	Alzheimer's disease: from molecular pathogenesis to innovative therapies. 2003 , 3, 619-30	7
1935	Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. 2003 , 278, 30748-54	105

1934	IL-4 down-regulates lipopolysaccharide-induced formyl peptide receptor 2 in murine microglial cells by inhibiting the activation of mitogen-activated protein kinases. 2003 , 171, 5482-8	26
1933	P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. 2003 , 278, 13309-17	367
1932	Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. 2003 , 170, 5764-71	61
1931	The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. 2003 , 278, 31825-30	63
1930	Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. 2003 , 60, 1591-7	43
1929	Interaction of atherosclerosis and inflammation in elderly subjects with poor cognitive function. 2003 , 61, 1695-701	58
1928	Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. 2003 , 289, 2819-26	693
1927	Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson's patients. 2003 , 12, 485	2
1926	Genetics of neurodegenerative disorders. 2003 , 349, 193-4; author reply 193-4	9
1925	Cerebrospinal fluid and serum antimicroglial antibodies: prospects for early diagnosis of Alzheimer's disease. 2003 , 3, 247-57	3
1924	Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. 2003 , 171, 2216-24	82
1923	Human immunoglobulins and Fc fragments promote microtubule assembly via tau proteins and induce conformational changes of neuronal microtubules in vitro. 2003 , 14, 117-21	8
1922	Scintigraphic visualization of inflammation in neurodegenerative disorders. 2003 , 24, 209-21	7
1921	A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. 2003 , 14, 2311-5	104
1920	A dietary supplement abolishes age-related cognitive decline in transgenic mice expressing elevated free radical processes. 2003 , 228, 800-10	37
1919	Possible involvement of small oligomers of amyloid-beta peptides in 15-deoxy-delta 12,14 prostaglandin J2-sensitive microglial activation. 2003 , 91, 330-3	28
1918	Deposition of Alpha2-Macroglobulin in Fibrillar Type of Senile Plaques in the Brain of PS/APP-Transgenic Mice.. 2003 , 36, 215-220	1
1917	Aluminum and copper interact in the promotion of oxidative but not inflammatory events: implications for Alzheimer's disease. 2003 , 5, 31-8	60

1916	Association of emphysema, gout, and inflammatory markers with long-term incidence of age-related maculopathy. 2003 , 121, 674-8	52
1915	Vitamin E (alpha-tocopherol) attenuates cyclo-oxygenase 2 transcription and synthesis in immortalized murine BV-2 microglia. 2003 , 370, 459-67	63
1914	Involvement of Wiskott-Aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of amyloid-beta(1-42) in rat microglia. 2003 , 92, 115-23	31
1913	A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. 2003 , 23, 2665-74	433
1912	Demenz. 2003 , 882-940	
1911	Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. 2003 , 23, 9796-804	303
1910	Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. 2003 , 23, 7504-9	424
1909	Neuronal induction of the immunoproteasome in Huntington's disease. 2003 , 23, 11653-61	218
1908	NSAIDs in the Treatment of Alzheimer's Disease. 487-491	
1907	Injured brain endothelial cells release neurotoxic thrombin. 2004 , 6, 275-81	28
1906	Alzheimer disease: mechanistic understanding predicts novel therapies. 2004 , 140, 627-38	206
1905	Identification of cathepsin B as a mediator of neuronal death induced by Abeta-activated microglial cells using a functional genomics approach. 2004 , 279, 5565-72	104
1904	Future directions in the treatment of Alzheimer's disease. 2004 , 13, 303-14	21
1903	Immunosenescence. 2004 , 9-21	
1902	Hormone therapy and Alzheimer's disease: benefit or harm?. 2004 , 5, 389-406	32
1901	Alzheimer's disease and immunotherapy. 2004 , 1, 149-63	26
1900	Immunotherapy for Alzheimer's disease. 2004 , 101 Suppl 2, 14657-62	142
1899	Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. 2004 , 10, 1009-13	62

1898	The marine toxin dinophysistoxin-2 induces differential apoptotic death of rat cerebellar neurons and astrocytes. 2004 , 80, 74-82	18
1897	In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. 2004 , 18, 179-82	74
1896	The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. 2004 , 18, 1297-9	186
1895	Alzheimer's disease: one disorder, too many genes?. 2004 , 13 Spec No 1, R135-41	134
1894	Current concepts in the pathogenesis of age-related macular degeneration. 2004 , 122, 598-614	836
1893	Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. 2004 , 45, 1247-58	187
1892	Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. 2004 , 24, 6457-65	232
1891	The top 10 hot topics in aging. 2004 , 59, 24-33	48
1890	Neurobiological Consequences of Long-Term Estrogen Therapy. 2004 , 13, 173-176	3
1889	Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. 2004 , 279, 46907-14	120
1888	Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. 2004 , 61, 668-72	563
1887	Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. 2004 , 279, 48238-45	53
1886	Serum levels of soluble intercellular adhesion molecule-1 and soluble endothelial leukocyte adhesion molecule-1 in Alzheimer's disease. 2004 , 17, 225-31	31
1885	Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. 2004 , 26, 563-6	92
1884	Vascular inflammatory, oxidative and protease-based processes: implications for neuronal cell death in Alzheimer's disease. 2004 , 26, 540-6	36
1883	Association between C-reactive protein and age-related macular degeneration. 2004 , 291, 704-10	310
1882	TGF-beta1 disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. 2004 , 173, 962-8	50
1881	Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor. 2004 , 172, 7078-85	166

1880	Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. 2004 , 24, 6049-56	168
1879	Tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. 2004 , 279, 49523-32	247
1878	Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. 2004 , 173, 4708-14	88
1877	Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. 2004 , 279, 37061-8	220
1876	Utilizing combination therapy in the treatment of Alzheimer's disease. 2004 , 4, 799-808	15
1875	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. 2004 , 42, 64-73	6
1874	Polymorphisms of the macrophage inhibitory factor and C-reactive protein genes in subjects with Alzheimer's dementia. 2004 , 18, 261-4	11
1873	1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility. 2004 , 42, 1-53	19
1872	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. 2004 , 42, 64-73	
1871	Aluminum-maltolate induces apoptosis and necrosis in neuro-2a cells: potential role for p53 signaling. 2005 , 83, 329-39	66
1870	Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. 2004 , 62, 1148-55	348
1869	Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-beta exposure. 2004 , 88, 604-11	48
1868	Macrophage colony stimulatory factor and interferon-gamma trigger distinct mechanisms for augmentation of beta-amyloid-induced microglia-mediated neurotoxicity. 2004 , 91, 623-33	33
1867	Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. 2004 , 91, 1199-210	99
1866	How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. 2004 , 3, 169-76	270
1865	Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. 2004 , 11, 1009-16	199
1864	Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis. 2004 , 20, 811-7	47
1863	Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. 2004 , 89, 484-93	72

1862	S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity. 2004 , 152, 73-7	23
1861	Differences in the amyloid-beta-induced inflammatory response in microglia from C57BL/6 and A/J strains of mice. 2004 , 153, 26-35	4
1860	Cat exposure induces both intra- and extracellular Hsp72: the role of adrenal hormones. 2004 , 29, 1142-52	107
1859	Biomarkers in non-Alzheimer dementias. 2004 , 3, 375-381	2
1858	Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal. 2004 , 39, 645-52	27
1857	Inflammatory mediators in the elderly. 2004 , 39, 687-99	701
1856	Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. 2004 , 39, 1661-7	50
1855	CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease. 2004 , 36, 1018-24	47
1854	Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. 2004 , 23, 151-5	12
1853	A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. 2004 , 23, 205-12	110
1852	Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. 2004 , 24, 115-22	25
1851	Alcohol, wine and mental health: focus on dementia and stroke. 2004 , 18, 449-56	36
1850	Microglia. 2004 , 19, 393-411	201
1849	Altered hippocampal transcript profile accompanies an age-related spatial memory deficit in mice. 2004 , 11, 253-60	121
1848	NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. 2004 , 1035, 68-84	103
1847	Microglia as a potential bridge between the amyloid beta-peptide and tau. 2004 , 1035, 85-103	104
1846	Inflammation and the degenerative diseases of aging. 2004 , 1035, 104-16	363
1845	Activation of vascular endothelial cells and perivascular cells by systemic inflammation-an immunohistochemical study of postmortem human brain tissues. 2004 , 107, 341-51	38

1844	Gene-gene interaction between interleukin-1A and interleukin-8 increases Alzheimer's disease risk. 2004 , 251, 482-3	18
1843	Factors associated with pre-stroke dementia: the cracow stroke database. 2004 , 251, 599-603	26
1842	Neuroinflammatory perspectives on the two faces of Alzheimer's disease. 2004 , 111, 281-94	151
1841	Common patterns of bcl-2 family gene expression in two traumatic brain injury models. 2004 , 6, 333-42	26
1840	Nutrition, différences vasculaires et maladie d'Alzheimer. 2004 , 18, 181-188	1
1839	The influence of brain inflammation upon neuronal adenosine A2B receptors. 2003 , 86, 220-7	38
1838	Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. 2004 , 56, 61-7	55
1837	Anti-Abeta: The good, the bad, and the unforeseen. 2004 , 75, 301-6	31
1836	Microglia and Alzheimer's disease pathogenesis. 2004 , 77, 1-8	255
1835	Interleukin-1: a master regulator of neuroinflammation. 2004 , 78, 151-6	263
1834	High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. 2004 , 78, 880-91	64
1833	Tools for anti-inflammatory drug design: in vitro models of leukocyte migration. 2004 , 24, 276-98	25
1832	Alzheimer's disease and immune activation: A translational perspective. 2004 , 35, 193-201	
1831	Synthesis and pharmacological evaluation of amide conjugates of NSAIDs with L-cysteine ethyl ester, combining potent antiinflammatory and antioxidant properties with significantly reduced gastrointestinal toxicity. 2004 , 14, 3639-43	64
1830	Association between tumor necrosis factor-alpha promoter polymorphism and Alzheimer's disease. 2004 , 62, 307-9	30
1829	Biomarkers in non-Alzheimer dementias. 2004 ,	
1828	Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model. 2004 ,	
1827	The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. 2004 ,	

1826	Meat-adaptive genes and the evolution of slower aging in humans. 2004 , 79, 3-50	146
1825	The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. 2004 , 50, 397-409	136
1824	Welcome to the Journal of Neuroinflammation!. 2004 , 1, 1	11
1823	Modelling neuroinflammatory phenotypes in vivo. 2004 , 1, 10	53
1822	Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors. 2004 , 1, 12	71
1821	Microglia and neuroinflammation: a pathological perspective. 2004 , 1, 14	664
1820	Using animal models to determine the significance of complement activation in Alzheimer's disease. 2004 , 1, 18	13
1819	Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide. 2004 , 1, 2	145
1818	Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. 2004 , 1, 21	64
1817	Inflammatory processes and Alzheimer's disease. 2004 , 4, 793-8	20
1816	Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. 2004 , 5, 213-9	148
1815	Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. 2004 , 23, 159-69	318
1814	Noradrenergic mechanisms in neurodegenerative diseases: a theory. 2004 , 45, 38-78	319
1813	Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. 2004 , 185, 241-53	27
1812	Neuroinflammation, COX-2, and ALS--a dual role?. 2004 , 187, 1-10	120
1811	Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. 2004 , 190, 245-53	124
1810	Molecular regulation of CD40 gene expression in macrophages and microglia. 2004 , 18, 7-12	92
1809	Cytokines and the aging brain - what we don't know might help us. 2004 , 27, 621-6	95

1808	Lymphocytes as a neural probe: potential for studying psychiatric disorders. 2004 , 28, 559-76		280
1807	Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. <i>Neurobiology of Aging</i> , 2004 , 25, 1153-67	5.6	64
1806	Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. <i>Neurobiology of Aging</i> , 2004 , 25, 1283-92	5.6	85
1805	The presence of the APP(swe) mutation in mice does not increase the vulnerability of cholinergic basal forebrain neurons to neuroinflammation. 2004 , 125, 769-76		10
1804	Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model. 2004 , 126, 639-49		23
1803	Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. 2004 , 165, 1643-52		147
1802	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. 2004 , 4, 1307-18		88
1801	Neuronal localization of C1q in preclinical Alzheimer's disease. 2004 , 15, 40-6		60
1800	Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. 2004 , 15, 11-20		166
1799	Paraoxonase 1 gene polymorphisms and dementia in humans. 2004 , 358, 41-4		29
1798	Interleukin 1alpha and interleukin 6 protect human neuronal SH-SY5Y cells from oxidative damage. 2004 , 361, 40-3		35
1797	The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease. 2004 , 366, 312-4		24
1796	Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. <i>Neurobiology of Aging</i> , 2004 , 25, 861-71	5.6	100
1795	Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 1009-15	5.6	118
1794	CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004 , 25, 991-9	5.6	66
1793	Caloric restriction, gene expression and aging. 2004 , 1260, 13-20		3
1792	Microglial activation around amyloid- β deposits in mouse and rat models. 2004 , 1260, 265-269		
1791	Clearance of amyloid- β in microglial culture model. 2004 , 1260, 271-274		

1790	Non-steroidal anti-inflammatory drugs protect amyloid beta protein-induced increase in the intracellular Cl ⁻ concentration in cultured rat hippocampal neurons. 2004 , 367, 156-9		10
1789	Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. <i>Neurobiology of Aging</i> , 2004 , 25, 315-24	5.6	73
1788	Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. <i>Neurobiology of Aging</i> , 2004 , 25, 431-9	5.6	192
1787	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. 2004 , 363, 1139-46		431
1786	Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat. 2004 , 17, 317-30		31
1785	Methods of Regulating Alzheimer Pathogenesis: Diet, Oxidative Damage and Inflammation. 2004 , 1-16		
1784	Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. 2004 , 6, 147-57		116
1783	The Clinical Importance of Proinflammatory Cytokines in Elderly Populations. 2004 , 4, 383-395		1
1782	Rosiglitazone improves contextual fear conditioning in aged rats. 2004 , 15, 2255-9		21
1781	Current concepts and future prospects for Alzheimer disease vaccines. 2004 , 18, 38-43		21
1780	Alcohol, wine and mental health: focus on dementia and stroke. 2004 , 18, 449-456		37
1779	Pathogenesis of Alzheimer Disease: Metabolic Factors. 2004 , 303-353		
1778	Stress and dementia. 2005 , 357-370		2
1777	Strategies to reduce the risk of cognitive decline and dementia. 2005 , 1, 107-116		10
1776	A population study of Alzheimer's disease: findings from the Cache County Study on Memory, Health, and Aging. 2005 , 6, 107-14		22
1775	Complement activation in very early Alzheimer disease. 2005 , 19, 55-66		88
1774	Role of microglia in the central nervous system's immune response. 2005 , 27, 685-91		193
1773	Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. 2005 , 36, 2637-41		151

1772	Association between dementia and infectious disease: evidence from a case-control study. 2005 , 19, 91-4	132
1771	Role of inflammation in neurodegenerative diseases. 2005 , 18, 315-21	258
1770	Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. 2005 , 7, 221-32; discussion 255-62	235
1769	Alzheimer's Disease: Current and Future Treatments. 2005 , 329-354	1
1768	Statins and cognition: what can we learn from existing randomized trials?. 2005 , 10, 867-74	21
1767	Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. 2005 , 62, 1539-44	153
1766	Omega 3 fatty acid for the prevention of dementia. 2005 ,	1
1765	Human Cytokine Response to ex vivo Amyloid- β Stimulation is Mediated by Genetic Factors. 2005 , 8, 132-137	12
1764	Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. 2005 , 391, 693-8	75
1763	Estrogen: a neuroprotective or proinflammatory hormone? Emerging evidence from reproductive aging models. 2005 , 1052, 75-90	32
1762	Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. 2005 , 27, 1-12	62
1761	S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. 2005 , 92, 546-53	75
1760	Peripheral injection of lipopolysaccharide enhances expression of inflammatory cytokines in murine locus coeruleus: possible role of increased norepinephrine turnover. 2005 , 94, 393-404	27
1759	Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. 2005 , 22, 2199-206	107
1758	Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. 2005 , 22, 2827-32	115
1757	Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype. 2005 , 31, 589-99	40
1756	Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. 2005 , 31, 395-404	234
1755	Amyloid beta peptide causes chronic glial cell activation and neuro-degeneration after intravitreal injection. 2005 , 31, 491-502	33

1754	Statins--a cure-all for the brain?. 2005 , 6, 325-31	94
1753	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. 2005 , 11, 545-50	254
1752	Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. 2005 , 90, 663-70	310
1751	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. 2005 , 86, 173-85	41
1750	Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. 2005 , 40, 165-71	76
1749	Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. 2005 , 40, 605-11	37
1748	Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. 2005 , 38, 1604-13	92
1747	IL-8 enhancement of amyloid-beta (Abeta 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. 2005 , 159, 66-74	72
1746	Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). 2005 , 159, 215-24	108
1745	Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease?. 2005 , 39, 535-43	69
1744	Roles of Ca ²⁺ and the Ca ²⁺ -sensing receptor (CASR) in the expression of inducible NOS (nitric oxide synthase)-2 and its BH ₄ (tetrahydrobiopterin)-dependent activation in cytokine-stimulated adult human astrocytes. 2005 , 96, 428-38	38
1743	Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity. 2005 , 51, 56-64	17
1742	Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human beta-amyloid. 2005 , 51, 209-16	44
1741	Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. 2005 , 51, 199-208	112
1740	Association studies of transforming growth factor-beta 1 and Alzheimer's disease. 2005 , 139B, 38-41	18
1739	Norepinephrine protects cortical neurons against microglial-induced cell death. 2005 , 81, 390-6	60
1738	Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. 2005 , 81, 412-25	73
1737	Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. 2005 , 81, 426-35	57

1736	Chromosome 13 dementias. 2005 , 62, 1814-25	51
1735	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. 2005 , 255, 269-78	50
1734	Neural plasticity: changes with age. 2005 , 112, 3-27	17
1733	Alzheimer's associated inflammation, potential drug targets and future therapies. 2005 , 112, 429-53	82
1732	The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer's disease. 2005 , 7, 125-41	27
1731	Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone. 2005 , 8, 267-76	36
1730	Pro- and anti-inflammatory cytokines regulate the ERK pathway: implication of the timing for the activation of microglial cells. 2005 , 8, 277-87	38
1729	Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade. 2005 , 1, 111-34	383
1728	Heparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia. 2005 , 2, 11	13
1727	Innate immunity and inflammation in ageing: a key for understanding age-related diseases. 2005 , 2, 8	323
1726	Associations of cortical astrogliosis with cognitive performance and dementia status. 2004 , 6, 595-604; discussion 673-81	65
1725	Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia. 2005 , 7, 25-35	32
1724	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. 2005 , 445-458	2
1723	Complement in Health and Disease. 2005 , 144-157	
1722	Predicting Alzheimer's disease in the Baltimore longitudinal study of aging. 2005 , 18, 192-5	7
1721	Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. 2005 , 62, 217-24	254
1720	Serum C-reactive protein and cognitive function in healthy elderly Italian community dwellers. 2005 , 60, 1017-21	39
1719	The dualistic nature of immune modulation in Alzheimer's disease: lessons from the transgenic models. 2005 , 11, 3335-52	3

1718	Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists. 2005 , 2, 187-9	21
1717	An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. 2005 , 60, 556-65	297
1716	Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. 2005 , 2, 355-65	124
1715	Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. 2005 , 2, 197-205	15
1714	Mechanisms of cell signaling and inflammation in Alzheimer's disease. 2005 , 4, 247-56	136
1713	CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2. 2005 , 19, 2032-4	72
1712	Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. 2005 , 25, 11165-74	132
1711	IL-4 inhibits the expression of mouse formyl peptide receptor 2, a receptor for amyloid beta1-42, in TNF-alpha-activated microglia. 2005 , 175, 6100-6	31
1710	Proteins in human brain cortex are modified by oxidation, glycooxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. 2005 , 280, 21522-30	208
1709	Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. 2005 , 102, 3070-5	83
1708	Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. 2005 , 25, 11125-32	148
1707	Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy. 2005 , 76, 696-9	28
1706	Physical activity and modulation of systemic low-level inflammation. 2005 , 78, 819-35	268
1705	Evidence that immunoglobulin-positive neurons in Alzheimer's disease are dying via the classical antibody-dependent complement pathway. 2005 , 20, 144-50	27
1704	Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. 2005 , 25, 2566-75	197
1703	A potential role of the curry spice curcumin in Alzheimer's disease. 2005 , 2, 131-6	386
1702	Biochemical markers and risk factors of Alzheimer's disease. 2005 , 2, 47-64	55
1701	Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: II. Effects of triflusal. 2005 , 36, 1782-9	30

1700	The amyloid-beta peptide suppresses transforming growth factor-beta1-induced matrix metalloproteinase-2 production via Smad7 expression in human monocytic THP-1 cells. 2005 , 280, 7845-53	34
1699	Drug Insight: using statins to treat neuroinflammatory disease. 2005 , 1, 106-12	27
1698	Vascular Dementia. 2005 ,	2
1697	Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. 2005 , 25, 10180-7	202
1696	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. 2005 , 25, 299-307	152
1695	The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. 2005 , 25, 7805-12	175
1694	Neuroinflammation alters the hippocampal pattern of behaviorally induced Arc expression. 2005 , 25, 723-31	109
1693	Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. 2005 , 25, 4082-90	135
1692	SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. 2005 , 280, 40364-74	569
1691	Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. 2005 , 19, 1899-901	153
1690	Amyloid Beta and the Cerebral Vasculature. 2005 , 267-273	
1689	Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. 2005 , 128, 1442-53	455
1688	Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer's disease patients. 2005 , 19, 106-12	26
1687	Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. 2005 , 25, 8843-53	514
1686	Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. 2005 , 25, 1149-58	178
1685	Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. 2005 , 25, 8240-9	362
1684	A complex dietary supplement extends longevity of mice. 2005 , 60, 275-9	23
1683	A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. 2005 , 102, 7227-32	1638

1682	Mechanisms of statin-mediated inhibition of small G-protein function. 2005 , 280, 34202-9	179
1681	Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment?. 2005 , 1, 20-1	2
1680	β -Amyloid and interleukin-1 β induce persistent NF- κ B activation in rat primary glial cells. 2005 , 16, 449	3
1679	Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. 2005 , 64, 743-53	144
1678	Effect of steroidal and non-steroidal drugs on the microglia activation pattern and the course of degeneration in the retinal degeneration slow mouse. 2005 , 37, 72-82	7
1677	Heat shock protein 70 and tumor necrosis factor alpha in Taiwanese patients with dementia. 2005 , 20, 1-7	17
1676	Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation. 2005 , 2, 6-15	32
1675	Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. 2005 , 123, 1501-6	48
1674	Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: inflammatory responses. 2005 , 36, 107-12	69
1673	Ibuprofen suppresses interleukin-1 β induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (A β) pathology in Alzheimer's models. 2005 , 30, 1111-20	90
1672	Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease. 2005 , 110, 393-401	67
1671	Site-specific nitration differentially influences tau assembly in vitro. 2005 , 44, 13997-4009	83
1670	Oxidative stress in Alzheimer's disease: implications for prevention and therapy. 2005 , 38, 65-78	67
1669	Refining an Alzheimer's vaccine to avoid an inflammatory response. 2005 , 5, 809-16	5
1668	Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. 2005 , 25, 1904-13	567
1667	COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. 2005 , 19, 805-19	29
1666	Clinical aspects of inflammation in Alzheimer's disease. 2005 , 17, 503-14	97
1665	Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. 2005 , 19, 1592-601	171

1664	Cytokines and Brain. 2005 , 41-80	0
1663	Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. 2005 , 352, 282-98	260
1662	Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. 2005 , 18, 134-42	246
1661	Antibody-bound beta-amyloid precursor protein stimulates the production of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 by cortical neurons. 2005 , 19, 129-41	13
1660	Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. 2005 , 18, 459-65	181
1659	Protection of rat primary hippocampal cultures from A beta cytotoxicity by pro-inflammatory molecules is mediated by astrocytes. 2005 , 19, 243-54	49
1658	Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. 2005 , 20, 858-70	95
1657	Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease. 2005 , 46, 551-7	42
1656	The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. 2005 , 382, 300-3	25
1655	C3a expressed in the central nervous system protects against LPS-induced shock. 2005 , 387, 68-71	45
1654	Macrosialin increases during normal brain aging are attenuated by caloric restriction. 2005 , 390, 76-80	55
1653	Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. 2005 , 390, 134-8	25
1652	Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. 2005 , 29, 381-93	284
1651	The role of inflammation in Alzheimer's disease. 2005 , 37, 289-305	547
1650	The neuroprotective efficacy of alpha-crystallin against acute inflammation in mice. 2005 , 67, 235-41	30
1649	Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. 2005 , 48, 16-42	371
1648	Humoral immunity in brain aging and Alzheimer's disease. 2005 , 48, 477-87	51
1647	Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. 2005 , 48, 240-50	115

1646	Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. 2005 , 48, 251-6		132
1645	Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. 2005 , 48, 400-8		58
1644	Decrease in brain serotonin level and short term memory loss in mice: a preliminary study. 2005 , 19, 367-70		4
1643	Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response. 2005 , 194, 31-42		26
1642	Amyloid-beta peptides induce cell proliferation and macrophage colony-stimulating factor expression via the PI3-kinase/Akt pathway in cultured Ra2 microglial cells. 2005 , 579, 1995-2000		23
1641	Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration. 2005 , 166, 241-51		162
1640	Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. 2005 , 166, 1163-72		108
1639	HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?. 2005 , 50, 194-206		45
1638	Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. <i>Neurobiology of Aging</i> , 2005 , 26, 9-16	5.6	63
1637	Developmental origins of aging in brain and blood vessels: an overview. <i>Neurobiology of Aging</i> , 2005 , 26, 281-91	5.6	58
1636	Human monoclonal antibodies against amyloid-beta from healthy adults. <i>Neurobiology of Aging</i> , 2005 , 26, 597-606	5.6	46
1635	Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. <i>Neurobiology of Aging</i> , 2005 , 26, 673-82	5.6	43
1634	Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. <i>Neurobiology of Aging</i> , 2005 , 26, 789-94	5.6	33
1633	The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2005 , 26, 1005-10	5.6	76
1632	Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. <i>Neurobiology of Aging</i> , 2005 , 26, 995-1000	5.6	262
1631	Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. <i>Neurobiology of Aging</i> , 2005 , 26, 581-3	5.6	30
1630	Sparing of age-related macular degeneration in rheumatoid arthritis. <i>Neurobiology of Aging</i> , 2005 , 26, 1199-203	5.6	38
1629	Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. <i>Neurobiology of Aging</i> , 2005 , 26 Suppl 1, 133-6	5.6	167

1628	Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. 2005 , 49, 1088-99	111
1627	Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease. 2005 , 134, 671-6	45
1626	Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. 2005 , 135, 1295-307	300
1625	Differential regulation of Abeta42-induced neuronal C1q synthesis and microglial activation. 2005 , 2, 1	18
1624	Platelet-activating factor enhancement of calcium influx and interleukin-6 expression, but not production, in human microglia. 2005 , 2, 11	19
1623	Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. 2005 , 2, 15	67
1622	5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. 2005 , 2, 21	30
1621	Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. 2005 , 2, 22	206
1620	The microglial "activation" continuum: from innate to adaptive responses. 2005 , 2, 24	318
1619	Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. 2005 , 2, 27	40
1618	Ginger--an herbal medicinal product with broad anti-inflammatory actions. 2005 , 8, 125-32	384
1617	Neuroinflammation: a potential therapeutic target. 2005 , 9, 887-900	82
1616	The role of soluble intercellular adhesion molecules in neurodegenerative disorders. 2005 , 228, 129-35	39
1615	Post-stroke dementia is associated with alpha(1)-antichymotrypsin polymorphism. 2005 , 234, 31-6	20
1614	Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. 2005 , 25, 9275-84	570
1613	A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. 2005 , 25, 3032-40	555
1612	Interleukins, inflammation, and mechanisms of Alzheimer's disease. 2006 , 74, 505-30	62
1611	Alzheimer: 100 Years and Beyond. 2006 ,	5

1610	Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?. 2006 , 20, 85-98	18
1609	Current Topics in Complement. 2006 ,	1
1608	Prevention and Treatment of Age-related Diseases. 2006 ,	2
1607	Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. 2006 , 26, 10939-48	269
1606	Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. 2006 , 1757, 1371-87	464
1605	Disease-modifying therapies in Alzheimer's disease: how far have we come?. 2006 , 66, 2075-93	61
1604	Astrogliosis is delayed in type 1 interleukin-1 receptor-null mice following a penetrating brain injury. 2006 , 3, 15	44
1603	Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells. 2006 , 3, 18	20
1602	Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. 2006 , 3, 28	110
1601	The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. 2006 , 3, 30	158
1600	Replication of the association of HLA-B7 with Alzheimer's disease: a role for homozygosity?. 2006 , 3, 33	9
1599	Omega 3 fatty acid for the prevention of dementia. 2006 , CD005379	61
1598	Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. 2006 , 245, 21-33	74
1597	Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. 2006 , 249, 110-4	38
1596	Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. 2006 , 45, 4314-26	41
1595	Multiple, parallel cellular suicide mechanisms participate in photoreceptor cell death. 2006 , 83, 380-9	133
1594	Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. 2006 , 198, 552-7	52
1593	PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. 2006 , 199, 245-8	49

1592	Circulating biomarkers of cognitive decline and dementia. 2006 , 364, 91-112	106
1591	Molecular chaperone alpha-crystallin prevents detrimental effects of neuroinflammation. 2006 , 1762, 284-93	57
1590	Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. 2006 , 175, 352-61	13
1589	Seungma-galgeun-tang attenuates proinflammatory activities through the inhibition of NF-kappaB signal pathway in the BV-2 microglial cells. 2006 , 107, 59-66	12
1588	Facilitatory effect of aspirin on glutamate release from rat hippocampal nerve terminals: involvement of protein kinase C pathway. 2006 , 48, 181-90	17
1587	Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. 2006 , 49, 170-82	159
1586	Dissociation between hippocampal neuronal loss, astroglial and microglial reactivity after pharmacologically induced reverse glutamate transport. 2006 , 49, 691-7	9
1585	Increased oxidative-related mechanisms in the spinal cord injury in old rats. 2006 , 393, 141-6	30
1584	Magnetic resonance imaging using hemagglutinating virus of Japan-envelope vector successfully detects localization of intra-cardially administered microglia in normal mouse brain. 2006 , 395, 42-5	13
1583	Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. 2006 , 401, 219-24	119
1582	Polymorphisms in the interleukin 6 and transforming growth factor beta1 gene and risk of dementia. The Rotterdam Study. 2006 , 402, 113-7	38
1581	Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. 2006 , 404, 217-21	15
1580	Expression of C/EBPalpha and C/EBPbeta in glial cells in vitro after inducing glial activation by different stimuli. 2006 , 410, 25-30	22
1579	Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. 2006 , 54, 235-53	82
1578	Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. 2006 , 56, 294-9	39
1577	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. 2006 , 24, 157-65	117
1576	Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. 2006 , 24, 167-76	320
1575	Autocrine peptide mediators of cerebral endothelial cells and their role in the regulation of blood-brain barrier. 2006 , 27, 211-22	11

1574	Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006 , 27, 262-9	5.6	152
1573	The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. <i>Neurobiology of Aging</i> , 2006 , 27, 691-701	5.6	31
1572	Effect of aging on the microglial response to peripheral nerve injury. <i>Neurobiology of Aging</i> , 2006 , 27, 1451-61	5.6	66
1571	Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006 , 27, 1763-8	5.6	153
1570	The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. 2006 , 50, 606-13		39
1569	Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. 2006 , 142, 1303-15		127
1568	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. 2006 , 29, 518-27		289
1567	Dysfunction of TGF-beta signaling in Alzheimer's disease. 2006 , 116, 2855-7		37
1566	Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease. 2006 , 6, 21-34		20
1565	Current and emerging pharmacological treatment options for dementia. 2006 , 17, 5-16		50
1564	Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. 2006 , 9, 51-8		121
1563	Psychiatric Pathophysiology: Dementia. 2006 , 154-158		
1562	Alzheimer's disease, model systems and experimental therapeutics. 565-586		
1561	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. 2006 , 10, 399-406		85
1560	Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. 2006 , 17, 411-24		104
1559	Guarding the blood-brain barrier: a role for estrogen in the etiology of neurodegenerative disease. 2007 , 13, 311-9		25
1558	Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. 2006 , 65, 1090-7		181
1557	Neuroprotective and disease-modifying effects of the ketogenic diet. 2006 , 17, 431-9		310

1556	Alzheimer disease and its management: a review. 2006 , 13, 516-26	22
1555	Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. 2006 , 21, 319-36	71
1554	Usefulness of measuring serum markers in addition to comprehensive geriatric assessment for cognitive impairment and depressive mood in the elderly. 2006 , 6, 7-14	3
1553	Sporadic and familial cerebral amyloid angiopathies. 2002 , 12, 343-57	137
1552	Genetic alterations of the BRI2 gene: familial British and Danish dementias. 2006 , 16, 71-9	38
1551	Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. 2006 , 98, 34-44	15
1550	Disease modifying therapy for AD?. 2006 , 99, 689-707	105
1549	Trade-offs between longevity and pathogen resistance in <i>Drosophila melanogaster</i> are mediated by NFkappaB signaling. 2006 , 5, 533-43	112
1548	In vivo evidence for microglial activation in neurodegenerative dementia. 2006 , 185, 107-14	54
1547	A perspective on inflammation in Alzheimer's disease. 2000 , 924, 132-5	53
1546	Effects of sodium ferulate on amyloid-beta-induced MKK3/MKK6-p38 MAPK-Hsp27 signal pathway and apoptosis in rat hippocampus. 2006 , 27, 1309-16	34
1545	Cardiovascular disease and Alzheimer's disease: common links. 2006 , 260, 211-23	197
1544	Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. 2006 , 32, 492-504	24
1543	Drug discovery in dementia: the role of rodent models. 2006 , 5, 956-70	158
1542	Immunology and immunotherapy of Alzheimer's disease. 2006 , 6, 404-16	262
1541	Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties. 2006 , 16, 825-9	18
1540	Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease. 2006 , 1089, 472-86	37
1539	Association between the polymorphism of CCR5 and Alzheimer's disease: results of a study performed on male and female patients from Northern Italy. 2006 , 1089, 454-61	18

1538	Age-related changes in neuroprotection: is estrogen pro-inflammatory for the reproductive senescent brain?. 2006 , 29, 191-7	26
1537	Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology. 2006 , 8, 151-62	15
1536	Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. 2006 , 113, 1753-61	17
1535	Alzheimer's disease, brain immune privilege and memory: a hypothesis. 2006 , 113, 1697-707	19
1534	The significance of neuroinflammation in understanding Alzheimer's disease. 2006 , 113, 1685-95	216
1533	Relapsing polychondritis with features of dementia with Lewy bodies. 2006 , 112, 217-25	12
1532	Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. 2006 , 112, 517-30	92
1531	Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects. 2006 , 253 Suppl 5, V25-32	11
1530	Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. 2006 , 27, 33-9	98
1529	Oxidized plasma high-density lipoprotein is decreased in Alzheimer's disease. 2006 , 41, 1542-7	11
1528	Kinins and neuroinflammation: dual effect on prostaglandin synthesis. 2006 , 546, 197-200	26
1527	Interleukin-1beta and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. 2006 , 41, 85-92	33
1526	Cholinergic neurons degenerate when exposed to conditioned medium of primary rat brain capillary endothelial cells: counteraction by NGF, MK-801 and inflammation. 2006 , 41, 609-18	17
1525	Inflammation in Alzheimer's disease. 2006 , 6, 247-260	22
1524	Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. 2006 , 1084, 1-15	115
1523	Complement and demyelinating disease: no MAC needed?. 2006 , 52, 58-68	27
1522	Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. 2006 , 127, 567-71	69
1521	MCP-1 chemokine receptor CCR2 is decreased on circulating monocytes in sporadic amyotrophic lateral sclerosis (sALS). 2006 , 179, 87-93	53

1520	Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. 2006 , 23, 140-51	64
1519	Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. 2006 , 23, 260-72	97
1518	Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. 2006 , 23, 433-44	16
1517	Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. 2006 , 24, 1-14	271
1516	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. 2006 , 24, 114-27	96
1515	Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. 2006 , 7, 78	137
1514	Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. 2006 , 53, 382-91	87
1513	Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. 2006 , 53, 776-82	171
1512	Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. 2006 , 83, 1461-70	183
1511	Interleukin-1alpha stimulates non-amyloidogenic pathway by alpha-secretase (ADAM-10 and ADAM-17) cleavage of APP in human astrocytic cells involving p38 MAP kinase. 2006 , 84, 106-18	54
1510	Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. 2006 , 84, 434-43	64
1509	High-sensitivity C-reactive protein and cognitive function in older women. 2006 , 17, 183-9	54
1508	Frailty of older age: the role of the endocrine-immune interaction. 2006 , 12, 3147-59	43
1507	Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. 2006 , 3, 298-304	24
1506	Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. 2006 , 66, 149-50	30
1505	Therapeutic options in Alzheimer's disease. 2006 , 6, 897-910	37
1504	Systemic inflammatory markers and risk of dementia. 2006 , 21, 258-62	64
1503	Cetirizine-induced dystonic movements. 2006 , 66, 143-4	19

1502	Therapeutic perspectives in Alzheimer's disease. 2006 , 1, 119-27	20
1501	Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. 2006 , 12, 4337-55	36
1500	Vaccine development for Alzheimer's disease. 2006 , 12, 4283-93	13
1499	Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. 2006 , 12, 3509-19	37
1498	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. 2006 , 3, 421-30	111
1497	Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. 2006 , 13, 2179-88	53
1496	Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. 2006 , 66, 146-7	53
1495	Role of toll-like receptor signalling in Abeta uptake and clearance. 2006 , 129, 3006-19	389
1494	Immunotherapy for conformational diseases. 2006 , 12, 2569-85	20
1493	Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. 2006 , 79, 596-610	130
1492	Pathways by which Abeta facilitates tau pathology. 2006 , 3, 437-48	148
1491	Suicide after deep brain stimulation of the internal globus pallidus for dystonia. 2006 , 66, 142-3	93
1490	Progression of the olivopontocerebellar form of adrenoleukodystrophy as shown by MRI. 2006 , 66, 144-5	5
1489	New Strategies in Evaluation of Therapeutic Efficacy in Fibromyalgia Syndrome. 2006 , 12, 67-71	11
1488	Presynaptic neuromuscular transmission defect in the Miller Fisher syndrome. 2006 , 66, 148-9	17
1487	An inflammatory pathomechanism for Parkinson's disease?. 2006 , 13, 591-602	54
1486	Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. 2006 , 281, 20842-20850	106
1485	PPAR-gamma agonists as regulators of microglial activation and brain inflammation. 2006 , 12, 93-109	166

1484	Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. 2006 , 20, 426-33	101
1483	Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. 2007 , 165, 375-82	47
1482	c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. 2006 , 20, 762-4	32
1481	Alternating hemiplegia of childhood successfully treated with topiramate: 18 months of follow-up. 2006 , 66, 146	68
1480	MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. 2006 , 281, 23658-67	120
1479	beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. 2006 , 103, 8852-7	40
1478	Stress increases vulnerability to inflammation in the rat prefrontal cortex. 2006 , 26, 5709-19	159
1477	Mediterranean diet, Alzheimer disease, and vascular mediation. 2006 , 63, 1709-17	274
1476	Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. 2006 , 63, 1165-9	72
1475	Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. 2006 , 63, 538-43	222
1474	Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. 2006 , 318, 571-8	57
1473	Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. 2006 , 26, 4644-8	95
1472	Heart disease and dementia: a population-based study. 2006 , 163, 135-41	42
1471	Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. 2006 , 103, 5048-53	123
1470	Clinical trials in mild cognitive impairment: lessons for the future. 2006 , 77, 429-38	98
1469	Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. 2006 , 103, 443-8	332
1468	Notice of Concern. 2006 , 58, 135-135	
1467	Emerging therapeutics for Alzheimer's disease. 2006 , 6, 695-704	27

1466	Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. 2006 , 281, 33422-32	66
1465	The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. 2006 , 586, 153-76	26
1464	Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. 2006 , 281, 3651-9	164
1463	Microglia recognize double-stranded RNA via TLR3. 2006 , 176, 3804-12	145
1462	Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. 2006 , 26, 1343-54	219
1461	Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. 2006 , 26, 11652-64	54
1460	The role of the complement system in CNS inflammatory diseases. 2006 , 2, 445-56	30
1459	Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. 2006 , 103, 19182-7	85
1458	Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. 2006 , 103, 17456-61	181
1457	Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. 2006 , 26, 10129-40	1834
1456	Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. 2007 , 27, 3712-21	127
1455	Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. 2007 , 21, 61-73	90
1454	Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. 2007 , 104, 12849-54	186
1453	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. 2007 , 7, 473-85	36
1452	Nutritional Intervention in Brain Aging. 2007 , 299-318	77
1451	Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. 2007 , 69, 275-82	93
1450	Heparin oligosaccharides as potential therapeutic agents in senile dementia. 2007 , 13, 1607-16	27
1449	Body mass index in midlife and risk of Alzheimer disease and vascular dementia. 2007 , 4, 103-9	308

1448	Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. 2007 , 4, 21-31	51
1447	Dual acting anti-inflammatory drugs. 2007 , 7, 265-75	85
1446	The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. 2007 , 8, 509-30	67
1445	Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. 2007 , 78, 807-11	39
1444	Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. 2007 , 5, 232-43	44
1443	Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. 2007 , 4, 159-64	87
1442	RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. 2007 , 7, 735-42	123
1441	Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. 2007 , 68, 1902-8	351
1440	Fate determinant expression in the lesioned brain: Olig2 induction and its implications for neuronal repair. 2007 , 4, 328-32	7
1439	Mediterranean diet and essential tremor. A case-control study. 2007 , 29, 170-7	14
1438	Endogenous sex hormones as risk factors for dementia in elderly men and women. 2007 , 62, 1035-41	31
1437	Brain infusion of lipopolysaccharide increases uterine growth as a function of estrogen replacement regimen: suppression of uterine estrogen receptor-alpha by constant, but not pulsed, estrogen replacement. 2007 , 148, 232-40	14
1436	Increase in core body temperature of Alzheimer's disease patients as a possible indicator of chronic neuroinflammation: a meta-analysis. 2007 , 53, 7-11	30
1435	Neuronal damage in brain inflammation. 2007 , 64, 185-9	136
1434	Tooth loss, dementia and neuropathology in the Nun study. 2007 , 138, 1314-22; quiz 1381-2	251
1433	Inflammation in the Pathogenesis of Chronic Diseases. 2007 ,	4
1432	Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study. 2007 , 48, 1983-8	44
1431	Targeting insulin-like growth factor-1 to treat Alzheimer's disease. 2007 , 11, 1535-42	30

1430	CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. 2007 , 282, 27392-27401	74
1429	Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases. 2007 , 219-42	45
1428	Systemic and acquired immune responses in Alzheimer's disease. 2007 , 82, 205-33	72
1427	Neurodegenerative diseases and memory. 2007 , 519-539	1
1426	Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. 2007 , 64, 366-70	104
1425	Oxidative Stress and Neuroinflammation in Alzheimer's Disease and Amyotrophic Lateral Sclerosis: From Biology to Therapeutic Strategies. 2007 , 297-311	
1424	BIBLIOGRAPHY. 2007 , 417-599	
1423	Serum high sensitivity C-reactive protein and cognitive function in elderly women. 2007 , 36, 443-8	65
1422	Atlas of Alzheimer's Disease. 2007 ,	6
1421	Proteomic analysis of exfoliation deposits. 2007 , 48, 1447-57	104
1420	Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. 2007 , 104, 10601-6	262
1419	Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. 2007 , 70, 279-90	19
1418	Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. 2007 , 11, 457-63	93
1417	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. 2007 , 30, 1-32	
1416	Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. 2007 , 11, 61-76	68
1415	Enhancement of innate immunity by curcuminoids and hormones as a therapeutic strategy in neurodegenerative disorders. 2007 , 2, 125-127	
1414	Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. 2007 , 66, 469-80	57
1413	C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. 2007 , 125, 1396-401	64

1412	NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. 2007 , 28, 536-43		96
1411	Regulation of glial cyclooxygenase by bradykinin. 2007 , 28, 845-50		4
1410	Inflammation in the nervous system--physiological and pathophysiological aspects. 2007 , 92, 121-8		44
1409	Effects of Alzheimer's peptide and alpha1-antichymotrypsin on astrocyte gene expression. <i>Neurobiology of Aging</i> , 2007 , 28, 51-61	5.6	10
1408	The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007 , 28, 515-8	5.6	19
1407	NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. <i>Neurobiology of Aging</i> , 2007 , 28, 639-47	5.6	397
1406	Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. <i>Neurobiology of Aging</i> , 2007 , 28, 1163-9	5.6	86
1405	Impact of the matrix metalloproteinase MMP-3 on dementia. <i>Neurobiology of Aging</i> , 2007 , 28, 1215-20	5.6	19
1404	Polymorphisms and haplotypes in the C-reactive protein gene and risk of dementia. <i>Neurobiology of Aging</i> , 2007 , 28, 1361-6	5.6	16
1403	Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. <i>Neurobiology of Aging</i> , 2007 , 28, 1810-20	5.6	143
1402	Inflammatory changes parallel the early stages of Alzheimer disease. <i>Neurobiology of Aging</i> , 2007 , 28, 1821-33	5.6	167
1401	The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo. 2007 , 52, 136-45		56
1400	Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. 2007 , 144, 950-60		88
1399	Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. 2007 , 144, 1516-22		70
1398	Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. 2007 , 114, 1722-7		95
1397	Relationship of hemoglobin A1c with the presence and severity of retinopathy upon initial screening of type II diabetes mellitus. 2007 , 144, 639-40; author reply 640		0
1396	Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. 2007 , 144, 638-9; author reply 639		1
1395	Reply. 2007 , 144, 639		

1394	Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. 2007 , 357, 1096-9	22
1393	Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. 2007 , 361, 800-4	10
1392	Gene expression profile in beta-amyloid-treated SH-SY5Y neuroblastoma cells. 2007 , 72, 225-31	8
1391	Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. 2007 , 80, 1977-83	35
1390	Microglia can be induced by IFN-gamma or IL-4 to express neural or dendritic-like markers. 2007 , 35, 490-500	70
1389	A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. 2007 , 7, 1685-94	8
1388	Alzheimer's disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. 2007 , 68, 378-88	59
1387	Role of complement in neurodegeneration and neuroinflammation. 2007 , 44, 999-1010	245
1386	Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. 2007 , 411, 133-7	18
1385	Minocycline does not affect amyloid beta phagocytosis by human microglial cells. 2007 , 416, 87-91	44
1384	Acute systemic inflammation induces central mitochondrial damage and mnesic deficit in adult Swiss mice. 2007 , 424, 106-10	62
1383	Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. 2007 , 581, 475-8	74
1382	Physical activity and cognitive health. 2007 , 3, 98-108	54
1381	Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. 2007 , 170, 680-92	283
1380	Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. 2007 , 171, 2012-20	198
1379	A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro. 2007 , 29, 96-102	24
1378	Abeta Peptide and Alzheimer's Disease. 2007 ,	1
1377	Pharmacological Mechanisms in Alzheimer's Therapeutics. 2007 ,	1

1376	Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. 2007 , 8, 1735-45	40
1375	Bone Marrow-Derived Progenitors. 2007 ,	1
1374	Ankle-to-brachial index and dementia: the Honolulu-Asia Aging Study. 2007 , 116, 2269-74	59
1373	NSAIDs for the chemoprevention of Alzheimer's disease. 2007 , 42, 229-48	37
1372	Looking for novel ways to treat the hallmarks of Alzheimer's disease. 2007 , 16, 1183-96	16
1371	Pro-inflammatory cytokines and their effects in the dentate gyrus. 2007 , 163, 339-54	151
1370	[Molecular and therapeutic approaches of the Alzheimer's disease]. 2007 , 91, 221-5	1
1369	Microglial activation in the hippocampus of hypercholesterolemic rabbits occurs independent of increased amyloid production. 2007 , 4, 20	24
1368	Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. 2007 , 4, 30	28
1367	Osteopetrotic (op/op) mice have reduced microglia, no A β deposition, and no changes in dopaminergic neurons. 2007 , 4, 31	26
1366	Chronic HIV infection leads to an Alzheimer's disease like illness. Involvement of the kynurenine pathway. 2007 , 1304, 324-334	7
1365	Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. 2007 , 82, 235-46	198
1364	Cajal's contributions to the study of Alzheimer's disease. 2007 , 12, 161-74	20
1363	The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: correlation with cognitive and functional decline. 2007 , 18, 207-15	40
1362	IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. 2007 , 11, 305-11	54
1361	The Interaction between Brain Inflammation and Systemic Infection. 2007 , 429-448	
1360	Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target. 2007 , 2, 77-90	5
1359	Norepinephrine in neurological disorders. 436-471	1

1358	Follow-up mapping supports the evidence for linkage in the candidate region at 9q22 in the NIMH Alzheimer's disease Genetics Initiative cohort. 2007 , 144B, 220-7	10
1357	Notch signaling modulates the activation of microglial cells. 2007 , 55, 1519-30	67
1356	In vivo imaging of brain lesions with [(11)C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors. 2007 , 55, 1459-68	52
1355	Inhibitory effects of blueberry extract on the production of inflammatory mediators in lipopolysaccharide-activated BV2 microglia. 2007 , 85, 1010-7	169
1354	The inflammation-sensitive protein alpha 1-anti-chymotrypsin neutralizes fibrillar aggregation and cytotoxicity of the beta-amyloid peptide more effectively than alpha 1-antitrypsin. 2007 , 40, 887-92	12
1353	Positron emission tomography imaging of neuroinflammation. 2007 , 4, 443-52	112
1352	The Alzheimer's disease beta-secretase enzyme, BACE1. 2007 , 2, 22	301
1351	Immune cells may fend off Alzheimer disease. 2007 , 13, 408-9	48
1350	Drug development for CNS disorders: strategies for balancing risk and reducing attrition. 2007 , 6, 521-32	238
1349	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. 2007 , 6, 295-303	241
1348	Systemic infections and inflammation affect chronic neurodegeneration. 2007 , 7, 161-7	747
1347	Inflammatory responses following Chlamydia pneumoniae infection of glial cells. 2007 , 25, 753-60	9
1346	CD4(+)CD25(-) effector T-cells inhibit hippocampal long-term potentiation in vitro. 2007 , 26, 1399-406	9
1345	Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. 2007 , 48, 1785-1800	93
1344	Tumor necrosis factor alpha stimulates NMDA receptor activity in mouse cortical neurons resulting in ERK-dependent death. 2007 , 100, 1407-20	60
1343	Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. 2007 , 101, 929-36	23
1342	Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. 2008 , 104, 696-707	74
1341	An Aging Interventions Testing Program: study design and interim report. 2007 , 6, 565-75	143

1340	Norepinephrine: The redheaded stepchild of Parkinson's disease. 2007 , 74, 177-90	181
1339	The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. 2007 , 1139, 1-5	38
1338	Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. 2007 , 43, 332-47	499
1337	The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. 2007 , 42, 28-36	83
1336	Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview. 2007 , 42, 64-9	12
1335	The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. 2007 , 42, 10-21	153
1334	Increased production of inflammatory cytokines in mild cognitive impairment. 2007 , 42, 233-40	103
1333	Beta-amyloid(1-42) induces a reduction in the parallel fiber responses of Purkinje cells: possible involvement of pro-inflammatory processes. 2007 , 42, 951-62	4
1332	The role of amyloid beta peptide 42 in Alzheimer's disease. 2007 , 116, 266-86	233
1331	Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach. 2007 , 128, 67-75	35
1330	Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture. 2007 , 26, 153-64	38
1329	BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. 2007 , 26, 134-45	236
1328	Abnormal processing of tau in the brain of aged TgCRND8 mice. 2007 , 27, 328-38	50
1327	Inflammatory processes in Alzheimer's disease. 2007 , 184, 69-91	575
1326	Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. 2007 , 188, 117-27	170
1325	Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. 2007 , 189, 169-74	12
1324	The brain as a target for inflammatory processes and neuroprotective strategies. 2007 , 1122, 23-34	142
1323	Differential course of HIV-1 infection and apolipoprotein E polymorphism. 2007 , 2, 404-416	

1322	Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: a model for CNS aging. 2007 , 14, 63-76	63
1321	Inflammation--a lifelong companion. Attempt at a non-analytical holistic view. 2007 , 52, 159-73	14
1320	Glial cell dysregulation: a new perspective on Alzheimer disease. 2007 , 12, 215-32	106
1319	The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. 2007 , 12, 247-62	38
1318	Causes of oxidative stress in Alzheimer disease. 2007 , 64, 2202-10	282
1317	Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. 2007 , 32, 577-95	591
1316	Alzheimer disease models and human neuropathology: similarities and differences. 2008 , 115, 5-38	299
1315	Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. 2007 , 35, 203-16	92
1314	The endocannabinoid system and Alzheimer's disease. 2007 , 36, 75-81	33
1313	The immunology of Alzheimer's disease: prospects towards harnessing disease mechanisms for therapeutic ends. 2007 , 2, 131-3	5
1312	Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. 2007 , 2, 222-31	105
1311	Statins--treatment option for central nervous system autoimmune disease?. 2007 , 4, 693-700	15
1310	Development and validation of a high-performance liquid chromatography-electrospray mass spectrometry method for the simultaneous determination of 23 eicosanoids. 2008 , 46, 653-62	45
1309	Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. 2008 , 117, 198-202	126
1308	Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. 2008 , 33, 450-8	136
1307	Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. 2008 , 33, 1085-9	61
1306	Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. 2008 , 115, 417-25	121
1305	Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. 2008 , 255, 539-44	64

1304	Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid. 2008 , 86, 2303-13	22
1303	Glial reactions in Parkinson's disease. 2008 , 23, 474-83	550
1302	Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. 2008 , 56, 154-63	125
1301	TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. 2008 , 56, 1438-47	177
1300	Minocycline reduces engraftment and activation of bone marrow-derived cells but sustains their phagocytic activity in a mouse model of Alzheimer's disease. 2008 , 56, 1767-79	40
1299	Vitamin E increases S100B-mediated microglial activation in an S100B-overexpressing mouse model of pathological aging. 2008 , 56, 1780-90	22
1298	Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. 2008 , 147B, 720-6	55
1297	Multiple sclerosis and Alzheimer's disease. 2008 , 63, 174-83	82
1296	PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. 2008 , 5, 481-9	229
1295	The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. 2008 , 32, 633-42	23
1294	Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells. 2008 , 19, 819-25	54
1293	Leukotriene A4 metabolites are endogenous ligands for the Ah receptor. 2008 , 47, 8445-55	49
1292	Cytokines and Chemokines. 2008 , 183-205	1
1291	Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. 2008 , 153 Suppl 1, S263-82	224
1290	Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. 2008 , 14, 681-7	353
1289	The role of the immune system in clearance of Abeta from the brain. 2008 , 18, 267-78	80
1288	Human herpes virus 6B: a possible role in epilepsy?. 2008 , 49, 1828-37	89
1287	Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. 2008 , 105, 445-59	72

1286	High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. 2008 , 106, 475-85	257
1285	Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?. 2008 , 9 Suppl 2, S7	46
1284	NADPH oxidase as a therapeutic target in Alzheimer's disease. 2008 , 9 Suppl 2, S8	127
1283	Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?. 2008 , 45, 1375-83	324
1282	Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. 2008 , 1207, 225-36	171
1281	Inflammation, genes and zinc in Alzheimer's disease. 2008 , 58, 96-105	88
1280	Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. 2008 , 59, 155-63	94
1279	Differential regulation of prostaglandin synthesis in neonatal rat microglia and astrocytes by somatostatin. 2008 , 584, 312-7	8
1278	Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. 2008 , 7, 41-9	113
1277	An aspirin a day for Alzheimer's disease?. 2008 , 7, 20-1	3
1276	S100B induces tau protein hyperphosphorylation via Dickkopf-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. 2008 , 12, 914-27	70
1275	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASsociated gene'--a new blood biomarker?. 2008 , 12, 1094-117	37
1274	Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. 2008 , 12, 762-80	164
1273	Systemic immune aberrations in Alzheimer's disease patients. 2008 , 193, 183-7	93
1272	Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. 2008 , 201-202, 121-7	32
1271	Triptolide inhibits amyloid-beta1-42-induced TNF-alpha and IL-1beta production in cultured rat microglia. 2008 , 205, 32-6	55
1270	Immunophenotypes in the circulation of patients with mild cognitive impairment. 2008 , 42, 240-6	16
1269	Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. 2008 , 29, 254-66	80

1268	Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. 2008 , 31, 145-58	25
1267	A possible link between astrocyte activation and tau nitration in Alzheimer's disease. 2008 , 31, 198-208	52
1266	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. 2008 , 32, 412-9	395
1265	Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and Saitohin Q7R polymorphisms with Alzheimer's disease. 2008 , 270, 148-51	27
1264	Gender-specific neuroimmunoendocrine aging in a triple-transgenic 3xTg-AD mouse model for Alzheimer's disease and its relation with longevity. 2008 , 15, 331-43	64
1263	Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. 2008 , 5, 2	167
1262	Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. 2008 , 5, 23	186
1261	Interactions between APP secretases and inflammatory mediators. 2008 , 5, 25	127
1260	Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. 2008 , 5, 37	480
1259	Inflammaging as a prodrome to Alzheimer's disease. 2008 , 5, 51	191
1258	The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. 2008 , 5, 7	312
1257	Immunosenescence and immunogenetics of human longevity. 2008 , 15, 224-40	139
1256	Serum albumin levels predict cognitive impairment in elderly hip fracture patients. 2008 , 23, 85-90	11
1255	Advances in Alzheimer's and Parkinson's Disease. 2008 ,	
1254	The Inflammatory Component of Neurodegenerative Diseases. 2008 , 395-406	
1253	Central Nervous System Diseases and Inflammation. 2008 ,	5
1252	The toxicity of beta-amyloid is attenuated by interaction with its specific human scFv E3 in vitro. 2008 , 82, 1249-55	7
1251	What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. 2008 , 71, 347-59	44

1250	Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation. 2008 , 45, 3244-52		8
1249	Lack of association between TNF-alpha polymorphisms and Alzheimer's disease in an Italian cohort. 2008 , 446, 139-42		18
1248	Physiological correlates of age-related decline in vibrotactile sensitivity. <i>Neurobiology of Aging</i> , 2008 , 29, 765-73	5.6	51
1247	Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008 , 29, 961-8	5.6	84
1246	Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. <i>Neurobiology of Aging</i> , 2008 , 29, 1380-93	5.6	158
1245	Association of a NOS1 promoter repeat with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008 , 29, 1359-65		28
1244	Calorie restriction ameliorates neurodegenerative phenotypes in forebrain-specific presenilin-1 and presenilin-2 double knockout mice. <i>Neurobiology of Aging</i> , 2008 , 29, 1502-11	5.6	77
1243	Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. <i>Neurobiology of Aging</i> , 2008 , 29, 1805-14	5.6	40
1242	Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. <i>Neurobiology of Aging</i> , 2008 , 29, 1894-901	5.6	68
1241	Effects of hypoxia on expression of transforming growth factor-beta1 and its receptors I and II in the amoeboid microglial cells and murine BV-2 cells. 2008 , 156, 662-72		13
1240	Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades. 2008 , 156, 898-910		168
1239	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. 2008 , 44, 289-98		31
1238	Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer's disease?. 2008 , 29, 287-93		22
1237	Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. 2008 , 326, 196-208		467
1236	Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. 2008 , 19, 349-57		22
1235	Inflammation and aging: can endocannabinoids help?. 2008 , 62, 212-7		26
1234	Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. 2008 , 213, 93-100		31
1233	Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment. 2008 , 22, 487-92		75

1232	Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. 2008 , 44, 283-7	29
1231	Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. 2008 , 172, 1520-8	74
1230	Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy. 2008 , 172, 98-111	33
1229	Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. 2008 , 172, 1342-54	136
1228	Inflammation and Alzheimer's disease: possible role of periodontal diseases. 2008 , 4, 242-50	212
1227	Pharmacodynamics of memantine: an update. 2008 , 6, 55-78	124
1226	Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. 2008 , 16, 999-1009	37
1225	The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. 2008 , 22, 1-14	121
1224	NO donor hybrid compounds as multifunctional therapeutic agents. 2008 , 18, 1111-1125	3
1223	Encyclopedia of Neuroscience. 2008 , 331-524	
1222	Encyclopedia of Neuroscience. 2008 , 2527-2912	
1221	Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain. 2008 , 25, 1087-98	45
1220	Molecular and cellular aspects of protein misfolding and disease. 2008 , 22, 2115-33	150
1219	The relationship between type 2 diabetes and dementia. 2008 , 88, 131-46	60
1218	Cytokines and brain injury: invited review. 2008 , 23, 236-49	101
1217	Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. 2008 , 28, 12052-61	49
1216	Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. 2008 , 28, 14156-64	122
1215	Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. 2008 , 56, 1065-73	102

1214	Cerebrospinal fluid/serum IgG index is correlated with medial temporal lobe atrophy in Alzheimer's disease. 2008 , 25, 144-7	8
1213	C-reactive protein: vascular risk marker in elderly patients with mental illness. 2008 , 26, 251-6	10
1212	Elevated DNA damage in a mouse model of oxidative stress: impacts of ionizing radiation and a protective dietary supplement. 2008 , 23, 473-82	26
1211	Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase. 2008 , 81, 204-20	10
1210	ACAT as a drug target for Alzheimer's disease. 2008 , 5, 212-4	37
1209	Anti-inflammatory agents and cognitive decline in a bi-racial population. 2008 , 30, 45-50	15
1208	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults. 2008 , 36, 289-310	566
1207	Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar beta amyloid peptide (1-42)-stimulated microglia. 2008 , 40, 11-8	52
1206	Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from Drusen. 2008 , 181, 712-20	64
1205	Nuclear receptors and inflammatory diseases. 2008 , 233, 496-506	57
1204	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. 2007 , 1-24	5
1203	Oxidative stress signaling in Alzheimer's disease. 2008 , 5, 525-32	189
1202	BACE1 structure and function in health and Alzheimer's disease. 2008 , 5, 100-20	75
1201	Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. 2008 , 28, 5784-93	250
1200	Relevance of abeta1-42 intrahippocampal injection as an animal model of inflamed Alzheimer's disease brain. 2008 , 5, 475-80	44
1199	PPAR γ Agonists for the Treatment of Alzheimer's Disease. 2007 , 81-106	
1198	Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk. 2008 , 70, 5-6	4
1197	Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. 2008 , 8, 47-53	39

1196	CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. 2008 , 205, 1593-9	20
1195	Asthma, eczema, rhinitis and the risk for dementia. 2008 , 25, 148-56	27
1194	Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. 2008 , 25, 278-86	26
1193	Insulin Resistance Alzheimer's Disease: Pathophysiology and Treatment. 2008 , 3,	1
1192	The inflammatory response in Alzheimer's disease. 2008 , 79, 1535-43	69
1191	Handbook of Neurochemistry and Molecular Neurobiology. 2008 ,	1
1190	Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. 2008 , 8, 633-42	3
1189	Biomarkers related to aging in human populations. 2008 , 46, 161-216	106
1188	Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. 2008 , 20, 871-89	16
1187	Chemokines, their Receptors and Significance in Brain Function. 2008 , 242-273	3
1186	[Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse]. 2008 , 48, 910-2	4
1185	An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. 2008 , 13, 241-53	67
1184	Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. 2008 , 14, 147-59	87
1183	Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. 2008 , 14, 1419-27	108
1182	Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. 2008 , 14, 2672-7	55
1181	Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. 2008 , 14, 3280-94	25
1180	Cholesterol lowering and beyond: role of statins in Alzheimer's disease. 2008 , 4, 171-180	3
1179	Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. 2008 , 13, 437-49	113

1178	Gossypium herbaceam extracts inhibited NF-kappaB activation to attenuate spatial memory impairment and hippocampal neurodegeneration induced by amyloid-beta in rats. 2008 , 14, 271-83	24
1177	Inflammation in neurodegenerative disorders: friend or foe?. 2008 , 1, 30-41	30
1176	Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. 2008 , 1, 29-39	32
1175	Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease. 2008 , 4, 865-76	74
1174	PPARs in Alzheimer's Disease. 2008 , 2008, 403896	47
1173	Vascular risk factors, cognitive decline, and dementia. 2008 , 4, 363-81	205
1172	Does wine prevent dementia?. 2009 , 41	4
1171	Biomarker discovery in neurological diseases: a metabolomic approach. 2009 , Volume 1, 27-41	1
1170	Increased inflammatory response both in brain and in periphery in presenilin 1 and presenilin 2 conditional double knock-out mice. 2009 , 18, 515-23	24
1169	Role of microglia in age-related changes to the nervous system. 2009 , 9, 1061-71	34
1168	Alzheimer's disease: another target for heparin therapy. 2009 , 9, 891-908	32
1167	Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins. 2009 , 17, 845-54	25
1166	Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease. 2009 , 8, 85-100	7
1165	Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. 2009 , 4, e6617	216
1164	Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. 2009 , 284, 3158-3169	90
1163	HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele. 2009 , 183, 3522-30	37
1162	Propagation of tau misfolding from the outside to the inside of a cell. 2009 , 284, 12845-52	806
1161	TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain. 2009 , 183, 3989-95	41

1160	Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. 2009 , 183, 1375-83	175
1159	Interleukin-1alpha -889 C/T polymorphism in Turkish patients with late-onset Alzheimer's disease. 2009 , 27, 82-7	11
1158	Toll-like receptors in Alzheimer's disease. 2009 , 336, 137-53	126
1157	Uric acid and dementia in community-dwelling older persons. 2009 , 27, 382-9	40
1156	Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. 2009 , 4, 311-329	4
1155	Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. 2009 , 8, 277-84	78
1154	AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. 2009 , 17, 803-9	52
1153	Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?. 2009 , 9, 307-30	28
1152	[From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]. 2009 , 77, 326-33	6
1151	To fold or not to fold: modulation and consequences of Hsp90 inhibition. 2009 , 1, 267-83	71
1150	Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. 2009 , 16, 643-51	34
1149	New perspectives for the diagnosis of Alzheimer's disease. 2009 , 4, 160-81	11
1148	Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. 2009 , 5, 73-92	82
1147	Towards retinoid therapy for Alzheimer's disease. 2009 , 6, 302-11	64
1146	Microglial activation in Alzheimer's disease. 2009 , 6, 554-63	67
1145	Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. 2009 , 132, 2464-77	63
1144	Amyloid deposition and inflammation in APP ^{swe} /PS1 ^{dE9} mouse model of Alzheimer's disease. 2009 , 6, 531-40	139
1143	CSF levels of PSA and PSA-ACT complexes in Alzheimer's disease. 2009 , 46, 477-83	7

1142	The brain expression of genes involved in inflammatory response, the ribosome, and learning and memory is altered by centrally injected lipopolysaccharide in mice. 2009 , 9, 116-26	51
1141	Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders. 2009 , 10, 2510-57	43
1140	Anti-inflammatory effects of daidzein on primary astroglial cell culture. 2009 , 12, 123-34	32
1139	Relevance of transgenic mouse models to human Alzheimer disease. 2009 , 284, 6033-7	108
1138	Effects of a cyclooxygenase-2 preferential inhibitor in young healthy dogs exposed to air pollution: a pilot study. 2009 , 37, 644-60	20
1137	Progranulin and beta-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. 2009 , 24, 456-60	17
1136	Biomarkers of Alzheimer's disease. 2009 , 35, 128-40	134
1135	GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. 2009 , 33, 193-206	128
1134	Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. 2009 , 34, 95-106	149
1133	Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. 2009 , 34, 163-77	204
1132	Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. 2009 , 34, 300-7	75
1131	Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. 2009 , 34, 525-34	107
1130	Protective effect of Z-ligustilide against amyloid beta-induced neurotoxicity is associated with decreased pro-inflammatory markers in rat brains. 2009 , 92, 635-41	60
1129	Distinct fractional Abeta release patterns in human mononuclear phagocytes. 2009 , 206, 1-4	3
1128	The complement factor C5a receptor is upregulated in NFL ^{-/-} mouse motor neurons. 2009 , 210, 52-62	30
1127	Immune blood biomarkers of Alzheimer disease patients. 2009 , 210, 67-72	43
1126	Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. 2009 , 43, 749-53	57
1125	Protective actions of sex steroid hormones in Alzheimer's disease. 2009 , 30, 239-58	345

1124	A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. 2009 , 13, 2911-25	259
1123	PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease. 2009 , 13, 1476-88	35
1122	Neuronal death in Alzheimer's disease and therapeutic opportunities. 2009 , 13, 4329-48	71
1121	Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. 2009 , 1247, 178-81	31
1120	Lipopolysaccharide extends the lifespan of mouse primary-cultured microglia. 2009 , 1279, 9-20	10
1119	Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. 2009 , 1282, 162-72	66
1118	Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. 2009 , 1291, 133-9	17
1117	Toll-like receptors in neurodegeneration. 2009 , 59, 278-92	315
1116	Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. 2009 , 61, 60-8	76
1115	Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. 2009 , 61, 69-80	135
1114	Neuroendocrine factors in the regulation of inflammation: excessive adiposity and calorie restriction. 2009 , 44, 41-5	58
1113	Die Alzheimer-Demenz: von der Pathologie zu therapeutischen Ansätzen. 2009 , 121, 3074-3105	37
1112	Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Abeta42. 2009 , 57, 320-35	19
1111	Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. 2009 , 57, 1227-38	61
1110	Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. 2010 , 58, 300-14	136
1109	CD38 regulation in activated astrocytes: implications for neuroinflammation and HIV-1 brain infection. 2009 , 87, 2326-39	39
1108	Alzheimer's disease: from pathology to therapeutic approaches. 2009 , 48, 3030-59	467
1107	Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. 2009 , 25, 1054-63	9

1106	Regulated secretion of complement factor H by RPE and its role in RPE migration. 2009 , 247, 651-9	55
1105	Cell death and stress signaling in glycogen storage disease type I. 2009 , 28, 139-48	6
1104	Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. 2009 , 117, 111-24	81
1103	Genetic analysis of interleukin-1A C(-889)T polymorphism with Alzheimer disease. 2009 , 29, 81-5	13
1102	TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. 2009 , 29, 406-15	105
1101	In silico identification of new genetic variations as potential risk factors for Alzheimer's disease in a microarray-oriented simulation. 2009 , 39, 242-7	5
1100	Imaging microglial activation during neuroinflammation and Alzheimer's disease. 2009 , 4, 227-43	123
1099	CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?. 2009 , 4, 462-75	147
1098	Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. 2009 , 15, 3-14	164
1097	Treatment with green tea extract attenuates secondary inflammatory response in an experimental model of spinal cord trauma. 2009 , 380, 179-92	28
1096	Does neuroinflammation fan the flame in neurodegenerative diseases?. 2009 , 4, 47	505
1095	The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. 2009 , 4, 8	42
1094	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. 2009 , 2, 2	349
1093	Does Alzheimer's disease begin in the brainstem?. 2009 , 35, 532-54	139
1092	Overweight in midlife and risk of dementia: a 40-year follow-up study. 2009 , 33, 893-8	125
1091	Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate. 2009 , 36, 1099-103	1
1090	Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. 2009 , 19, 392-8	165
1089	Albumin, apolipoprotein E-epsilon4 and cognitive decline in community-dwelling Chinese older adults. 2009 , 57, 101-6	24

1088	NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. 2009 , 111, 766-76		18
1087	Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. 2009 , 111, 683-95		10
1086	Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. 2009 , 111, 1409-24		80
1085	Attenuation of iNOS and COX2 by blueberry polyphenols is mediated through the suppression of NF- κ B activation. 2009 , 1, 274-283		49
1084	Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. 2009 , 215, 5-19		181
1083	Autoradiographical imaging of PPARgamma agonist effects on PBR/TSPO binding in TASTPM mice. 2009 , 216, 459-70		14
1082	Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. 2009 , 217, 177-83		22
1081	Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. 2009 , 6, 45-53		119
1080	Frataxin deficiency induces Schwann cell inflammation and death. 2009 , 1792, 1052-61		62
1079	Impairment of long-term depression induced by chronic brain inflammation in rats. 2009 , 383, 93-7		13
1078	Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion. <i>Neurobiology of Aging</i> , 2009 , 30, 229-40	5.6	29
1077	Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. <i>Neurobiology of Aging</i> , 2009 , 30, 210-21	5.6	20
1076	Age-related accumulation of Reelin in amyloid-like deposits. <i>Neurobiology of Aging</i> , 2009 , 30, 697-716	5.6	77
1075	Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. <i>Neurobiology of Aging</i> , 2009 , 30, 759-68	5.6	172
1074	Epistasis in sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009 , 30, 1333-49	5.6	94
1073	Inhibition of LTP by beta-amyloid is prevented by activation of beta2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway. <i>Neurobiology of Aging</i> , 2009 , 30, 1608-13	5.6	44
1072	Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. <i>Neurobiology of Aging</i> , 2009 , 30, 1792-804	5.6	35
1071	Inflammatory markers in AD and MCI patients with different biomarker profiles. <i>Neurobiology of Aging</i> , 2009 , 30, 1885-9	5.6	107

1070	Immune activation in brain aging and neurodegeneration: too much or too little?. 2009 , 64, 110-22	519
1069	Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. 2009 , 158, 1062-73	193
1068	Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. 2009 , 159, 1055-69	169
1067	Effects of memantine on soluble Alphas(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. 2009 , 164, 1199-209	27
1066	Phospholipids block nuclear factor-kappa B and tau phosphorylation and inhibit amyloid-beta secretion in human neuroblastoma cells. 2009 , 164, 1744-53	19
1065	Omega-3 fatty acids and dementia. 2009 , 81, 213-21	149
1064	Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. 2009 , 87, 181-94	275
1063	Statins: mechanisms of neuroprotection. 2009 , 88, 64-75	196
1062	Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice. 2009 , 453, 41-4	58
1061	Chronic brain inflammation impairs two forms of long-term potentiation in the rat hippocampal CA1 area. 2009 , 456, 20-4	65
1060	Releasing factors from mature neurons modulate microglial survival via purinergic receptor activation. 2009 , 456, 64-8	1
1059	The chemistry of Alzheimer's disease. 2009 , 38, 2698-715	339
1058	NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. 2009 , 119, 3692-702	89
1057	Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. 2009 , 65, 304-12	395
1056	Molecular dynamics simulations of Ibuprofen binding to Abeta peptides. 2009 , 97, 2070-9	51
1055	Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease. 2009 , 120, 709-18	22
1054	Brain effects of melanocortins. 2009 , 59, 13-47	76
1053	Encyclopedia of Neuroscience. 2009 , 2620-2623	1

1052	Microglial physiology: unique stimuli, specialized responses. 2009 , 27, 119-45	1343
1051	Activated astrocytes: a therapeutic target in Alzheimer's disease?. 2009 , 9, 1585-94	69
1050	Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. 2009 , 175, 1586-97	49
1049	Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. 2009 , 6, 1	169
1048	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. 2009 , 6, 22	41
1047	Expression of complement system components during aging and amyloid deposition in APP transgenic mice. 2009 , 6, 35	65
1046	Neural progenitor cells attenuate inflammatory reactivity and neuronal loss in an animal model of inflamed AD brain. 2009 , 6, 39	53
1045	Encyclopedia of Neuroscience. 2008 , 382-382	
1044	A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. 2009 , 21, 102-10	108
1043	Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. 2009 , 16, 787-808	45
1042	Encyclopedia of Neuroscience. 2008 , 462-472	
1041	Toll-like Receptors: Roles in Infection and Neuropathology. 2009 ,	3
1040	CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. 2009 , 29, 11982-92	409
1039	Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. 2009 , 1, 5	65
1038	Encyclopedia of Neuroscience. 2008 , 492-493	
1037	Encyclopedia of Neuroscience. 2009 , 2606-2606	
1036	Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. 2009 , 5, 140-52	182
1035	Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer's Disease?. 2009 , 1275-1289	1

1034 Encyclopedia of Neuroscience. **2008**, 391-394

1033 Encyclopedia of Neuroscience. **2009**, 2608-2608

1032 Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment. **2009**, 23, 993-1002 52

1031 Can peripheral leukocytes be used as Alzheimer's disease biomarkers?. **2009**, 9, 1623-33 29

1030 Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?. **2009**, 5, 348-60 132

1029 Association of C-reactive protein with mild cognitive impairment. **2009**, 5, 398-405 82

1028 Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. **2009**, 5, 318-23 63

1027 Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. **2009**, 15, 358-74 113

1026 Aging and Alzheimer's Disease. **2009**, 3049-3083

1025 Complexity of microglial activation state: can modifying microglial activation treat Alzheimer's disease?. **2009**, 4, 137-139

1024 Whole blood viscosity and microvascular abnormalities in Alzheimer's Disease. **2009**, 41, 229-39 31

1023 Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. **2009**, 16, 389-97 85

1022 SOLUBLE CD40 LIGAND IN DEMENTIA. **2009**, 34, 333-340 13

1021 Alzheimer's Disease and Other Dementias (Including Pseudodementias). 543-615 28

1020 Macelignan attenuates activations of mitogen-activated protein kinases and nuclear factor kappa B induced by lipopolysaccharide in microglial cells. **2009**, 32, 1085-90 25

1019 Inflammation and NF-kappaB in Alzheimer's disease and diabetes. **2009**, 16, 809-21 132

1018 Alzheimer's disease: from pathogenesis to novel therapeutic approaches. **2009**, 6, 259-277 1

1017 Brain Inflammation and the Neuronal Fate: from Neurogenesis to Neurodegeneration. **2009**, 319-344

1016	Implication of complement system and its regulators in Alzheimer's disease. 2009 , 7, 1-8	46
1015	Cognitive decline following major surgery is associated with gliosis, amyloid accumulation, and p phosphorylation in old mice. 2010 , 38, 2190-8	118
1014	Functional genomics of brain aging and Alzheimer's disease: focus on selective neuronal vulnerability. 2010 , 11, 618-33	56
1013	Characteristics of dyschoric capillary cerebral amyloid angiopathy. 2010 , 69, 1158-67	51
1012	Interleukin-18, from neuroinflammation to Alzheimer's disease. 2010 , 16, 4213-24	67
1011	Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. 2010 , 7, 625-36	23
1010	Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. 2010 , 9, 132-9	84
1009	Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. 2010 , 22, 295-306	88
1008	Infiltration of T lymphocytes and expression of icam-1 in the hippocampus of patients with hippocampal sclerosis. 2010 , 43, 157-62	28
1007	Combined volumetry and DTI in subcortical structures of mild cognitive impairment and Alzheimer's disease patients. 2010 , 19, 1273-82	89
1006	Biomarkers and Surrogate Markers in Drug Development. 2010 , 101-166	
1005	Identification of KT-15073 as an inhibitor of lipopolysaccharide-induced microglial activation. 2010 , 33, 461-7	4
1004	Resveratrol Attenuates Neuroinflammation-mediated Cognitive Deficits in Rats. 2010 , 56, 655-663	6
1003	Midlife alcohol consumption and later risk of cognitive impairment: a twin follow-up study. 2010 , 22, 939-48	28
1002	Increased pro-inflammatory response by dendritic cells from patients with Alzheimer's disease. 2010 , 19, 559-72	45
1001	Chapter 22:PPAR in Alzheimer's Disease. 2010 , 153-165	
1000	Systemic Inflammation and Cognition in the Elderly. 2010 , 177-198	1
999	Alzheimer's disease. 2010 , 362, 329-44	3463

998	[Premature immunosenescence: a pathogenetic factor in Alzheimer's disease?]. 2010 , 81, 837-43	6
997	Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. 2010 , 39, 877-88	44
996	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. 2010 , 120, 369-84	105
995	Sensory circumventricular organs in health and disease. 2010 , 120, 689-705	101
994	Necrosis in yeast. 2010 , 15, 257-68	117
993	Peripheral inflammatory biomarkers of Alzheimer's disease: the role of platelets. 2010 , 11, 627-33	48
992	Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease. 2010 , 26, 77-84	9
991	Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer's disease patients. 2010 , 14, 758-61	30
990	Targeting glial cells to elucidate the pathogenesis of Huntington's disease. 2010 , 41, 248-55	44
989	Microglia activation and anti-inflammatory regulation in Alzheimer's disease. 2010 , 41, 115-28	130
988	Why pleiotropic interventions are needed for Alzheimer's disease. 2010 , 41, 392-409	124
987	Evaluation of capsular and acapsular strains of <i>S. aureus</i> in an experimental brain abscess model. 2010 , 218, 83-93	7
986	Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. 2010 , 221, 62-7	13
985	Inflammation, microglia, and Alzheimer's disease. 2010 , 37, 503-9	350
984	Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. 2010 , 38, 482-91	39
983	Thinking outside the box about COX-1 in Alzheimer's disease. 2010 , 38, 492-4	7
982	Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: a pro-inflammatory pathway in rats. 2010 , 96, 52-8	76
981	Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. 2010 , 17, 950-5	66

980	Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. 2010 , 45, 57-63	36
979	Interleukin-6 receptor gene polymorphisms were associated with sporadic Alzheimer's disease in Chinese Han. 2010 , 1327, 1-5	11
978	Neuroglia in neurodegeneration. 2010 , 63, 189-211	212
977	Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes. 2010 , 22, 871-81	50
976	Kynurenines, neurodegeneration and Alzheimer's disease. 2010 , 14, 2045-54	46
975	The role and therapeutic potential of monocytic cells in Alzheimer's disease. 2010 , 58, 889-900	66
974	Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. 2010 , 58, 1235-46	119
973	Current and Future Therapies for Alzheimer Disease. 2010 , 711-774	
972	Synthesis and biodistribution of [¹¹ C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). 2010 , 18, 5202-7	79
971	The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. 2010 , 11, 162	43
970	Screening for hypothyroidism in older hospitalized patients with anemia: a new insight into an old disease. 2010 , 58, 1825-7	18
969	Regional brain cortical thinning and systemic inflammation in older persons without dementia. 2010 , 58, 1823-5	14
968	Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. 2010 , 112, 1099-114	180
967	Naturally occurring phytochemicals for the prevention of Alzheimer's disease. 2010 , 112, 1415-30	255
966	The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. 2010 , 113, 447-53	67
965	Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. 2010 , 115, 551-62	50
964	Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. 2010 , 48, 230-238	73
963	Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. 2010 , 30, 1817-20	72

962	Dietary fatty acids and the aging brain. 2010 , 68 Suppl 2, S102-11	55
961	Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. 2010 , 31, 852-63	32
960	Toll-like receptors 1 and 2 cooperatively mediate immune responses to curli, a common amyloid from enterobacterial biofilms. 2010 , 12, 1495-505	111
959	. 2010 ,	5
958	Amyloid imaging using high-field magnetic resonance. 2010 , 9, 95-9	24
957	Anti-inflammatory impact of minocycline in a mouse model of tauopathy. 2010 , 1, 136	70
956	Age-related neuroinflammatory changes negatively impact on neuronal function. 2010 , 1, 6	130
955	Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation. 2010 , 3, 1812-1841	53
954	Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. 2010 , 2010,	72
953	The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. 2010 , 2,	42
952	Inhibition of double-stranded RNA-dependent protein kinase strongly decreases cytokine production and release in peripheral blood mononuclear cells from patients with Alzheimer's disease. 2010 , 21, 1217-31	18
951	Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia. 2010 , 2010,	12
950	Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. 2010 , 2010, 864625	6
949	Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. 2010 , 51, 1151-63	70
948	Amyloid-Beta Peptide, Oxidative Stress and Inflammation in Alzheimer's Disease: Potential Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids. 2010 , 2010, 1-10	16
947	Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. 2010 , 19, 551-7	20
946	The role of macrophage migration inhibitory factor in Alzheimer's disease. 2010 , 16, 116-21	61
945	Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease. 2010 , 2010,	16

944	Low levels of antibodies against phosphorylcholine in Alzheimer's disease. 2010 , 21, 577-84	11
943	Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. 2010 , 30, 9651-8	102
942	Tooth loss, apolipoprotein E, and decline in delayed word recall. 2010 , 89, 473-7	51
941	Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease. 2010 , 30, 12676-89	101
940	DHA may prevent age-related dementia. 2010 , 140, 869-74	86
939	Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer's disease mouse model. 2010 , 38, 1305-12	18
938	Association between NOS3 gene G894T polymorphism and late-onset Alzheimer disease in a sample from Iran. 2010 , 24, 204-8	9
937	Omega-3 fatty acids, cognitive impairment and Alzheimer's disease. 2010 , 20, 219-238	3
936	Galantamine for Alzheimer's disease. 2010 , 6, 345-54	51
935	Decreased rhythmic GABAergic septal activity and memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat. 2010 , 30, 10991-1003	73
934	Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. 2010 , 2010,	20
933	Overweight in midlife is related to lower cognitive function 30 years later: a prospective study with longitudinal assessments. 2010 , 29, 543-52	64
932	Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. 2010 , 30, 569-78	85
931	Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. 2010 , 30, 15369-73	80
930	Reimagining Alzheimer's disease--an age-based hypothesis. 2010 , 30, 16755-62	267
929	Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. 2010 , 22, 483-92	170
928	Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure. 2010 , 24, 4250-61	60
927	PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease. 2010 , 21, 927-38	89

926	Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. 2010 , 24, 548-59	236
925	Annexin A1: a central player in the anti-inflammatory and neuroprotective role of microglia. 2010 , 185, 6317-28	135
924	Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. 2010 , 30, 11414-25	78
923	RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. 2010 , 24, 1043-55	221
922	Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?. 2010 , 21, 1089-99	56
921	Systemic immune responses in Alzheimer's disease: in vitro mononuclear cell activation and cytokine production. 2010 , 21, 181-92	60
920	Putative mechanisms of cognitive dysfunction in chemotherapy-naïve diffuse large B-cell lymphoma: a case report and review of the literature. 2010 , 17, 223-33	2
919	Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. 2010 , 2010,	79
918	Targeted hydrolysis of Beta-amyloid with engineered antibody fragment. 2010 , 7, 214-22	10
917	Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. 2010 , 219683	22
916	Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. 2010 , 16, 2766-78	436
915	Targeting heat shock proteins in tauopathies. 2010 , 7, 677-84	10
914	Specific reaction of Met 35 in amyloid beta peptide with hypochlorous acid. 2010 , 44, 734-41	
913	How does diabetes accelerate Alzheimer disease pathology?. 2010 , 6, 551-9	294
912	Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry. 2010 , 82, 9858-64	70
911	Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescence. 2010 , 1, 112-121	49
910	A meta-analysis of cytokines in Alzheimer's disease. 2010 , 68, 930-41	669
909	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. 2010 , 68, 903-12	298

908	WITHDRAWN: Analysis of serum levels of homocysteine and oxidative stress markers in patients with Alzheimer disease. 2010 ,	2
907	Cell cycle regulation via inter-nuclear communication during the early embryonic development of <i>Drosophila melanogaster</i> . 2010 , 9, 2908-10	62
906	Microglial activation and neuroinflammation in Alzheimer's disease: a critical examination of recent history. 2010 , 2, 22	55
905	Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. 2010 , 24, 383-8	27
904	Microglia in neurodegenerative disease. 2010 , 6, 193-201	1119
903	Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. 2010 , 49, 4501-8	15
902	Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?. 2010 , 10, 411-8	171
901	Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-caeruleus-injured APP-transgenic mouse. 2010 , 468, 243-7	17
900	A multimodal MRI investigation of the subventricular zone in mild cognitive impairment and Alzheimer's disease patients. 2010 , 469, 214-8	28
899	Aging attenuates radiation-induced expression of pro-inflammatory mediators in rat brain. 2010 , 476, 89-93	28
898	The interleukin-6 gene -572C/G promoter polymorphism modifies Alzheimer's risk in APOE epsilon 4 carriers. 2010 , 482, 260-3	27
897	Chrysin suppresses LPS-stimulated proinflammatory responses by blocking NF- κ B and JNK activations in microglia cells. 2010 , 485, 143-7	127
896	Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. 2010 , 45, 408-17	107
895	Proline-rich polypeptide complex (PRP) regulates secretion of inflammatory mediators by its effect on NF-kappaB activity. 2010 , 64, 16-20	9
894	Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. 2010 , 21, 496-502	133
893	Inflammation in transgenic mouse models of neurodegenerative disorders. 2010 , 1802, 889-902	74
892	Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. 2010 , 24, 493-501	44
891	The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. 2010 , 209, 165-73	89

890	Abeta-induced BACE-1 cleaves N-terminal sequence of mPGES-2. 2010 , 393, 728-33		10
889	Mechanisms underlying inflammation in neurodegeneration. 2010 , 140, 918-34		2275
888	Protein synthesis dependent effects of kinins on astrocyte prostaglandin synthesis. 2010 , 31, 651-6		7
887	Chlamydia pneumoniae infection enhances microglial activation in atherosclerotic mice. <i>Neurobiology of Aging</i> , 2010 , 31, 1766-73	5.6	2
886	Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010 , 31, 1877-84	5.6	85
885	Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. 2010 , 58, 561-8		251
884	Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis. 2010 , 176, 1-7		47
883	CCL3 correlates with the number of mood disturbances and personality changes in patients with Alzheimer's disease. 2010 , 176, 261-4		12
882	Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. 2010 , 7, 263-74		19
881	REVIEW: Curcumin and Alzheimer's disease. 2010 , 16, 285-97		295
880	Nuclear receptors, inflammation, and neurodegenerative diseases. 2010 , 106, 21-59		27
879	Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. 2010 , 53, 61-76		70
878	Signaling effect of amyloid-beta(42) on the processing of AbetaPP. 2010 , 221, 18-25		46
877	Soluble oligomeric forms of beta-amyloid (Abeta) peptide stimulate Abeta production via astrogliosis in the rat brain. 2010 , 223, 410-21		31
876	The endocannabinoid system and amyloid-related diseases. 2010 , 224, 66-73		11
875	White matter is altered with parental family history of Alzheimer's disease. 2010 , 6, 394-403		85
874	CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. 2010 , 177, 2549-62		339
873	Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. 2010 , 332, 505-14		57

872	Perispinal etanercept: a new therapeutic paradigm in neurology. 2010 , 10, 985-1002	48
871	Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. 2010 , 13, 301-13	75
870	Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. 2010 , 19, 355-61	279
869	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. 2010 , 2, 1	142
868	Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. 2010 , 285, 7440-6	47
867	Proinflammatory cytokines, sickness behavior, and Alzheimer disease. 2011 , 77, 212-8	152
866	Targeting progressive neuroaxonal injury: lessons from multiple sclerosis. 2011 , 25, 783-99	21
865	Nuclear receptors as therapeutic targets for Alzheimer's disease. 2011 , 15, 1085-97	87
864	Do inhalational anesthetics cause cognitive dysfunction?. 2011 , 49, 149-53	19
863	Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. 2011 , 121, 367-87	350
862	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. 2011 , 15, 83-102	24
861	Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. 2011 , 64, 180-6	60
860	The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: a meta-analysis. 2011 , 303, 133-8	32
859	Increased plasma levels of lipocalin 2 in mild cognitive impairment. 2011 , 305, 28-33	71
858	Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. 2011 , 17, 276-82	108
857	Neurobiological aspects of Alzheimer's disease. 2011 , 15, 535-55	35
856	Review of cerebral microangiopathy and Alzheimer's disease: relation between white matter hyperintensities and microbleeds. 2011 , 32, 367-78	37
855	Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. 2011 , 6, 20	26

854	Role of purinergic receptors in CNS function and neuroprotection. 2011 , 61, 495-528	27
853	Novel anti-inflammatory compound SEN1176 alleviates behavioral deficits induced following bilateral intrahippocampal injection of aggregated amyloid- β . 2011 , 25, 219-29	19
852	Inflammation induced by infection potentiates tau pathological features in transgenic mice. 2011 , 178, 2811-22	136
851	MyD88 deficiency ameliorates β amyloidosis in an animal model of Alzheimer's disease. 2011 , 179, 1095-103	47
850	Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF- β suppressive therapeutic strategies in the brain. 2011 , 179, 2053-70	74
849	Depletion of CXCR2 inhibits β secretase activity and amyloid- β production in a murine model of Alzheimer's disease. 2011 , 53, 163-9	30
848	Roles of β adrenergic receptors in Alzheimer's disease: implications for novel therapeutics. 2011 , 84, 111-7	37
847	What has gene expression profiling taught us about glaucoma?. 2011 , 93, 191-5	9
846	Hypolipidemic and anti-inflammatory properties of Abacopterin A from Abacopteris penangiana in high-fat diet-induced hyperlipidemia mice. 2011 , 49, 3206-10	30
845	S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF- κ B pathway in rats. 2011 , 25, 110-9	85
844	Immune modulation of learning, memory, neural plasticity and neurogenesis. 2011 , 25, 181-213	1022
843	Neuroinflammation and the plasticity-related immediate-early gene Arc. 2011 , 25 Suppl 1, S39-49	29
842	Chronic exercise ameliorates the neuroinflammation in mice carrying NSE/htau23. 2011 , 406, 359-65	56
841	Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line. 2011 , 414, 700-5	30
840	Tetrandrine suppresses amyloid- β induced inflammatory cytokines by inhibiting NF- κ B pathway in murine BV2 microglial cells. 2011 , 11, 1220-5	36
839	The in vivo functions of a histidine-rich protein Hpn in Helicobacter pylori: linking gastric and Alzheimer's diseases together?. 2011 , 77, 788-90	12
838	Association between late-onset Alzheimer's disease and microsatellite polymorphisms in intron II of the human toll-like receptor 2 gene. 2011 , 489, 164-7	23
837	Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF- κ B activation in a rat model of amyloid-beta-induced Alzheimer's disease. 2011 , 491, 127-32	101

836	Region-specific distribution of β amyloid peptide and cytokine expression in TgCRND8 mice. 2011 , 492, 5-10		15
835	Effects of <i>Scutellaria baicalensis</i> on chronic cerebral hypoperfusion-induced memory impairments and chronic lipopolysaccharide infusion-induced memory impairments. 2011 , 137, 681-9		30
834	Short amyloid-beta immunogens show strong immunogenicity and avoid stimulating pro-inflammatory pathways in bone marrow-derived dendritic cells from C57BL/6J mice in vitro. 2011 , 32, 1617-25		7
833	Autoimmune and inflammatory mechanisms of CNS damage. 2011 , 95, 301-33		55
832	Curcumin enhances neuronal survival in N-methyl-d-aspartic acid toxicity by inducing RANTES expression in astrocytes via PI-3K and MAPK signaling pathways. 2011 , 35, 931-8		35
831	Stress is critical for LPS-induced activation of microglia and damage in the rat hippocampus. <i>Neurobiology of Aging</i> , 2011 , 32, 85-102	5.6	108
830	Progression from MCI to AD: predictive value of CSF A β 2 is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011 , 32, 1372-8	5.6	9
829	The selective and competitive N-methyl-D-aspartate receptor antagonist, (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid- β in mice. 2011 , 192, 631-41		15
828	Gami-Chunghyuldan ameliorates memory impairment and neurodegeneration induced by intrahippocampal A β -42 oligomer injection. 2011 , 96, 306-14		21
827	Metabolic, immune, epigenetic, endocrine and phenotypic abnormalities found in individuals with autism spectrum disorders, Down syndrome and Alzheimer disease may be caused by congenital and/or acquired chronic cerebral toxoplasmosis. 2011 , 5, 14-59		19
826	Protective effects of Econotoxin on amyloid- β induced damage in PC12 cells. 2011 , 206, 325-38		6
825	The multiplicity of action of cannabinoids: implications for treating neurodegeneration. 2011 , 17, 637-44		75
824	LPS-mediated production of pro/anti-inflammatory cytokines and eicosanoids in whole blood samples: biological effects of +896A/G TLR4 polymorphism in a Sicilian population of healthy subjects. 2011 , 132, 86-92		24
823	C-reactive protein level is decreased in patients with Alzheimer's disease and related to cognitive function and survival time. 2011 , 44, 1205-8		27
822	Neuroinflamm-aging and neurodegenerative diseases: an overview. 2011 , 10, 621-34		69
821	Associations of gene sequence variation and serum levels of C-reactive protein and interleukin-6 with Alzheimer's disease and dementia. 2011 , 23, 361-9		35
820	Glycogen synthase kinase-3 β a mediator of inflammation in Alzheimer's disease?. 2011 , 2011, 129753		23
819	Adenosine A(2A) Receptor and IL-10 in Peripheral Blood Mononuclear Cells of Patients with Mild Cognitive Impairment. 2011 , 2011, 484021		5

818	Chemokines in CSF of Alzheimer's disease patients. 2011 , 69, 455-9	51
817	A β internalization by neurons and glia. 2011 , 2011, 127984	62
816	History of innate immunity in neurodegenerative disorders. 2011 , 2, 77	38
815	Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. 2011 , 4, 18	68
814	Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. 2011 , 8, 2980-3018	189
813	WNT5A signaling contributes to A β -induced neuroinflammation and neurotoxicity. 2011 , 6, e22920	55
812	Deficits in spatial learning and memory is associated with hippocampal volume loss in aged apolipoprotein E4 mice. 2011 , 27, 89-98	27
811	Pyrazole compound 2-MBAPA as a novel inhibitor of microglial activation and neurotoxicity in vitro and in vivo. 2011 , 27, 531-41	7
810	Future targeted disease modifying drugs for Alzheimer's disease. 2011 , 6, 65-76	
809	Exploring potential sources of differential vulnerability and susceptibility in risk from environmental hazards to expand the scope of risk assessment. 2011 , 101 Suppl 1, S94-101	35
808	Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. 2011 , 10, 57-67	31
807	Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. 2011 , 17, 508-20	44
806	Increased serum levels of dehydroepiandrosterone (DHEA) and interleukin-6 (IL-6) in women with mild to moderate Alzheimer's disease. 2011 , 23, 1386-92	21
805	The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. 2011 , 8, 142-50	82
804	Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer's disease: focus on TNF- α and IL-1 β . 2011 , 6, 757-769	9
803	Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. 2011 , 24, 175-85	95
802	Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. 2011 , 25, 59-76	65
801	PICALM and CR1 variants are not associated with sporadic Alzheimer's disease in Chinese patients. 2011 , 25, 111-7	31

800	The role of CNI-1493 in the function of primary microglia with respect to amyloid- β . 2011 , 26, 69-80	20
799	Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. 2011 , 27, 1-10	34
798	Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. 2011 , 71, 365-76	217
797	Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cells. 2011 , 164, 1008-25	129
796	Lipid peroxidation in Alzheimer's disease: emphasis on metal-mediated neurotoxicity. 2011 , 124, 295-301	27
795	Neurovascular function in Alzheimer's disease patients and experimental models. 2011 , 31, 1354-70	121
794	Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease. 2011 , 18, 1071-81	101
793	Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism. 2011 , 21, 279-97	90
792	Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. 2011 , 15, 1807-21	178
791	Inflammation and gliosis in neurological diseases--clinical implications. 2011 , 231, 78-85	64
790	Cytokines regulate neuronal gene expression: differential effects of Th1, Th2 and monocyte/macrophage cytokines. 2011 , 238, 19-33	30
789	Inflammation in the early stages of neurodegenerative pathology. 2011 , 238, 1-11	160
788	Chronic ibuprofen treatment does not affect the secondary pathology in the thalamus or improve behavioral outcome in middle cerebral artery occlusion rats. 2011 , 99, 468-74	10
787	Parallel findings in age-related macular degeneration and Alzheimer's disease. 2011 , 30, 217-38	183
786	Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?. 2011 , 6, 79	69
785	Cytokines and neuronal channels: a molecular basis for age-related decline of neuronal function?. 2011 , 46, 199-206	33
784	NOS-mediated morphological and molecular modifications in rats infused with A β (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1. 2011 , 46, 273-81	7
783	The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study. 2011 , 46, 1010-9	24

782	Role of microglia in CNS inflammation. 2011 , 585, 3798-805	259
781	Inflammation as "common soil" of the multifactorial diseases. 2011 , 10, 369-74	183
780	Evaluating the role of Toll-like receptors in diseases of the central nervous system. 2011 , 81, 825-37	115
779	ERK pathway activation is required for amyloid- β (1-40)(-)-induced neurotoxicity of THP-1 human monocytes towards SK-N-SH neuroblastoma. 2011 , 1378, 9-17	9
778	Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF- κ B activation in a rat model of Alzheimer's disease induced by amyloid- β (1-42). 2011 , 1384, 89-96	84
777	Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. 2011 , 1387, 141-8	39
776	Neurotoxic factors released by stimulated human monocytes and THP-1 cells. 2011 , 1400, 99-111	14
775	Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. 2012 , 27, 364-74	69
774	HSV1 in Alzheimer's disease: Myth or reality?. 2011 , 2,	3
773	A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. 2011 , 286, 34914-22	71
772	Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. 2011 , 26, 2364-70	16
771	Apoptosis inhibition can be threatening in A β induced neuroinflammation, through promoting cell proliferation. 2011 , 36, 39-48	35
770	Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. 2011 , 258, 2181-5	50
769	S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF- κ B pathway in rats. 2011 , 40, 601-10	37
768	Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease. 2011 , 384, 115-24	30
767	APP transgenic mice: their use and limitations. 2011 , 13, 117-37	54
766	c-Abl in neurodegenerative disease. 2011 , 45, 445-52	83
765	Neurobiology of the aging dog. 2011 , 33, 485-96	35

764	Neuroimmune pharmacology from a neuroscience perspective. 2011 , 6, 10-9	12
763	The effects of amyloid- β 2 oligomer on the proliferation and activation of astrocytes in vitro. 2011 , 47, 573-80	33
762	Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. 2011 , 11, 51	50
761	Sinomenine inhibits microglial activation by A β and confers neuroprotection. 2011 , 8, 117	37
760	The contribution of activated astrocytes to A β production: implications for Alzheimer's disease pathogenesis. 2011 , 8, 150	223
759	Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β . 2011 , 8, 152	69
758	Neuroinflammation in Alzheimer's disease wanes with age. 2011 , 8, 171	58
757	Periodontal Disease and Periodontal Disease-Related Bacteria Involved in the Pathogenesis of Alzheimer's Disease. 2020 , 13, 275-283	13
756	Epigenetic differences in inflammation genes of monozygotic twins are related to parent-child emotional availability and health. 2020 , 5, 100084	1
755	Anti-neuroinflammatory Effect of Short-Chain Fatty Acid Acetate against Alzheimer's Disease via Upregulating GPR41 and Inhibiting ERK/JNK/NF- κ B. 2020 , 68, 7152-7161	24
754	The role of innate immunity in Alzheimer's disease. 2020 , 297, 225-246	31
753	Mass Defect-Based DiLeu Tagging for Multiplexed Data-Independent Acquisition. 2020 , 92, 11119-11126	9
752	Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease. 2020 , 11, 2549-2565	8
751	Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. 2020 , 11, 1097	13
750	Genetic Dissection of Alzheimer's Disease Using Models. 2020 , 21,	10
749	The molecular processes underpinning prion-like spreading and seed amplification in protein aggregation. 2020 , 61, 58-64	15
748	Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia. 2020 , 328, 113257	26
747	Metabolomics as an Approach to Characterise the Contrasting Roles of CCR5 in the Presence and Absence of Disease. 2020 , 21,	4

746	Bifenthrin insecticide promotes oxidative stress and increases inflammatory mediators in human neuroblastoma cells through NF-kappaB pathway. 2020 , 65, 104792	6
745	Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease. 2020 , 17, 58	13
744	Cyclical amyloid beta-astrocyte activity induces oxidative stress in Alzheimer's disease. 2020 , 171-172, 38-42	4
743	A novel role for SHARPIN in amyloid- β phagocytosis and inflammation by peripheral blood-derived macrophages in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 93, 131-141	5.6 10
742	Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid. 2020 , 73, 1615-1626	13
741	Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains. 2020 , 21,	47
740	Relationship of Wine Consumption with Alzheimer's Disease. 2020 , 12,	13
739	Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease. 2019 , 11, 369	40
738	FAM222A encodes a protein which accumulates in plaques in Alzheimer's disease. 2020 , 11, 411	8
737	Lipids Nutrients in Parkinson and Alzheimer's Diseases: Cell Death and Cytoprotection. 2020 , 21,	6
736	Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases. 2020 , 18, 348-407	25
735	5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease. 2020 , 88, 844-855	13
734	Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. 2020 , 25,	44
733	Microglia alterations in neurodegenerative diseases and their modeling with human induced pluripotent stem cell and other platforms. 2020 , 190, 101805	20
732	Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease. 2020 , 84, 106479	49
731	Asymmetric dimethylarginine exacerbates cognitive dysfunction associated with cerebrovascular pathology. 2020 , 34, 6808-6823	7
730	Medroxyprogesterone Acetate Impairs Amyloid Beta Degradation in a Matrix Metalloproteinase-9 Dependent Manner. 2020 , 12, 92	2
729	Amyloid- β oligomers in cellular models of Alzheimer's disease. 2020 , 155, 348-369	19

728	TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease. 2020 , 11, 724	52
727	10-Hydroxydecanoic acid inhibits LPS-induced inflammation by targeting p53 in microglial cells. 2020 , 84, 106501	3
726	Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins. 2020 , 2020, 3267172	11
725	Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the axis in mouse hippocampal neuronal cells. 2020 , 318, C1123-C1135	5
724	Possible Epigenetic Role of Vitexin in Regulating Neuroinflammation in Alzheimer's Disease. 2020 , 2020, 9469210	13
723	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. 2020 , 11, 456	87
722	Immune Suppression of Glia Maturation Factor Reverses Behavioral Impairment, Attenuates Amyloid Plaque Pathology and Neuroinflammation in an Alzheimer's Disease Mouse Model. 2021 , 16, 363-375	1
721	Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3 β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents. 2021 , 209, 112874	17
720	Effects of <i>Salvia officinalis</i> L. and <i>Chamaemelum nobile</i> (L.) extracts on inflammatory responses in two models of human cells: Primary subcutaneous adipocytes and neuroblastoma cell line (SK-N-SH). 2021 , 268, 113614	3
719	Metabolomics analysis of microbiota-gut-brain axis in neurodegenerative and psychiatric diseases. 2021 , 194, 113681	19
718	Glutaminase in microglia: A novel regulator of neuroinflammation. 2021 , 92, 139-156	9
717	Clinical trials of promising apoptosis modulating drugs. 2021 , 329-391	1
716	Spatiotemporal immunolocalisation of REST in the brain of healthy ageing and Alzheimer's disease rats. 2021 , 11, 146-163	0
715	Lipopolysaccharide-Induced Exosomal miR-146a Is Involved in Altered Expression of Alzheimer's Risk Genes Via Suppression of TLR4 Signaling. 2021 , 71, 1245-1255	6
714	Changes in the brain transcriptome after DNA A β 2 trimer immunization in a 3xTg-AD mouse model. 2021 , 148, 105221	1
713	Experimental diffuse brain injury and a model of Alzheimer's disease exhibit disease-specific changes in sleep and incongruous peripheral inflammation. 2021 , 99, 1136-1160	3
712	Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?. 2021 , 17, 157-172	262
711	Circulating inflammatory cytokine levels correlates with cognitive impairment. 2021 , 12, 66-71	1

710	Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 97, 129-143	5.6	3
709	Association Between Immune Response to Cytomegalovirus and Cognition in the Health and Retirement Study. 2021 , 190, 786-797		5
708	Multi Sensorial Stimulation Lab: A New Approach for Severe Dementia. 2021 , 65-81		
707	COVID-19 2021 , 140-149		
706	Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. 2021 , 218,		12
705	Mechanisms of Action of Nutritionally Rich Therapeutic Uses in Major Common Chronic Diseases: A Literature Review. 2021 , 1-8		2
704	An Insight in Pathophysiological Mechanism of Alzheimer's Disease and its Management Using Plant Natural Products. 2021 , 21, 35-57		8
703	Mesenchymal stem cell-derived extracellular vesicles ameliorate Alzheimer's disease-like phenotypes in a preclinical mouse model. 2021 , 11, 8129-8142		13
702	Immune Regulation of Adult Neurogenic Niches in Health and Disease. 2020 , 14, 571071		3
701	Rare genetic variants prioritize molecular pathways for semaphorin interactions in Alzheimer's disease patients. 2021 , 35, 1256-1262		2
700	Association Between GlycA and Cognitive Function: Cross-Sectional Results From the ELSA-Brasil Study. 2021 , 35, 128-134		0
699	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. 2021 , 11, 1965		9
698	Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy. 2021 , 13, 32		2
697	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. 2021 , 367-412		
696	Treatment with TNF-inhibitors versus methotrexate and the association with dementia and Alzheimer's disease. 2021 , 7, e12163		2
695	The relationship between white matter microstructure and self-perceived cognitive decline. 2021 , 32, 102794		0
694	Late-onset epilepsy and subsequent increased risk of dementia. 2021 , 13, 3573-3587		5
693	Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases. 2021 , 53, 100-121		2

692	Combining bioscaffolds and iPSCs in the treatment of neural trauma and Alzheimer's disease. 2021 , 123-162	
691	Alzheimer's Disease and Protein Kinases. 2021 , 1275, 285-321	5
690	Mechanisms of Insulin Resistance at the Crossroad of Obesity with Associated Metabolic Abnormalities and Cognitive Dysfunction. 2021 , 22,	17
689	Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go. 2021 , 4, 74-95	4
688	Therapeutic Potential of Neu1 in Alzheimer's Disease Via the Immune System. 2021 , 36, 1533317521996147	4
687	African Medicinal Plants Useful for Cognition and Memory: Therapeutic Implications for Alzheimer's Disease. 2021 , 87, 107-134	2
686	COVID-19 and Alzheimer's Disease. 2021 , 11,	26
685	Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. 2021 , 34, 127756	2
684	Neuroinflammation in Alzheimer's disease and beneficial action of luteolin. 2021 , 47, 207-217	14
683	The 4-(Phenylsulfanyl) butan-2-one Improves Impaired Fear Memory Retrieval and Reduces Excessive Inflammatory Response in Triple Transgenic Alzheimer's Disease Mice. 2021 , 13, 615079	2
682	Neuroimmune Response Mediated by Cytokines in Natural Scrapie after Chronic Dexamethasone Treatment. 2021 , 11,	2
681	Association of dementia with immunoglobulin G N-glycans in a Chinese Han Population. 2021 , 7, 3	9
680	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models. 2021 , 10,	6
679	6-Gingerol, an active constituent of ginger, attenuates lipopolysaccharide-induced oxidation, inflammation, cognitive deficits, neuroplasticity, and amyloidogenesis in rat. 2021 , 45, e13660	4
678	Epigenetics and Communication Mechanisms in Microglia Activation with a View on Technological Approaches. 2021 , 11,	3
677	Anti-Neuroinflammatory Potential of Polyphenols by Inhibiting NF- κ B to Halt Alzheimer's Disease. 2021 , 27, 402-414	14
676	Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus. 2021 , 99, 308-318	2
675	Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. 2021 , 1495, 78-98	6

674	Ibrutinib modulates A β tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease. 2021 , 20, e13332	8
673	Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease. 2021 , 144, 104958	4
672	Neuroprotective Effects of the FGF21 Analogue LY2405319. 2021 , 80, 357-369	5
671	Neuroimmunology in neurological and psychiatric disorders. 2021 , 12, 92-100	
670	The Role of Prokineticin 2 in Oxidative Stress and in Neuropathological Processes. 2021 , 12, 640441	1
669	Evaluation of Fluorinated Cromolyn Derivatives as Potential Therapeutics for Alzheimer's Disease. 2021 , 80, 775-786	2
668	Evaluation of [H]CPPC as a Tool Radioligand for CSF-1R. 2021 , 12, 998-1006	6
667	Investigating the Spatial Associations Between Amyloid- β Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer's Disease. 2021 , 80, 113-132	0
666	Association between Previous Statin Use and Alzheimer's Disease: A Nested Case-Control Study Using a National Health Screening Cohort. 2021 , 11,	3
665	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer's Disease. 2021 , 10,	4
664	Novel Botanical Therapeutic NB-02 Effectively Treats Alzheimer's Neuropathophysiology in an APP/PS1 Mouse Model. 2021 , 8,	0
663	Tooth Loss Induces Memory Impairment and Gliosis in App Knock-In Mouse Models of Alzheimer's Disease. 2021 , 80, 1687-1704	2
662	Hepcidin Increases Cytokines in Alzheimer's Disease and Down's Syndrome Dementia: Implication of Impaired Iron Homeostasis in Neuroinflammation. 2021 , 13, 653591	2
661	Preclinical Marmoset Model for Targeting Chronic Inflammation as a Strategy to Prevent Alzheimer's Disease. 2021 , 9,	1
660	Thunb. Leaves Ameliorate Cognitive Deficit and Neuronal Damage in a Mouse Model of Amyloid- β Induced Alzheimer's Disease. 2021 , 12, 607403	2
659	Amyloid- β Differentially stimulates proliferation, activation of oxidative stress and inflammatory responses in male and female hippocampal astrocyte cultures. 2021 , 195, 111462	1
658	Network-based analysis on genetic variants reveals the immunological mechanism underlying Alzheimer's disease. 2021 , 128, 803-816	1
657	Body Mass Index and Polygenic Risk for Alzheimer's Disease Predict Conversion to Alzheimer's Disease. 2021 , 76, 1415-1422	3

656	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. 2021 , 11,	7
655	Antimicrobials from Medicinal Plants: An Emergent Strategy to Control Oral Biofilms. 2021 , 11, 4020	2
654	Pyruvate kinase M2 in chronic inflammations: a potpourri of crucial protein-protein interactions. 2021 , 37, 653-678	4
653	Validation of Induced Microglia-Like Cells (iMG Cells) for Future Studies of Brain Diseases. 2021 , 15, 629279	8
652	New Insights Regarding Diagnosis and Medication for Schizophrenia Based on Neuronal Synapse-Microglia Interaction. 2021 , 11,	0
651	Alternative Medicine: A Recent Overview.	
650	Neuroinflammation in Alzheimer's Disease. 2021 , 9,	30
649	Alzheimer's disease: a step closer to understanding type 3 diabetes in African Americans. 2021 , 36, 1803-1816	1
648	nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. 2021 , 11, 9711	1
647	From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease. 2021 , 19, 832-867	4
646	Astrocyte subtype-specific approach to Alzheimer's disease treatment. 2021 , 145, 104956	2
645	miR-146a Dysregulates Energy Metabolism During Neuroinflammation. 2021 , 1	2
644	NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline. 2021 , 11, 10283	0
643	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. 2021 ,	11
642	Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease. 2021 , 12, 1905-1918	3
641	Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer's disease diagnosis in a case-control analysis.	1
640	PET Agents in Dementia: An Overview. 2021 , 51, 196-229	10
639	Non-invasive vagus nerve stimulation improves clinical and molecular biomarkers of Parkinson's disease in patients with freezing of gait. 2021 , 7, 46	7

638	Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD. 2021 , 158, 311-327	6
637	Neuroimmune reactivity marker expression in rodent models of chemotherapy-induced cognitive impairment: A systematic scoping review. 2021 , 94, 392-409	4
636	Tacrolimus Protects against Age-Associated Microstructural Changes in the Beagle Brain. 2021 , 41, 5124-5133	3
635	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. 2021 , 13, 624330	5
634	Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders. 2021 , 44, 487-498	5
633	Disease-modifying treatment with l imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil. 2021 , 178, 3017-3033	2
632	Role of the Renin-Angiotensin-Aldosterone System in Various Disease Processes: An Overview.	4
631	Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis. 2021 , 118,	3
630	Impaired Iron Homeostasis and Haematopoiesis Impacts Inflammation in the Ageing Process in Down Syndrome Dementia. 2021 , 10,	2
629	Hepcidin contributes to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss. 2021 , 9, 31	3
628	Immature Persimmon Suppresses Amyloid Beta (A β) Mediated Cognitive Dysfunction via Tau Pathology in ICR Mice. 2021 , 43, 405-422	1
627	MOGONET integrates multi-omics data using graph convolutional networks allowing patient classification and biomarker identification. 2021 , 12, 3445	17
626	Alzheimer's Disease Genetics: A Dampened Microglial Response?. 2021 , 10738584211024531	4
625	Age-related changes in brain phospholipids and bioactive lipids in the APP knock-in mouse model of Alzheimer's disease. 2021 , 9, 116	6
624	Neuroinflammation-Driven Lymphangiogenesis in CNS Diseases. 2021 , 15, 683676	4
623	NLRP3 and Infections: β Amyloid in Inflammasome beyond Neurodegeneration. 2021 , 22,	5
622	Amyloid- β , p-tau, and reactive microglia load are correlates of MRI cortical atrophy in Alzheimer's disease.	0
621	Therapeutic Potential of Phytoconstituents in Management of Alzheimer's Disease. 2021 , 2021, 5578574	10

620	Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer's Disease. 2021 , 19, 908-924	3
619	Evolutionary Changes in Pathways and Networks of Genes Expressed in the Brains of Humans and Macaques. 2021 , 71, 1825-1837	0
618	Human Monocytes Plasticity in Neurodegeneration. 2021 , 9,	2
617	An Overview of β -Amyloid Cleaving Enzyme 1 (Bace1) in Alzheimer's Disease Therapy Elucidating its Exosite-Binding Antibody and Allosteric Inhibitor. 2021 ,	2
616	Immunohistochemical evidence of P2X7R, P2X4R and CaMKK2 in pyramidal neurons of frontal cortex does not align with Alzheimer's disease. 2021 , 120, 104636	1
615	Immunotherapies for Neurodegenerative Diseases. 2021 , 12, 654739	3
614	Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.. 2022 , 12, 511-531	4
613	P38 β MAPK phosphorylates Snapin and reduces Snapin-mediated BACE1 transportation in APP-transgenic mice. 2021 , 35, e21691	0
612	Amyloidogenic, neuroinflammatory and memory dysfunction effects of HIV-1 gp120. 2021 , 44, 689-701	0
611	Potential application of human neural crest-derived nasal turbinate stem cells for the treatment of neuropathology and impaired cognition in models of Alzheimer's disease. 2021 , 12, 402	2
610	Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. 2021 , 1	4
609	Dementia-associated changes of immune cell composition within the cerebrospinal fluid. 2021 , 14, 100218	3
608	Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease. 2021 , 197, 108737	2
607	Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies-A Non-Systematic Review. 2021 , 22,	3
606	Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. 2021 , 19, 1323-1344	5
605	Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors. 2021 , 44, 116294	2
604	Diabetes and Alzheimer's Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?. 2021 , 10,	6
603	Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products. 2021 , 2021, 9982954	8

602	Role of the Extracellular Matrix in Alzheimer's Disease. 2021 , 13, 707466	3
601	Explore the role of CR1 genetic variants in late-onset Alzheimer's disease susceptibility. 2021 , 31, 216-229	1
600	Segmented Linear Mixed Model Analysis Reveals Association of the APOEε4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression. 2021 , 82, 921-937	5
599	Nerve Growth Factor Compromise in Down Syndrome. 2021 , 13, 719507	
598	Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease. 2021 ,	5
597	Redox Properties of Small Molecules Essential for Multiple Reactivities with Pathological Factors in Alzheimer's Disease. 2021 , 42, 1272	3
596	PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in Treatment of Alzheimer's Disease. 2021 ,	3
595	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. 2021 , 83, 5-22	10
594	Associations between Certain Polymorphisms in Proinflammatory Cytokines and Predisposition of Alzheimer's Disease: A Meta-Analysis. 2021 , 50, 224-230	0
593	Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. 2021 ,	2
592	Sex Differences in Locus Coeruleus: A Heuristic Approach That May Explain the Increased Risk of Alzheimer's Disease in Females. 2021 , 83, 505-522	1
591	Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. 2021 ,	2
590	The "Neuro-Glial-Vascular" Unit: The Role of Glia in Neurovascular Unit Formation and Dysfunction. 2021 , 9, 732820	8
589	Primary Cilia in Glial Cells: An Oasis in the Journey to Overcoming Neurodegenerative Diseases. 2021 , 15, 736888	5
588	Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases. 2021 , 70, 101414	6
587	An overview on therapeutic and medicinal potential of poly-hydroxy flavone viz. Heptamethoxyflavone, Kaempferitrin, Vitexin and Amentoflavone for management of Alzheimer's and Parkinson's diseases: a critical analysis on mechanistic insight. 2021 , 1-24	1
586	Deciphering the focal role of endostatin in Alzheimer's disease. 2021 , 28, 61998-62011	2
585	Multomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate. 2021 , 13,	10

584	The Role of Complement in Synaptic Pruning and Neurodegeneration. 2021 , 10, 373-386	7
583	Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. 2021 ,	1
582	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. 2021 , 10,	9
581	Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. 2021 , 13, 718426	3
580	Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease. 2021 ,	3
579	Computational Interspecies Translation Between Alzheimer's Disease Mouse Models and Human Subjects Identifies Innate Immune Complement, TYROBP, and TAM Receptor Agonist Signatures, Distinct From Influences of Aging. 2021 , 15, 727784	
578	Investigating Changes in the Serum Inflammatory Factors in Alzheimer's Disease and Their Correlation with Cognitive Function. 2021 , 84, 835-842	1
577	ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease. 2021 , 148, 105104	6
576	METTL3-dependent RNA mA dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events. 2021 , 16, 70	15
575	Roles of microglia in Alzheimer's disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. 2021 , 192, 114754	7
574	Comprehensive analysis of O-glycosylation of amyloid precursor protein (APP) using targeted and multi-fragmentation MS strategy. 2021 , 1865, 129954	1
573	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. 2021 , 158, 105452	0
572	Defining circadian disruption in neurodegenerative disorders. 2021 , 131,	6
571	Artemisia absinthium improves spatial performance and neuronal injury induced by amyloid- beta in the CA1 hippocampal area of male Wistar rats. 2021 , 185, 107506	
570	Immune function, cortisol, and cognitive decline & dementia in an aging latino population. 2021 , 133, 105414	1
569	Mediterranean diet and cognitive function: From methodology to mechanisms of action. 2021 , 176, 105-117	6
568	High-fat diet alters stress behavior, inflammatory parameters and gut microbiota in Tg APP mice in a sex-specific manner. 2021 , 159, 105495	1
567	Attenuation of spatial memory in 5xFAD mice by targeting cholinesterases, oxidative stress and inflammatory signaling using 2-(hydroxyl-(2-nitrophenyl)methyl)cyclopentanone. 2021 , 100, 108083	2

566	Can platelet activation result in increased plasma A β levels and contribute to the pathogenesis of Alzheimer's disease?. 2021 , 71, 101420		6
565	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021 , 107, 1-10	5.6	2
564	Potential of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease. 2021 , 90, 102196		3
563	Molecular aspects of neuroinflammation: Contribution of eicosanoids, cytokines, and chemokines. 2022 , 1-22		
562	Thioperamide attenuates neuroinflammation and cognitive impairments in Alzheimer's disease via inhibiting gliosis. 2022 , 347, 113870		1
561	Qisheng Wan formula ameliorates cognitive impairment of Alzheimer's disease rat via inflammation inhibition and intestinal microbiota regulation. 2022 , 282, 114598		3
560	Oroxylum indicum Kurz (L.) seed extract exerts antioxidant and anti-inflammatory effects on lipopolysaccharide-stimulated BV2 microglial cells. 2021 , 17, 288		1
559	Dabigatran reduces thrombin-induced neuroinflammation and AD markers in vitro: Therapeutic relevance for Alzheimer's disease. 2021 , 2, 100014		
558	References. 2021 , 243-287		
557	Design, Synthesis, and Activity Study of Cinnamic Acid Derivatives as Potent Antineuroinflammatory Agents. 2021 , 12, 419-429		2
556	The Association of Blood-Based Inflammatory Factors IL-1 β , TGF- β and CRP with Cognitive Function in Alzheimer's Disease and Mild Cognitive Impairment. 2021 , 18, 11-18		3
555	Understanding and Treating Alzheimer's Disease. 2006 , 49-70		1
554	Peptide Mediators of the Brain Endothelium. 2007 , 191-208		2
553	Role of Glia in CNS Inflammation. 2008 , 309-330		2
552	Cholesterol and β Amyloid. 2007 , 93-111		1
551	Opposite Modulation of Peripheral Inflammation and Neuroinflammation by Adenosine A2A Receptors. 2007 , 53-79		4
550	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A β 2-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD). 2007 , 167-193		1
549	Role of Chemokines and Chemokine Receptors in Diseases of Ageing. 2007 , 92-105		1

548	Inflammatory Processes Exacerbate Degenerative Neurological Disorders. 2009 , 117-124	2
547	Role of TLR Polymorphisms in Immunosenescence. 2009 , 659-671	1
546	Particulate Air Pollution and CNS Health. 2015 , 269-288	3
545	Amyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer's Disease. 2014 , 1597-1620	2
544	Quinolinic acid in the pathogenesis of Alzheimer's disease. 2003 , 527, 167-76	81
543	Physiology and Pathophysiology of Microglial Cell Function. 2002 , 1-14	5
542	Microglia and Aging in the Brain. 2002 , 275-305	15
541	Microglia as a Source and Target of Cytokine Activities in the Brain. 2002 , 79-124	5
540	Neurodegenerative Diseases. 2014 , 437-453	1
539	Functional Imaging and Psychopathological Consequences of Inflammation in Alzheimer's Dementia. 2005 , 75-83	1
538	Basal Forebrain Cholinergic Lesion by 192 IgG-Saporin. 2005 , 59-86	1
537	The Role of Rodent Models in the Drug Discovery Pipeline for Dementia. 2011 , 35-49	1
536	The Involvement of A β in the Neuroinflammatory Response. 2007 , 52-82	1
535	The gero-inflammatory manifold. 2001 , 237-256	1
534	Experimental Human Endotoxemia, Sickness Behavior, and Neuropsychiatric Diseases. 2015 , 63-82	2
533	Inferring Human Phenotype Networks from Genome-Wide Genetic Associations. 2013 , 23-34	4
532	Lipoprotein Genes and Diet in the Evolution of Human Intelligence and Longevity. 2003 , 33-67	3
531	Microglia and the response to brain injury. 2002 , 11-24	19

530	Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures. 2002 , 25-44	7
529	Neuroinflammation in Alzheimer's disease: potential targets for disease-modifying drugs. 2002 , 159-78	1
528	Sleep duration and health outcomes: an umbrella review. 2021 , 1	4
527	Insulin activates microglia and increases COX-2/IL-1 β expression in young but not in aged hippocampus. 2020 , 1741, 146884	4
526	Neuroprotective effects of Syringic acid against aluminium chloride induced oxidative stress mediated neuroinflammation in rat model of Alzheimer's disease. 2020 , 71, 104009	17
525	Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease. 2020 , 174, 108118	7
524	Synergistic neuroprotective effect of schisandrin and nootkatone on regulating inflammation, apoptosis and autophagy via the PI3K/AKT pathway. 2020 , 11, 2427-2438	22
523	Microglial Cells. 2013 ,	3
522	Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats. 2014 , 121, 773-85	54
521	Association of plasma proteins with rate of cognitive decline and dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies.	0
520	Multiscale causal network models of Alzheimer's disease identify VGF as a key regulator of disease.	4
519	Innate immunity, local inflammation, and degenerative disease. 2002 , 2002, re3	43
518	Immunotherapy for Alzheimer's disease. 2004 , 2004, pe29	5
517	Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. 2003 , 112, 415-22	122
516	Alzheimer disease therapy: Can the amyloid cascade be halted?. 2003 , 111, 11-18	116
515	Inhibition of GSK3 β -mediated BACE1 expression reduces Alzheimer-associated phenotypes. 2013 , 123, 224-35	243
514	Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. 2014 , 124, 1000-12	63
513	Blood will out: vascular contributions to Alzheimer's disease. 2018 , 128, 556-563	52

512	Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease. 2002 , 72, 628-635	20
511	Alzheimer's disease. 2003 , 57-116	3
510	Individuality, phenotypic differentiation, dormancy and 'persistence' in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. 2015 , 4, 179	41
509	Individuality, phenotypic differentiation, dormancy and persistence in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. 2015 , 4, 179	42
508	A Clinical Significance of High-Sensitivity C-reactive Protein Level in Alzheimer's Disease and Vascular Dementia. 2012 , 11, 131	1
507	Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. 2009 , 4, e7642	45
506	T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease. 2010 , 5, e10830	60
505	Presenilin 2 is the predominant β -secretase in microglia and modulates cytokine release. 2010 , 5, e15743	42
504	Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. 2012 , 7, e39186	45
503	Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. 2012 , 7, e49468	9
502	Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β -secretase in a mouse model of Alzheimer's disease. 2013 , 8, e55091	50
501	Ferulic acid is a nutraceutical β -secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. 2013 , 8, e55774	118
500	A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and APP ^{swe} -PS1 ^{dE9} mice. 2013 , 8, e63643	10
499	Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. 2013 , 8, e64971	83
498	Leucine-rich α -glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex. 2013 , 8, e74453	35
497	Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of A β and tau. 2013 , 8, e80706	21
496	CCAAT-enhancer binding protein- β expression and elevation in Alzheimer's disease and microglial cell cultures. 2014 , 9, e86617	30
495	Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice. 2014 , 9, e87185	15

494	Loading into nanoparticles improves quercetin's efficacy in preventing neuroinflammation induced by oxysterols. 2014 , 9, e96795	58
493	Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. 2014 , 9, e106342	43
492	Characterization of Novel Src Family Kinase Inhibitors to Attenuate Microgliosis. 2015 , 10, e0132604	10
491	Interleukin17A Promotes Postoperative Cognitive Dysfunction by Triggering β Amyloid Accumulation via the Transforming Growth Factor- β /Smad Signaling Pathway. 2015 , 10, e0141596	25
490	Network Analysis of a Comprehensive Knowledge Repository Reveals a Dual Role for Ceramide in Alzheimer's Disease. 2016 , 11, e0148431	11
489	Rheumatoid Arthritis Was Negatively Associated with Alzheimer's Disease: A Population-Based Case-Control Study. 2016 , 11, e0168106	15
488	Three-way interaction model to trace the mechanisms involved in Alzheimer's disease transgenic mice. 2017 , 12, e0184697	8
487	Infectious hypothesis of Alzheimer disease. 2020 , 16, e1008596	11
486	Effects of Curcumin on Cognitive Function: A Systematic Review of Randomized Controlled Trials. 2019 , 4, 1-11	7
485	PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. 2016 , 3, 243-259	49
484	Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease. 2015 , 6, 400-5	23
483	The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis. 2020 , 11, 705-724	18
482	Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. 2019 , 34, 843-856	18
481	Fragmentation of brain apolipoprotein E (ApoE) and its relevance in Alzheimer's disease. 2020 , 31, 589-603	2
480	QSAR Analysis of Cyclooxygenase Inhibitors Selectivity Index (COX1/COX2): Application of SVM-RBF and MLR Methods. 2015 , 21, 86-93	4
479	Individual Cytokines Modulate the Neurological Symptoms of ATM Deficiency in a Region Specific Manner. 2015 , 2,	12
478	EFFECT OF CURCUMIN LIPOSOMAL FORM ON ANGIOTENSIN CONVERTING ACTIVITY, CYTOKINES AND COGNITIVE CHARACTERISTICS OF THE RATS WITH ALZHEIMER'S DISEASE MODEL. 2015 , 8, 48-55	7
477	A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation. 2009 , 1, 350-3	10

476	Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. 2017 , 8, 7116-7137	24
475	VGF expression by T lymphocytes in patients with Alzheimer's disease. 2015 , 6, 14843-51	15
474	Metabolic Routes in Inflammation: The Citrate Pathway and its Potential as Therapeutic Target. 2019 , 26, 7104-7116	32
473	The normal and pathologic roles of the Alzheimer's secretase, BACE1. 2014 , 11, 441-9	37
472	What Metabolic Syndrome Contributes to Brain Outcomes in African American & Caucasian Cohorts. 2015 , 12, 640-7	16
471	Upregulation of Suppressor of Cytokine Signaling 3 in Microglia by Cinnamic Acid. 2018 , 15, 894-904	17
470	Consideration of a Pharmacological Combinatorial Approach to Inhibit Chronic Inflammation in Alzheimer's Disease. 2019 , 16, 1007-1017	2
469	Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease. 2016 , 16, 849-57	61
468	Periodontal Pathogens and Neuropsychiatric Health. 2020 , 20, 1353-1397	7
467	Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer's Disease. 2014 , 12, 239-55	121
466	Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease. 2017 , 15, 480-494	28
465	YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. 2017 , 15, 906-917	37
464	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. 2019 , 17, 563-579	22
463	The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology. 2020 , 18, 229-249	13
462	The Links between Cardiovascular Diseases and Alzheimer's Disease. 2021 , 19, 152-169	8
461	Naturally Inspired Pyrimidines Analogues for Alzheimer's Disease. 2021 , 19, 136-151	3
460	Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research. 2019 , 15, 456-470	23
459	Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. 2010 , 9, 140-8	59

458	Microglia and inflammation in Alzheimer's disease. 2010 , 9, 156-67	275
457	Impact of the CD40-CD40L dyad in Alzheimer's disease. 2010 , 9, 149-55	26
456	Targeting TNF- α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. 2011 , 10, 391-403	150
455	Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease. 2014 , 13, 909-20	5
454	The Relationship between Tourette's Syndrome and Infections. 2012 , 6, 124-8	11
453	Effects of Video Game Training on Behavioral and Electrophysiological Measures of Attention and Memory: Protocol for a Randomized Controlled Trial. 2017 , 6, e8	9
452	The contribution of S100B to the glioprotective effects of valproic and arundic acids. 2019 , 22, 557-562	2
451	Obesity and dementia: lifecourse evidence and mechanisms. 2006 , 2, 571-578	1
450	Infectious agents as a risk factor for Alzheimer's disease. 2020 , 12, 5-13	1
449	BACE2 distribution in major brain cell types and identification of novel substrates. 2018 , 1, e201800026	27
448	The Clinical Issues. 2016 , 19-50	1
447	Potential immunotherapy for Alzheimer disease and age-related dementia. 2019 , 21, 21-25	11
446	Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. 2014 , 8, 112	298
445	Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome. 2020 , 21,	6
444	Obesity and Diabetes Mediated Chronic Inflammation: A Potential Biomarker in Alzheimer's Disease. 2020 , 10,	15
443	Benefits of aged garlic extract on Alzheimer's disease: Possible mechanisms of action. 2020 , 19, 1560-1564	6
442	Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimer's disease. 2016 , 3, 138-157	2
441	Headmasters: Microglial regulation of learning and memory in health and disease. 2018 , 5, 63-89	5

440	Identification of $\alpha 7$ nicotinic acetylcholine receptor on hippocampal astrocytes cultured in vitro and its role on inflammatory mediator secretion. 2012 , 7, 1709-14	8
439	Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. 2015 , 3, 136	386
438	Atrial Fibrillation and Risk of Dementia/Cognitive Decline. 2016 , 8, 1353	13
437	Anti-neuroinflammatory Effects of 12-Dehydrogingerdione in LPS-Activated Microglia through Inhibiting Akt/IKK/NF- κ B Pathway and Activating Nrf-2/HO-1 Pathway. 2019 , 27, 92-100	17
436	Caffeic Acid Phenethyl Ester (CAPE) Prevents Development of STZ-ICV Induced dementia in Rats. 2017 , 13, S10-S15	25
435	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. 2018 , 13, 1995-2004	11
434	Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer's disease. 2019 , 14, 1880-1892	31
433	Association between Periodontitis and Alzheimer's Disease. 2015 , 7, 241-6	65
432	Neurological dysfunction after cardiac surgery and cardiac intensive care admission: A narrative review part 2: Cognitive dysfunction after critical illness; potential contributors in surgery and intensive care; pathogenesis; and therapies to prevent/treat perioperative neurological dysfunction. 2020 , 23, 391-400	3
431	Alzheimer's disease: An alternative approach. 2017 , 145, 723-729	10
430	The enigma of neuroinflammation. 2017 , 65, 703-705	1
429	Antioxidant activity and inhibitory effect on nitric oxide production of rang chuet (<i>Thunbergia laurifolia</i> Lindl.) leaf extracts in lipopolysaccharide-stimulated BV2 microglial cells. 2020 , 16, 581	1
428	Time-Dependent Compensatory Responses to Chronic Neuroinflammation in Hippocampus and Brainstem: The Potential Role of Glutamate Neurotransmission. 2013 , 3, 110	10
427	Pharmacological manipulation of cannabinoid neurotransmission reduces neuroinflammation associated with normal aging. 2012 , 04, 679-684	4
426	The interrelationship between insulin resistance and Alzheimer development. 2013 , 06, 754-773	2
425	The Use of Anti-Diabetic Drugs in Alzheimer's Disease, New Therapeutic Options and Future Perspective. 2018 , 09, 157-174	2
424	The Influence of Vitamin D Treatment on the Inducible Nitric Oxide Synthase (iNOS) Expression in Primary Hippocampal Neurons. 2014 , 51, 163-168	18
423	Associations of Pulmonary Function with Dementia and Depression in an Older Korean Population. 2015 , 12, 443-50	8

422	Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease. 2019 , 23, S54-62	22
421	Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?. 2010 , 43, 649-55	33
420	Attenuation of beta-amyloid-induced neuroinflammation by KHG21834 in vivo. 2010 , 43, 413-8	9
419	Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review. 2020 , 53, 10-19	55
418	Platelet biomarkers in Alzheimer's disease. 2012 , 2, 95-101	19
417	Effect of Endurance Training with Royal Jelly on CRP Gene Expression in Muscle Tissue of Rats with Alzheimer's Disease. 2020 , 7,	0
416	Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease. 2011 , 9, 54-66	7
415	Pathophysiological Ionotropic Glutamate Signalling in Neuroinflammatory Disease as a Therapeutic Target. 2021 , 15, 741280	1
414	The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease. 2021 , 10,	2
413	Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease. 2021 , 13,	2
412	A novel neuroinflammation-responsive hydrogel based on mimicking naked mole rat brain microenvironment retards neurovascular dysfunction and cognitive decline in Alzheimer's disease. 2021 , 133090	0
411	Hypoxia-Induced Neuroinflammation in Alzheimer's Disease: Potential Neuroprotective Effects of. 2021 , 12, 712317	1
410	The potential anti-amyloidogenic candidate, SPA1413, for Alzheimer's disease. 2021 ,	0
409	Influence of PICALM and CLU risk variants on beta EEG activity in Alzheimer's disease patients. 2021 , 11, 20465	1
408	Activation of Astrocytes in Neurodegenerative Diseases. 2022 , 39-70	
407	Site selective synthesis and anti-inflammatory evaluation of Spiro-isoxazoline stitched adducts of arteannuin B. 2021 , 117, 105408	1
406	Processo Inflamatório e Neuroimunomodulação na Doença de Alzheimer. 2011 , 19, 300-313	
405	Patterns of Tissue Pathology in Neurological Diseases. 2002 , 49-55	

404 Beta Amyloid Protein Clearance and Microglial Activation. **2002**, 245-274

403 CNS diseases amenable to gene therapy. **2003**, 117-58

402 Mitochondria, Aging, and Disease. **2003**,

401 Microglia and the Cerebral Defence System. **2004**, 181-202

1

400 Markers of Excitotoxicity in Patients: Tool for Diagnosis or Therapy?. **2004**, 317-337

399 cAMP-specific Pde4B mediates A β -induced microglial activation. **2004**, 382-384

398 Camp-Specific Pde4B Mediates A β -Induced Microglial Activation. **2004**, 382-384

397 Role of Microglia and Astrocytes in Alzheimer's Disease. **2004**, 299-311

396 Water quality and cholesterol-induced pathology: differential effects of the M-1 muscarinic receptor agonist AF267B on accumulation of Alzheimer-like amyloid in rabbit brain DL Sparks, J Lochhead, A Fisher, T Martin. **2005**, 219-226

395 Cholesterol and the A β -cascade: pathological implication of apolipoprotein E in Alzheimer's disease. **2005**, 155-160

394 Cognitive Function in the Elderly with Diabetes Mellitus. **2006**, 38, 19-24

393 Immunotherapeutic Approaches for Alzheimer's Disease. **2006**, 197-211

392 The Role of Sex Steroids in Alzheimer's Disease: Prevention and Treatment. **2007**, 295-306

391 Neuroinflammation, Alzheimer Disease, and Other Aging Disorders. **2007**, 149-166

390 Aging and Cognitive Decline: Neuroprotective Strategies. **2007**, 245-268

389 Neuroinflammation and Mitochondrial Dysfunction in Alzheimer's and Prion's Diseases. **2007**, 309-331

388 3. ??????????. **2007**, 38, 189-195

387 Long-Term Potentiation and A β -Targeting A β -Species, Cellular Mechanisms and Putative Receptors. **2008**, 157-167

386 Endocannabinoids in Alzheimer's Disease. **2008**, 395-405

385 Roles of Cytosolic and Secretory Phospholipases A2 in Oxidative and Inflammatory Signaling Pathways in the CNS. **2009**, 517-534

384 Marrow Stromal Mesenchymal Stem Cells. **2010**, 121-138

383 Ernährung und Gedächtnis. **2010**, 115-120

382 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis. **1**

381 The Search for Biomarkers in Alzheimer's Disease. **2010**, 2, 4

380 CNS Cytokines. **2011**, 359-382

379 Roles of Innate Immunity and Inflammation in the Aging Brain. **2011**,

378 Gene Expression Analysis of the Human Astrocytoma Cell after A β 1-35 Stimulation Followed by Ibuprofen Administration. **2011**, 15, 144-161

377 Biological Targeting and Activity of Pre-fibrillar A β Assemblies. **2012**, 103-133

376 Thinking Outside the Box in Alzheimer Disease Treatment.

375 Mitochondrial Dysfunction in Sporadic Alzheimer's Disease: Mechanisms, Consequences and Interventions. **2012**, 49-65

374 The Amyloid β -Protein and Alzheimer's Disease. **2012**, 1-85

373 Complement Component (3b/4b) Receptor 1 (CR1). **2013**, 77-101

1

372 Demenz und Diabetes mellitus. **2013**, 233-247

371 Alzheimer Disease. **2013**,

370 Microglia in the Alzheimers brain: a help or a hindrance?. **2014**, 1, 210-224

369 Proinflammatory Chemical Signaling: Cytokines. **2014**, 145-173

1

368 Cerebral ageing-the role of insulin and insulin-like growth factor signalling: A review. **2014**, 4, 12

367 Diabetes. **2014**, 115-146

366 Inflammation. **2014**, 15-99

365 Introduction. **2014**, 1-14

364 [Cytokines neuroinflammatory reaction to the action of homoaggregatic and liposomal forms of b-amyloid 1-40 in rats]. **2015**, 61, 373-80

1

363 Biomarkers in Alzheimer's Disease: From Pathogenic Initiation to Downstream Outcomes. **2015**, 341-354

362 Immunology of Autism. **2015**, 93-115

361 Late Onset Bipolar Disorder Versus Alzheimer Disease. **2016**, 377-384

360 [Periodontitis determining the onset and progression of Huntington's disease: review of the literature]. **2015**, 15, e6293

1

359 The Immune System of the Older Horse. 23-30

358 Prevention of Dementia. **2016**, 9-32

357 Compendium of Inflammatory Diseases. **2016**, 34-43

356 The Role of Chronic Inflammation in the Etiology of Parkinson's Disease. **2016**, 63-74

355 Encyclopedia of Signaling Molecules. **2016**, 1-8

354 Aging shapes the population-mean and -dispersion of gene expression in human brains.

353 Physical Activity Reduces Levels of Systemic Inflammation and the Risk of Internal Diseases. **2016**, 1, 59-62

352 Association between Interleukin 16 Gene Polymorphisms (rs1131445, rs4072111) and Late Onset of Alzheimer's Disease in Iranian Patients. **2016**, 11, 64-71

351 Can Exposure to Volatile Anesthetics Be a Tipping Point for AD Susceptible Populations?. **2017**, 1, 007-012

- 350 Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimer's disease like pathology. 1
- 349 Role of TLR Polymorphisms in Aging and Age-Related Diseases. **2018**, 1-18
- 348 CCAAT-Enhancer Binding Protein-beta (C/EBPP) Regulates Deltasecretase Expression, Mediating the Pathogenesis in Alzheimer's Disease.
- 347 Therapeutic Potential of FGF21 in Alzheimer's Disease. **2018**, 02, 1-17 1
- 346 Encyclopedia of Signaling Molecules. **2018**, 3142-3149
- 345 Voluntary Physical, Not Forced Exercise, Ameliorates Tau Pathology and Cognition in Tauopathy Model Mice. **2018**, 64, 74-79
- 344 Diyet Yağları Alzheimer Hastalığı Patolojisi Üzerine Potansiyel Koruyucu Etkileri.
- 343 Alzheimer's Disease: Potential of Nanotailored Nutraceuticals. **2018**, 105-120
- 342 The Physiopathological Crossroads of Aging. **2019**, 07, 102-128
- 341 Role of TLR Polymorphisms in Aging and Age-Related Diseases. **2019**, 1091-1107
- 340 Exposure to a single immobilization or lipopolysaccharide challenge increases expression of genes implicated in the development of Alzheimer's disease in the mice brain cortex. **2019**, 53, 100-109
- 339 The comparisons of blood plasma and cerebrospinal fluid S100B protein concentrations in patients with Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis. **2019**, 1, 22-27
- 338 Defining and predicting transdiagnostic categories of neurodegenerative disease.
- 337 Isolation housing exacerbates Alzheimer's Disease phenotype in aged APP KI mice.
- 336 Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity?. **2021**, 132, 1157-1157 2
- 335 Investigation of 1, 3, 4 Oxadiazole Derivative in PTZ-Induced Neurodegeneration: A Simulation and Molecular Approach. **2021**, 14, 5659-5679 1
- 334 Psychiatric Disorders in Dementia. **2021**, 317-385
- 333 PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. **2022**, 292, 118320 6

332	Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease. 2022 , 227, 113973	3
331	Dementia: Alzheimer's Disease. 2021 , 397-457	
330	Neuroinflammation in Alzheimer's disease continuum. 2020 , 37, 155	1
329	Salivary Biomarkers and Neurodegenerative Conditions. 2020 , 263-286	
328	Importance of Microglial Cytoskeleton and the Actin-interacting Proteins in Alzheimer's Disease. 2020 , 26, 1-7	0
327	Boswellic Acids as Promising Leads in Drug Development against Alzheimer's Disease. 2020 , 27, 14-31	2
326	Literaturverzeichnis. 2008 , 113-147	
325	Bioluminescent Imaging of Excitotoxic and Endotoxic Brain Injury in Living Mice. 2008 , 175-182	
324	Inflamm-Aging. 2009 , 893-918	
323	Alzheimer disease therapy: can the amyloid cascade be halted?. 2003 , 111, 11-8	42
322	Glial Cells and A β Peptides in Alzheimer's Disease Pathogenesis. 2007 , 216-233	
321	Antidementiva. 2008 , 643-665	
320	Interactions of A β -42 Peptide and Its Three Fragments (A β -12, A β -13, and A β -16) with Selected Nonsteroidal Drugs and Compounds of Natural Origin. 2020 , 12, 1579	
319	TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. 2006 , 8, 25	103
318	L-arginine and Alzheimer's disease. 2009 , 2, 211-38	36
317	Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. 2007 , 3, 365-72	32
316	Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin. 2010 , 1, 37-59	7
315	Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis. 2010 , 6, 19-27	19

314	The effect of tai chi on cognition in elders with cognitive impairment. 2011 , 20, 63-9; quiz 70	15
313	Multiple cytokines are involved in the early events leading to the Alzheimer's disease pathology. 2008 , 1, 359-373	4
312	Regulation by reversible S-glutathionylation: molecular targets implicated in inflammatory diseases. 2008 , 25, 332-46	93
311	Microglial chemotactic signaling factors in Alzheimer's disease. 2012 , 1, 199-204	18
310	Ccr2-64i and Ccr5 B2 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 B2 Polymorphisms in Alzheimer's disease). 2012 , 15, 937-44	13
309	Immunity and inflammation in neurodegenerative diseases. 2013 , 2, 89-107	76
308	Plasma acetylcholinesterase activity correlates with intracerebral amyloid load. 2013 , 10, 48-56	22
307	Alzheimer's Disease in Down Syndrome. 2012 , 1, 353-364	61
306	An Association Study on IL16 Gene Polymorphisms with the Risk of Sporadic Alzheimer's Disease. 2015 , 7, 128-32	6
305	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. 2016 , 5, 1-28	13
304	An overview on therapeutics attenuating amyloid level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. 2016 , 8, 246-69	30
303	Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic rats. 2016 , 5, 102-30	18
302	Recent development and advances in the fabrication and biomedical applications of nanoparticle-based drug delivery systems for metformin.	
301	Microglia in Alzheimer's Disease: A Target for Therapeutic Intervention.. 2021 , 15, 749587	2
300	Osteoblastic Swedish mutant APP expedites brain deficits by inducing endoplasmic reticulum stress-driven senescence. 2021 , 4, 1326	0
299	Is There Any Evidence of Monocytes Involvement in Alzheimer's Disease? A Pilot Study on Human Postmortem Brain.. 2021 , 5, 887-897	0
298	Amyloid- β -p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease.. 2021 , 3, fcab281	0
297	The effect of polycyclic aromatic hydrocarbons on changes in the brain structure of firefighters: An analysis using data from the Firefighters Research on Enhancement of Safety & Health study. 2021 , 816, 151655	2

296	Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease. 2021 , 18, 273	0
295	Immunosenescence and Alzheimer's Disease. 2022 , 177-199	0
294	Potential Nutrients from Natural and Synthetic Sources Targeting Inflammaging-A Review of Literature, Clinical Data and Patents. 2021 , 13,	2
293	Microglia and immunotherapy in Alzheimer's disease. 2021 ,	5
292	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. 2021 ,	17
291	Novel Positron Emission Tomography Radiotracers for Imaging Mitochondrial Complex I. 2021 ,	1
290	A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease. 2021 ,	0
289	Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment. 2021 ,	1
288	Systemic inflammasome activation and pyroptosis associate with the progression of amnesic mild cognitive impairment and Alzheimer's disease. 2021 , 18, 280	5
287	The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases. 2021 , 117, 103683	1
286	Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP/PS1 transgenic mice. 2021 , 18, 281	2
285	Research Progress of Microglia Related Role in Alzheimer's Disease. 2021 , 11, 6079-6085	0
284	Neuroprotective effects of the extract against an Alzheimer-like rat model of amyloid intrahippocampal injection.. 2021 , 12, 545-560	
283	Inflammation in obesity, diabetes, and related disorders.. 2022 , 55, 31-55	28
282	A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.. 2021 , 74, 101542	1
281	ALZHEIMER'S DISEASE - UNDERSTANDING SIDDHA MEDICINE LOOMS IN SPECIAL REFERENCE WITH MATA ALIVU. 2020 , p4, 2486-2493	
280	Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry.. 2022 , 12, 1282	0
279	Association of Circulating Magnesium Levels in Patients With Alzheimer's Disease From 1991 to 2021: A Systematic Review and Meta-Analysis.. 2021 , 13, 799824	2

278	Overview of Polyamines as Nutrients for Human Healthy Long Life and Effect of Increased Polyamine Intake on DNA Methylation.. 2022 , 11,	1
277	Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer's disease.. 2022 , 2,	0
276	Cognitive Function and Neuropsychiatric Disorders after COVID-19: A Long Term Social and Clinical Problem?. 2022 , 2, 50-59	1
275	Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.. 2022 , 2022, 9484217	4
274	Implication of Adult Hippocampal Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches.. 2022 , 11,	1
273	Mechanistic Link between Vitamin B12 and Alzheimer's Disease.. 2022 , 12,	2
272	Characteristics of Dysregulated Proinflammatory Cytokines and Cognitive Dysfunction in Late-Life Depression and Amnesic Mild Cognitive Impairment.. 2021 , 12, 803633	0
271	Impact of APOE B and E genotypes on plasma proteome signatures in Alzheimer's disease.	0
270	SRPK2 Expression and Beta-Amyloid Accumulation Are Associated With BV2 Microglia Activation.. 2021 , 15, 742377	
269	Cognitive Impairment in Heart Failure-A Review.. 2022 , 11,	0
268	Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019.. 2022 , 35,	1
267	Microglial inflammation and cognitive dysfunction in comorbid rat models of striatal ischemic stroke and Alzheimer's disease: effects of antioxidant catalase-SKL on behavioral and cellular pathology.. 2022 ,	1
266	Do Periodontal Pathogens or Associated Virulence Factors Have a Deleterious Effect on the Blood-Brain Barrier, Contributing to Alzheimer's Disease?. 2021 ,	0
265	Alzheimer's Disease Enhanced Tonic Inhibition is Correlated With Upregulated Astrocyte GABA Transporter-3/4 in a Knock-In Mouse Model.. 2022 , 13, 822499	1
264	Spousal caregiving, widowhood, and cognition: A systematic review and a biopsychosocial framework for understanding the relationship between interpersonal losses and dementia risk in older adulthood.. 2021 , 134, 104487-104487	1
263	Involvement of environmentally relevant toxic metal mixture in Alzheimer's disease pathway alteration and protective role of berberine: Bioinformatics analysis and toxicogenomic screening.. 2022 , 161, 112839	1
262	Saponins and flavonoids from Bacopa floribunda plant extract exhibit antioxidant and anti-inflammatory effects on amyloid beta 1-42-induced Alzheimer's disease in BALB/c mice.. 2022 , 288, 114997	4
261	FKBP52 in Neuronal Signaling and Neurodegenerative Diseases: A Microtubule Story.. 2022 , 23,	0

260	Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings.. 2022 , 197, 114945	2
259	Design, synthesis, and biological evaluation of new thalidomideβonepezil hybrids as neuroprotective agents targeting cholinesterases and neuroinflammation.	0
258	Phytochemicals as Micronutrients: What Is their Therapeutic Promise in the Management of Alzheimer's Disease?. 2022 , 277-308	
257	Development of early biomarkers of Alzheimer's disease: A precision medicine perspective. 2022 ,	
256	Bioavailability and Health Impact of Ingested Amyloid-like Protein Fibrils and their Link with Inflammatory Status: A Need for More Research?. 2022 , e2101032	0
255	Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age.. 2022 , 12,	5
254	Curing inflammatory diseases using phosphorous dendrimers.. 2022 , e1783	0
253	Decreased Netrin-1 in Mild Cognitive Impairment and Alzheimer's Disease Patients.. 2021 , 13, 762649	1
252	Immune system and blood-brain barrier-wide biomarker analyses provide causal evidence for autoimmunity in dementia.	
251	Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics.. 2022 , 18, e1009903	2
250	Identification and Analysis of // Competing Endogenous RNA Axis in Late-Onset Alzheimer's Disease Using Bioinformatic and Experimental Approaches.. 2022 , 14, 812169	0
249	Dietary Polyphenols as Therapeutic Intervention for Alzheimer's Disease: A Mechanistic Insight.. 2022 , 11,	3
248	Therapeutic Devices for Motor Symptoms in Parkinson's Disease: Current Progress and a Systematic Review of Recent Randomized Controlled Trials.. 2022 , 14, 807909	0
247	The ATP-dependent pathways and human diseases.. 2022 ,	2
246	Brain cellular senescence in mouse models of Alzheimer's disease.. 2022 , 1	0
245	Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APP Alzheimer's Disease Mouse Model.. 2022 , 23,	1
244	Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis.. 2022 , 1	1
243	From synapses to circuits and back: bridging levels of understanding in animal models of Alzheimer disease.. 2022 ,	0

242	Network Preservation Analysis Reveals Dysregulated Synaptic Modules and Regulatory Hubs Shared Between Alzheimer's Disease and Temporal Lobe Epilepsy.. 2022 , 13, 821343	1
241	Alzheimer's Disease: An Insightful Review on the Future Trends of the Effective Therapeutics.	0
240	Short-term administration of tibolone reduces inflammation and oxidative stress in the hippocampus of ovariectomized rats fed high-fat and high-fructose.. 2022 , 1-15	1
239	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022 , 17, 18	3
238	Long-chain Omega-3 fatty acids supplementation and cognitive performance throughout adulthood: A 6-month randomized controlled trial.. 2022 , 178, 102415	1
237	Protective Effect of Human-Neural-Crest-Derived Nasal Turbinate Stem Cells against Amyloid- β Neurotoxicity through Inhibition of Osteopontin in a Human Cerebral Organoid Model of Alzheimer's Disease.. 2022 , 11,	1
236	Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer's model.. 2022 , 11,	1
235	Oleuropein-Rich Olive Leaf Extract Attenuates Neuroinflammation in the Alzheimer's Disease Mouse Model.. 2022 ,	2
234	Causal Relationships Between Osteoarthritis and Senile Central Nerve System Dysfunction: A Bidirectional Two-Sample Mendelian Randomization Study.. 2021 , 13, 793023	1
233	Formulating The Structural Aspects Of Various Benzimidazole Cognates. 2021 ,	0
232	Two new metabolites from <i>Portulaca oleracea</i> and their anti-inflammatory activities. 2022 , 48, 114-119	2
231	The relationship of platelet-to-lymphocyte ratio with cognitive decline in T2DM.. 2021 , 13, 151	0
230	Bidirectional Association Between Sleep and Brain Atrophy in Aging.. 2021 , 13, 726662	
229	Biologic TNF- β inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.. 2021 , 18, 312	6
228	In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains.. 2021 ,	4
227	Umuhengerin Neuroprotective Effects in Streptozotocin-Induced Alzheimer's Disease Mouse Model via Targeting Nrf2 and NF- κ B Signaling Cascades.. 2021 , 10,	0
226	A New Insight into an Alternative Therapeutic Approach to Restore Redox Homeostasis and Functional Mitochondria in Neurodegenerative Diseases.. 2021 , 11,	1
225	A Leaky Blood-Brain Barrier to Fibrinogen Contributes to Oxidative Damage in Alzheimer's Disease.. 2021 , 11,	1

224	Etiology and management of Alzheimer’s disease: Potential role of gut microbiota modulation with probiotics supplementation.. 2021 , e14043	3
223	Disrupting Neurons and Glial Cells Oneness in the Brain-The Possible Causal Role of Herpes Simplex Virus Type 1 (HSV-1) in Alzheimer’s Disease.. 2021 , 23,	1
222	YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease.. 2021 , 58,	1
221	Experimental modelling of Alzheimer’s disease for therapeutic screening. 2022 , 100044	
220	The Top-Cited Original Articles on the Role of Microglia in Neurodegenerative Diseases: A Bibliometric and Visualized Study.. 2022 , 14, 869964	0
219	New potential biomarkers of Alzheimer’s disease: markers of endothelial dysfunction and neuroinflammation.. 2022 , 14, 35-42	1
218	Associations of Polygenic Risk Score for Late-Onset Alzheimer’s Disease With Biomarkers.. 2022 , 14, 849443	0
217	Glial Cells in Alzheimer’s Disease: From Neuropathological Changes to Therapeutic Implications.. 2022 , 101622	4
216	image_1.tif. 2018 ,	
215	image_2.tif. 2018 ,	
214	image_3.tif. 2018 ,	
213	table_1.xls. 2018 ,	
212	Data_Sheet_1.pdf. 2019 ,	
211	Video_1.MP4. 2019 ,	
210	Video_2.MP4. 2019 ,	
209	Video_3.MP4. 2019 ,	
208	Image_1.pdf. 2018 ,	
207	Image_2.pdf. 2018 ,	

206 Image_3.pdf. **2018,**

205 Table_1.pdf. **2018,**

204 Table_2.pdf. **2018,**

203 Table_3.pdf. **2018,**

202 Table_4.pdf. **2018,**

201 Table_1.PDF. **2018,**

200 Table_2.PDF. **2018,**

199 Image_1.TIF. **2020,**

198 Image_2.TIF. **2020,**

197 Image_3.TIF. **2020,**

196 Image_4.TIF. **2020,**

195 Image_5.TIF. **2020,**

194 Image_6.TIF. **2020,**

193 Image_7.TIF. **2020,**

192 Data_Sheet_1.docx. **2019,**

191 Data_Sheet_2.xlsx. **2019,**

190 Image1.pdf. **2018,**

189 Table1.xlsx. **2018,**

188	Table2.xlsx. 2018,	
187	Table_1.DOCX. 2018,	
186	Table_2.docx. 2018,	
185	Elevation of phospholipase C- β expression by amyloid- β facilitates calcium overload in neuronal cells.. 2022, 147924	0
184	Increased gene expression of interleukin-1alpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment. 2001, 17, 341-50	5
183	Targeting cytokine expression in glial cells by cellular delivery of an NF-kappaB decoy. 2007, 31, 209-19	14
182	High-fat diet-induced diabetes couples to Alzheimer's disease through inflammation-activated C/EBP β /AEP pathway.. 2022,	1
181	Solid fuel use in relation to dementia risk in middle-aged and older adults: A prospective cohort study.	
180	The aging immune system in Alzheimer's and Parkinson's diseases.. 2022, 1	1
179	Repetitive transcranial magnetic stimulation (rTMS) for multiple neurological conditions in rodent animal models: A systematic review.. 2022, 105356	
178	Peripheral inflammation and neurodegeneration; a potential for therapeutic intervention in Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). 2022, 37,	1
177	Exploring the Therapeutic Potential of Phytochemicals in Alzheimer's Disease: Focus on Polyphenols and Monoterpenes. 2022, 13,	1
176	Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. 2022, 13,	1
175	Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: in vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10.. 2022, 416, 113175	0
174	Recent Advances in Microglia Modelling to Address Translational Outcomes in Neurodegenerative Diseases. 2022, 11, 1662	0
173	Effect of Nanoemulsions Containing Astaxanthin or Its Esters on the Spatial Behavior of 5XFAD Mice. 2022, 17, 227-234	
172	Intermittent systemic exposure to lipopolysaccharide-induced inflammation disrupts hippocampal long-term potentiation and impairs cognition in aging male mice.	
171	A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?. 2022, 438, 120294	1

- 170 The Locus Coeruleus α -Noradrenaline system: Looking into Alzheimer's therapeutics with rose coloured glasses. **2022**, 151, 113179
- 169 Altered Blood and Brain Expression of Inflammation and Redox Genes in Alzheimer's Disease, Common to APPV7171 \times AUP301L Mice and Patients. **2022**, 23, 5799
- 168 A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413 0
- 167 C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease. 0
- 166 A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer's Disease. **2022**, 1-13 1
- 165 Role of Propolis as a pharmaceutical candidate on interleukin-1 β proinflammatory cytokine expression in Alzheimer's rat. **2021**, 31, 388-396
- 164 Some Noncommunicable Diseases of the Central Nervous System with a Possible Infectious Etiology (in Collaboration with V.A. Orlova, I.I. Mikhailova, A.A. Garbuzov, D.A. Khavkina, P.V. Chukhliaev, T.A. Ruzhentsova I. L. Naidenova, A. B. Danilov, A.V. Simonova, E.G. Filatova, I.A. Pavlovsky, O.V. Bystrova, A.M. Zatevalov, S.L. Bezrodny, T.Sh. Sadekov). **2022**, 299-359
- 163 Neuroimmune contributions to Alzheimer's disease: a focus on human data. 0
- 162 Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography. **2022**, 14, 1
- 161 Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. **2022**, 74, 600-629 5
- 160 Probiotic Bifidobacterium breve MCC1274 Mitigates Alzheimer's Disease-Related Pathologies in Wild-Type Mice. **2022**, 14, 2543 2
- 159 Alzheimer's Disease Association with Metals and Metalloids Concentration in Blood and Urine. **2022**, 19, 7309 3
- 158 B Lymphocytes in Alzheimer's Disease: A Comprehensive Review. **2022**, 1-22 1
- 157 Computational Analysis of Pathogenetic Pathways in Alzheimer's Disease and Prediction of Potential Therapeutic Drugs. **2022**, 12, 827
- 156 The Periodontal Pathogen *Fusobacterium nucleatum* Exacerbates Alzheimer's Pathogenesis via Specific Pathways. 14, 3
- 155 Dexmedetomidine attenuates lipopolysaccharide-induced inflammation through macrophageal IL-10 expression following α 7 nAChR activation. **2022**, 109, 108920 0
- 154 Interoceptive anxiety-related processes: Importance for understanding COVID-19 and future pandemic mental health and addictive behaviors and their comorbidity. **2022**, 156, 104141 0
- 153 Impact of a Novel Anti-Inflammatory Ketoprofen-Lysine Prodrug on Cerebral Pathology and Cognition in a Comorbid APP21 Transgenic Rat with Diet-Induced Metabolic Syndrome.

152	Infection-Induced Systemic Inflammation and Dementia. 2022 , 31-61	
151	Mechanistic Models of Protein Aggregation Across Length-Scales and Time-Scales: From the Test Tube to Neurodegenerative Disease. 16,	1
150	Roles of Fatty Acids in Microglial Polarization: Evidence from In Vitro and In Vivo Studies on Neurodegenerative Diseases. 2022 , 23, 7300	0
149	Bacillus Calmette-Guérin in Immuno-Regulation of Alzheimer's Disease. 14,	1
148	A Dichotomous Role for FABP7 in Sleep and Alzheimer's Disease Pathogenesis: A Hypothesis. 16,	
147	Preventive effects of arctigenin from <i>Arctium lappa</i> L against LPS-induced neuroinflammation and cognitive impairments in mice. 2022 , 37, 2039-2052	0
146	Iron, Neuroinflammation and Neurodegeneration. 2022 , 23, 7267	1
145	Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease. 2022 , 65, 8550-8595	0
144	Effects of δ GABA A receptor modulation on social interaction, memory, and neuroinflammation in a mouse model of Alzheimer's disease.	0
143	Arachidonic Acid Cascade and Eicosanoid Production Are Elevated While LTC ₄ Synthase Modulates the Lipidomics Profile in the Brain of the HIVgp120-Transgenic Mouse Model of NeuroHIV. 2022 , 11, 2123	0
142	Polygenic risk score analysis identifies deleterious protein-coding variants in novel immune pathway genes ATP8B4, FCGR1A, and LILRB1 that associate with Alzheimer's disease.	
141	Atrial Fibrillation and the Risk of Early-Onset Dementia: A Systematic Review and Meta-Analysis.	1
140	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. 14,	1
139	Peripheral Inflammation Marker Relationships to Cognition in Healthy Older Adults - A Systematic Review. 2022 , 105870	0
138	Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease. 2022 , 82, 104175	1
137	Exploring the management approaches of cytokines including viral infection and neuroinflammation for neurological disorders. 2022 , 157, 155962	3
136	Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming. 2022 ,	0
135	Implication of Paraprobiotics in Age-Associated Gut Dysbiosis and Neurodegenerative Diseases.	0

134	Efficacy of Phytochemicals and Natural Products in the Management/Treatment of Neurodegenerative Diseases. 2022 , 178-210	
133	Multivariate genome-wide association study of depression, cognition, and memory phenotypes and validation analysis identify 12 cross-ethnic variants. 2022 , 12,	
132	Adeno-associated virus (AAV) 9-mediated gene delivery of Nurr1 and Foxa2 ameliorates symptoms and pathologies of Alzheimer disease model mice by suppressing neuro-inflammation and glial pathology.	0
131	Neuroprotective effect of Hypericum perforatum extract against Aluminum-maltolate induced toxicity in SH-SY5Y cells.	
130	Quality of dietary fat and risk of Alzheimer's disease and dementia in adults aged 50 years: a systematic review. 66,	
129	Irigenin, a novel lead from Iris confusa for management of Helicobacter pylori infection with selective COX-2 and HpIMP2DH inhibitory potential. 2022 , 12,	2
128	The past, present, and future of research on neuroinflammation-induced mild cognitive impairment: A bibliometric analysis. 14,	
127	Oxidative Stress: Glutathione and Its Potential to Protect Methionine-35 of A β Peptide from Oxidation. 2022 , 7, 27052-27061	1
126	Microglial Activation and Oxidative Stress in PM2.5-Induced Neurodegenerative Disorders. 2022 , 11, 1482	1
125	Adenosine receptor signalling in Alzheimer's disease. 2022 , 18, 359-381	0
124	Neuronal cell death mechanisms in Alzheimer's disease: An insight. 15,	2
123	Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. 2022 , 23, 9583	
122	Alzheimer's and Parkinson's disease therapies in the clinic.	1
121	Mental health and periodontal and peri-implant diseases.	3
120	Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease. 2022 , 19,	4
119	Nanomedicines targeting the Inflammasome as a promising therapeutic approach for cell senescence. 2022 ,	0
118	SVR-based Multimodal Active Subspace Analysis for the Brain using Neuroimaging Data.	
117	ALZHEIMER HASTALIKIIE PERİDONTAL HASTALIKLAR ARASINDA BİR İKİTOLABİR Mİ.	

- 116 Biological determinants of blood-based cytokines in the Alzheimer's disease clinical continuum. 0
- 115 Rodent model preclinical assessment of PEGylated block copolymer targeting cognition and oxidative stress insults of Alzheimer's disease.
- 114 C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease. **2022**, 10,
- 113 Mechanoimmunology: Are inflammatory epigenetic states of macrophages tuned by biophysical factors?. **2022**, 6, 031502 1
- 112 Association between daily sleep duration and the risk of incident dementia according to the presence or absence of diseases among older Japanese individuals in the New Integrated Suburban Seniority Investigation (NISSIN) project. **2022**, 100, 190-195 0
- 111 Epigenetic Biomarkers. **2023**, 303-321 0
- 110 Investigation of the Protective Effect of Long-Term Exercise on Molecular Pathways and Cognitive Behaviors in Alzheimer Disease Model. 0
- 109 Therapeutic Potential of PPARs in Alzheimer's Disease. **2022**, 387-415 0
- 108 The role of wheat embryo globulin nutrients in improving cognitive dysfunction in AD rats. **2022**, 13, 9856-9867 0
- 107 Anti-inflammatory and memory-enhancing properties of Chinese herbal extracts: The possible application in Alzheimer's disease. **2022**, 0 0
- 106 A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer's disease mouse model. **2022**, 119, 2
- 105 Bifidobacterium breve MCC1274 Supplementation Increased the Plasma Levels of Metabolites with Potential Anti-Oxidative Activity in APP Knock-In Mice. **2022**, 1-13 2
- 104 Contribution of hyperglycemia-induced changes in microglia to Alzheimer's disease pathology. 0
- 103 Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease. **2022**, 15, 0
- 102 Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer's disease. 14, 0
- 101 Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. **2022**, 17, 0
- 100 Porphyromonas gingivalis Conditioned Medium Induces Amyloidogenic Processing of the Amyloid- β Protein Precursor upon in vitro Infection of SH-SY5Y Cells. **2022**, 6, 577-587 1
- 99 Strategies for Manipulating Microglia to Determine Their Role in the Healthy and Diseased Brain. 0

98	The Role of Extracellular Matrix in Human Neurodegenerative Diseases. 2022 , 23, 11085	2
97	Editorial: Regulation of neuroinflammation by multiorgan network. 14,	0
96	Interleukin 22 and its association with neurodegenerative disease activity. 13,	0
95	The Role of Inflammation in Cognitive Impairment of Obstructive Sleep Apnea Syndrome. 2022 , 12, 1303	1
94	ACAT1/SOAT1 Blockade Suppresses LPS-Mediated Neuroinflammation by Modulating the Fate of Toll-Like Receptor 4 in Microglia.	1
93	Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease. 14,	1
92	Altered CD8+ T cell associated aging gene signature in the peripheral blood of patients with Alzheimer's disease	0
91	Müller cell degeneration and microglial dysfunction in the Alzheimer's retina. 2022 , 10,	1
90	Ad libitum consumption of milk supplemented with omega 3, 6, and 9 oils from infancy to middle age alters behavioral and oxidative outcomes in male mice. 55,	0
89	A Pathophysiological Intersection of Diabetes and Alzheimer's Disease. 2022 , 23, 11562	1
88	A Multisystem Physiological Perspective of Human Frailty and Its Modulation by Physical Activity.	2
87	The Role of a Pathological Interaction between Amyloid and Mitochondria in the Occurrence and Development of Alzheimer's Disease. 2022 , 14, 19-34	0
86	Amyloid beta and its naturally occurring N-terminal variants are potent activators of human and mouse formyl peptide receptor 1. 2022 , 102642	0
85	Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases. 2022 , 2, 956-972	0
84	Retinal Pathological Features and Proteome Signatures of Alzheimer's.	0
83	Alzheimer's Disease as a Major Public Health Concern: Role of Dietary Saponins in Mitigating Neurodegenerative Disorders and Their Underlying Mechanisms. 2022 , 27, 6804	3
82	Periodontitis and Its Inflammatory Changes Linked to Various Systemic Diseases: A Review of Its Underlying Mechanisms. 2022 , 10, 2659	0
81	In Vitro and In Vivo Neuroprotective Effects of Sarcosine. 2022 , 2022, 1-11	0

- 80 COVID-19 as a Risk Factor for Alzheimer's Disease. **2022**, 1-24 ○
- 79 Long Non-Coding RNAs, Extracellular Vesicles and Inflammation in Alzheimer's Disease. **2022**, 23, 13171 ○
- 78 Guanidine-based β -amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. **2022**, 74, 117047 1
- 77 Immunosenscence and Aging: Neuroinflammation Is a Prominent Feature of Alzheimer's Disease and Is a Likely Contributor to Neurodegenerative Disease Pathogenesis. **2022**, 12, 1817 1
- 76 COVID-19 Trauma: The New Complex Adverse Childhood Experience. **2022**, 177-210 ○
- 75 Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer's Disease. **2022**, 14, 2447 1
- 74 Muscular Swedish mutant APP-to-Brain axis in the development of Alzheimer's disease. **2022**, 13, ○
- 73 Late-long-term potentiation magnitude, but not A β levels and amyloid pathology, is associated with behavioral performance in a rat knock-in model of Alzheimer disease. 14, ○
- 72 Ependymal cells and neurodegenerative disease: outcomes of compromised ependymal barrier function. ○
- 71 Interleukin-17 Promotes the Infiltration of CD8+ T Cells into the Brain in a Mouse Model for Alzheimer's Disease. 1-19 ○
- 70 Sporadic Alzheimer's disease animal model using streptozotocin and APP/PS1 mice. **2023**, 17-30 ○
- 69 Association of solid fuel use with a risk score capturing dementia risk among middle-aged and older adults: A prospective cohort study. **2023**, 218, 115022 ○
- 68 From degenerative disease to malignant tumors: Insight to the function of ApoE. **2023**, 158, 114127 ○
- 67 Intermittent systemic exposure to lipopolysaccharide-induced inflammation disrupts hippocampal long-term potentiation and impairs cognition in aging male mice. **2023**, 108, 279-291 ○
- 66 Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis. **2023**, 225, 109373 ○
- 65 Trace elements and Alzheimer dementia in population-based studies: A bibliometric and meta-analysis. **2023**, 318, 120782 1
- 64 Clinical and immunological effects of choline alfoscerate in the treatment of amnesic type Mild Cognitive Impairment. **2022**, 122, 59 ○
- 63 Spin state dependent peroxidase activity of heme bound amyloid β peptides relevant to Alzheimer's disease. **2022**, 13, 14305-14319 ○

- 62 How Alpha Linolenic Acid May Sustain BloodBrain Barrier Integrity and Boost Brain Resilience against Alzheimer's Disease. **2022**, 14, 5091 0
- 61 The Role of Caspases in Alzheimer's Disease: Pathophysiology Implications and Pharmacologic Modulation. **2022**, 1-20 1
- 60 The Contribution of the Locus CoeruleusNoradrenaline System Degeneration during the Progression of Alzheimer's Disease. **2022**, 11, 1822 0
- 59 Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective. **2022**, 1-24 0
- 58 Alzheimer's disease and COVID-19. **2022**, 14, 89-97 0
- 57 Ex vivo Detection of Amyloid- β in Naturally Formed Oral Biofilm. **2022**, 6, 757-773 0
- 56 The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer's disease. **2022**, 12, 1
- 55 The Role of Lipid Domains and Physical Properties of Membranes in the Development of Age-Related Neurodegenerative Diseases. **2022**, 16, 268-281 0
- 54 Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study. **2022**, 22, 0
- 53 Naringin enhances long-term potentiation and recovers learning and memory deficits of amyloid-beta induced Alzheimer's disease-like behavioral rat model. **2022**, 2
- 52 Inflammation context in Alzheimer's disease, a relationship intricate to define. **2022**, 55, 1
- 51 Is Periodontitis Associated with Age-Related Cognitive Impairment? The Systematic Review, Confounders Assessment and Meta-Analysis of Clinical Studies. **2022**, 23, 15320 0
- 50 Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders. 0
- 49 Rodent Model Preclinical Assessment of PEGylated Block Copolymer Targeting Cognition and Oxidative Stress Insults of Alzheimer's Disease. 0
- 48 Cognitive impairment in patients with heart failure: molecular mechanism and therapy. 0
- 47 Employment and Family Income in Psychological and Immune Outcomes Post-Bereavement. **2023**, 106024 0
- 46 Locus Coeruleus Dysfunction and Trigeminal Mesencephalic Nucleus Degeneration: A Cue for Periodontal Infection Mediated Damage in Alzheimer's Disease?. **2023**, 20, 1007 1
- 45 Regulatory mechanism of icariin in cardiovascular and neurological diseases. **2023**, 158, 114156 0

- 44 Neuronal deletion of nSMase2 reduces the production of A β and directly protects neurons. **2023**, 177, 105987 ○
- 43 PI3K/AKT/mTOR, NF- κ B and ERS pathway participated in the attenuation of H2O2-induced IPEC-J2 cell injury by koumine. **2023**, 304, 116028 ○
- 42 Two new ester alkaloids from *Portulaca oleracea* L. and their bioactivities. 1-8 ○
- 41 Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer β disease protects against mitochondrial dysfunction and mitigates brain pathology. **2022**, 11, 1 ○
- 40 Phytochemicals as Modulators of Signaling in Inflammation. **2011**, 230-246 ○
- 39 Alzheimer Disease. **2016**, 1-10 ○
- 38 Alzheimer β Disease. **2016**, 1-10 ○
- 37 Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. 1 ○
- 36 Chronic Neuroinflammation and Cognitive Decline in Patients with Cardiac Disease: Evidence, Relevance, and Therapeutic Implications. **2023**, 13, 329 1 ○
- 35 COVID-19: Scientific progress. **2023**, 11-48 ○
- 34 A Focused Review on Cognitive Improvement by the Genus *Salvia* L. (Sage) β From Ethnopharmacology to Clinical Evidence. **2023**, 16, 171 ○
- 33 Variability Analysis and Machine Learning of Non-CSF Body Fluids SELDI-TOF-MS Data for Alzheimer β Disease Diagnoses. **2023**, 646-658 ○
- 32 Vascular Dysfunction in Alzheimer β Disease: Alterations in the Plasma Contact and Fibrinolytic Systems. **2023**, 24, 7046 ○
- 31 Rhodanine composite fluorescence probes to detect amyloid-beta aggregated species in Alzheimer's disease models. ○
- 30 The association of dietary and nutrient patterns on neurocognitive decline: A systematic review of MRI and PET studies. **2023**, 87, 101892 ○
- 29 The association between dietary patterns, plasma lipid profiles, and inflammatory potential in a vascular dementia cohort. ○
- 28 Chemiexcitation: Mammalian Photochemistry in the Dark □ **2023**, 99, 251-276 ○
- 27 Smart Farming Enhances Bioactive Compounds Content of *Panax ginseng* on Moderating Scopolamine-Induced Memory Deficits and Neuroinflammation. **2023**, 12, 640 ○

- 26 Deletion of UCP1 in Tg2576 Mice Increases Body Temperature and Exacerbates Alzheimer β Disease-Related Pathologies. **2023**, 24, 2741 ○
- 25 AVE 0991 Suppresses Astrocyte-Mediated Neuroinflammation of Alzheimer β Disease by Enhancing Autophagy. Volume 16, 391-406 1
- 24 Physical activity for cognitive health promotion: An overview of the underlying neurobiological mechanisms. **2023**, 86, 101868 1
- 23 Liver-Specific Polygenic Risk Score Is Associated with Alzheimer β Disease Diagnosis. **2023**, 92, 395-409 ○
- 22 Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. **2023**, 375, 110387 ○
- 21 Antioxidant and Antineuroinflammatory Mechanisms of Kaempferol-3-O- β -D-Glucuronate on Lipopolysaccharide-Stimulated BV2 Microglial Cells through the Nrf2/HO-1 Signaling Cascade and MAPK/NF- κ B Pathway. **2023**, 8, 6538-6549 ○
- 20 Retinal pathological features and proteome signatures of Alzheimer β disease. **2023**, 145, 409-438 1
- 19 Inflammation: What's There and What's New?. **2023**, 13, 2312 ○
- 18 Extracellular vesicles derived from Porphyromonas gingivalis induce trigeminal nerve-mediated cognitive impairment. **2023**, ○
- 17 Thymol in Trachyspermum ammi seed extract exhibits neuroprotection, learning, and memory enhancement in scopolamine-induced Alzheimer's disease mouse model. ○
- 16 The effects of microglia-associated neuroinflammation on Alzheimer β disease. 14, ○
- 15 Therapeutic Inhalation of Hydrogen Gas for Alzheimer β Disease Patients and Subsequent Long-Term Follow-Up as a Disease-Modifying Treatment: An Open Label Pilot Study. **2023**, 16, 434 ○
- 14 YB-1 Protein Prevents Age-Related Decline in Plasma Estradiol in Aging Female 5xFAD Transgenic Mice. **2023**, 59, 232-243 ○
- 13 Ergothioneine, a dietary antioxidant improves amyloid beta clearance in the neuroretina of a mouse model of Alzheimer β disease. 17, 1
- 12 Testing a polygenic risk score for morphological microglial activation in Alzheimer β disease and aging. ○
- 11 ACAT1/SOAT1 Blockade Suppresses LPS-Mediated Neuroinflammation by Modulating the Fate of Toll-like Receptor 4 in Microglia. **2023**, 24, 5616 ○
- 10 The viral hypothesis in Alzheimer β disease: SARS-CoV-2 on the cusp. 15, ○
- 9 Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer β disease pathogenesis. 1-29 ○

- 8 Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. **2023**, 39-70 ○
- 7 Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. **2023**, 244, 108394 ○
- 6 Inflammatory Processes in Alzheimer's Disease Pathomechanism, Diagnosis and Treatment: A Review. **2023**, 24, 6518 ○
- 5 Radical Scavenging Is Not Involved in Thymoquinone-Induced Cell Protection in Neural Oxidative Stress Models. **2023**, 12, 858 ○
- 4 Recent Development in the Understanding of Molecular and Cellular Mechanisms Underlying the Etiopathogenesis of Alzheimer's Disease. **2023**, 24, 7258 ○
- 3 Blood brain barrier disruption following COVID-19 infection and neurological manifestations. **2023**, 171-201 ○
- 2 The Multifaceted Role of WNT Signaling in Alzheimer's Disease Onset and Age-Related Progression. **2023**, 12, 1204 ○
- 1 Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease. **2023**, 11, ○